i SUMMARY OF CHANGES ‚Äì Protocol 
 For Protocol Amendment # to: A Phase 1 / 2 Study of Olaparib in Combination with 
Ramucirumab in Metastatic Gastric and Ga stroesophageal Junction Adenocarcinoma (10017760) 
 NCI Protocol #: # 10066 Local Protocol #: 200021407  NCI Version Date: Protocol Date: 6/2/2022   
I. Protocol Changes Requested by CTEP:  
# Section Comments 
1. Title 
Page  The study coordinator, data manager and research coordinator were updated 
to Christina Wiess.  
2. Title 
Page  The protocol amendment dates were updated on the title page.  
3. All The protocol version date was updated in the header. 
4. Schema  Reinserted text regarding including ch est, abdomen, and pelvis imaging and  
reducing imaging intervals to 12 week (+/-  7 day) intervals for patients that 
remain on study for > 6 months. Correct schema picture also reinserted.  
5. 10 Reinserted row for adverse event e valuation in the study calendar. 
6. 10 Reinserted text and footnotes regardi ng tumor measurements and radiologic 
evaluations. 
7. Title 
page  Reinserted Clinicaltr ials.gov identifier.  
8. TOC  Updated table of contents. 
9. 9.3.6  The correlative study section as updated to include language for shipping 
plasma from Yale University to the NCLN Genomics Laboratory for circulating tumor DNA analysis.  
10. Appendix 
D The wallet card was updated per CTEP recommendations.  
1  
NCI Protocol #:  10066  
 Local Protocol #: 2000021407  
 Study Registry ID: [REMOVED]8  
 TITLE: A Phase 1 / 2 Study of Olaparib in Combin ation with Ramucirumab in Metastatic 
Gastric and Gastroesophageal Junc tion Adenocarcinoma (10017760)  
 Corresponding Organization:  LAO-CT018 / Yale University Cancer Center LAO  
 Principal Investigator:  Michael Cecchini  MD 
Yale Cancer Center 333 Cedar Street New Haven, CT 06520 PO Box 208028 Office: (203) 494-8566 Fax (203) 785 - 3788 michael.cecchini@yale.edu 
 Participating Organizations  
LAO-11030  / University Health Network Princess Margaret Cancer Center LAO 
LAO-CA043 / City of Hope Comprehensive Cancer Center LAO 
LAO-MA036 / Dana-Farber - Harvard Cancer Center LAO 
LAO-MD017 / JHU Sidney Kimmel Comprehensive Cancer Center LAO 
LAO-MN026 / Mayo Clinic Cancer Center LAO 
LAO-NC010 / Duke University - Duke Cancer Institute LAO 
LAO-NJ066 / Rutgers University - Cancer Institute of New Jersey LAO 
LAO-OH007 / Ohio State University Comprehensive Cancer Center LAO 
LAO-PA015 / University of Pittsburgh Cancer Institute LAO 
LAO-TX035 / University of Texas MD Anderson Cancer Center LAO 
LAO-NCI  / National Cancer Institute LAO 
 
Co-investigator: 
Patricia LoRusso Yale Cancer Center 333 Cedar St WWW211 PO Box 208028 New Haven CT 06520 Phone (203) 785-3333 Fax (203) 785-3788 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 2Patricia.lorusso@yale.edu 
 Co-investigator: Jill Lacy MD Yale Cancer Center 333 Cedar Street New Haven, CT 06520 PO Box 208028 Office: (203) 737-1600 Fax (203) 785 - 3788 Jill.lacy@yale.edu  Statistician:   Study Coordinator:  
 Yu Shyr Christina Wiess  Center for Quantitative Sciences 300 George St  571 Preston Building New Haven CT 06511  Nashville, TN 37232-6848  Phone: (615) 636-2572 Telephone (203) 785-2836  Fax: (615) 936-2602 Fax (203) 785-5792  Yu.shyr@vanderbilt.edu Christina.wiess@yale.edu  Responsible Research Coordinato r: Responsible Data Manager: 
 Christina Wiess Name Christina Wiess 
 Address 20 York St Address 300 George St  Address New Haven CT 06250 Address New Haven CT 06511 
 Telephone (203) 785-2836 Telephone  Fax (203) 785-5792 Fax  christina.wiess@yale.edu christina.wiess@yale.edu  NCI-Supplied Agent(s):  Olaparib, NSC 747856 
Other Agent(s):  Ramucirumab, NSC 749128 commercially  available through Eli Lilly 
 IND #:   
IND Sponsor:  DCTD, NCI  
 Protocol Type / Version # / Version Date:  Original / Version 1 / Version Date 7/25/16 
    Revision / Version 2 / Version Date 2/15/17     Revision / Version 3 / Version Date 3/31/17     Revision / Version 4 / Version Date 6/26/17     Revision / Version 5 / Version Date 9/12/17     Amendment / Version 6 / Version Date 1/29/18  
    Amendment / Version 7 / Version Date 4/30/18 
    Amendment / Version 8 / Version Date 7/25/18     Amendment / Version 9 / Version Date 1/31/19 
Amendment / Version 10 / Version Date 3/25/19 (Withdrawn by CTEP) 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 3    Amendment / Version 11 / Version Date 5/29/19 
           Amendment / Version 12 / Version Date 6/2/2022    SCHEMA  This study begins with a phase 1 dose escalati on lead-in with olaparib  and ramucirumab for 
eligible patients with metastatic gastric or gastroesophag eal junction adenocarcinoma who have 
previously received at least one line of chemot herapy in the metastatic  setting. A 3+3 dose 
escalation design will be done for olaparib at doses of 200mg BID and 300mg BID (tablet 
formulation) with standard ramucirumab dosing of 8 mg/ kg every 2 weeks. After the 
recommended phase 2 dose is determined, the ph ase 2 part of the study will begin. In phase 2, 
patients will be enrolled and trea ted with olaparib twice daily and ramucirumab 8 mg/kg every 2 
weeks. Response assessment scans will be done  every 6 weeks (imaging should include the 
chest, abdomen and pelvis), and treatment wi ll continue until di sease progression or 
unacceptable toxicity. Patients that remain on treatment for > 6 months may decrease the 
response assessment scan interval to every 12 weeks (+/- 7 days) at the discretion of the 
investigator. All patients will undergo a biopsy prior to treatment, which will be used for 
integrated biomarker analysis with the BROCA-HR panel to assess for the presence of mutations 
in homologous repair genes. The patients in pha se 2 will also undergo an optional repeat biopsy 
at 16 weeks for correlative analysis including de velopment of a post treatment PDX. Within the 
BROCA-HR panel we estimate the 17 genes charac teristic of homologous  repair deficiency 
(HRD) to be present in 30-40% of our study population. Deleterious mutations in the following 
genes will be considered a positive result for the BROCA-HR biomarke r: ATM, ATR, BARD1, 
BLM, BRCA1, BRCA2, BRIP1, CHEK2, MR E11A, NBN, PALB2, RAD51, RAD51C, 
RAD51D, RBBP8, SLX4, XRCC2, CDK 12. Because we do not know the true distribution of our 
biomarker, we will proceed with this 40 patient pilot study to help plan a larger study based on 
both our observed biomarker prev alence and our response rates. If response rates are observed 
regardless of biomarker status the subsequent study may not be biomarker driven. Based on 
published data in the COSMIC and TCGA database s we expect the BROCA-HR biomarker to be 
positive in approximately 35% of cases and we will enroll to 40 patients in phase 2 and proceed as follows:   
1. If there are 6 or more BROCA-HR+ patie nts (34 or less BROCA-HR- patients): 
If there are no responses in BROCA-HR+  patients and no response in BROCA-
HR- patients, then it is unlikely we will proceed to a larger study with this combination.  
x For BROCA- +5SDWLHQWVWKHSUREDELOLW\RI ¬ïUHVSRQVHVLV!LIWKH
WUXHUHVSRQVHUDWH¬ï  
x For BROCA-HR- SDWLHQWV7KHSUREDELOLW\RI¬ï UHVSRQVHLV!LIWKH
WUXHUHVSRQVHUDWHLV¬ïDQGWKHSUREDELOLW\RI¬ïUHVSRQVH RILIWKH
WUXHUHVSRQVHUDWHLV¬ï  
 
2. If there are 6 or more BROCA-HR+ patients (34 or fewer BROCA-HR-): For 
BROCA-HR- patients, the st udy will require at least 4 responses for success if 
we have at least 26 BROCA-HR- patients (65% incidence rate). The probability 
NCI Protocol #: 10066
Version Date: 6/2/2022
4of 4 responses is 80% if the true resp onse rate is 20%. The study will require at 
least 3 responses for success if we ha ve at least 20 BROCA -HR- patients (50% 
LQFLGHQFHUDWHWKH SUREDELOLW\RI¬ïUHV SRQVHV LIWKHW UXHUHVSRQVHUDWH 
20%. It is very unlikely the incidence rate of BROCA-HR- will be less than 50%.
3. If there are less than 6 BROCA-HR+ patients (35 or more BROCA-HR-
patients): If no responses are observed in ei ther cohort, then it is unlikely we will 
SURFHHGWRDODUJHUVWXG\ZLWKW KLVFRPELQDWLRQ7KHSUREDELOLW \RI¬ï%52&$ -
HR+ patients is > 85% if the true incidence of BROCA- +5LV¬ï7KH
SUREDELOLW\RI¬ï%52&$ -HR+ patients is > 99% if the true incidence rate of 
BROCA-+5LV¬ï
Based upon the results in the above scenarios we will discuss with CTEP on the plan to proceed 
to a larger study.
Dose Escalation Schedule
Dose LevelDose*
Olaparib Ramucirumab N/A

NCI Protocol #: 10066 
Version Date: 6/2/2022  
 5(m
g) (m g/kg) 
-2 100 mg, twice daily 8 mg/kg every 2 
weeks, intravenous  
-1 150 mg, twice daily 8 mg/kg every 2 
weeks, intravenous  
1 (starting dose) 200 mg twice daily, 
orally 8mg/kg every 2 
weeks, intravenous  
2 300 mg twice daily, 
orally 8mg/kg every 2 
weeks, intravenous  
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 6TABLE OF CONTENTS 
 
SCHEMA ........................................................................................................................ .................3
 
1. OBJECTIVES .................................................................................................................... ..8 
1.1 Primary Objectives ...................................................................................................8  
1.2 Secondary Objectives ...............................................................................................8  
2. BACKGROUND .................................................................................................................8  
2.1 Gastric and Gastroesopha geal Adenocarcinoma .....................................................8  
2.2 CTEP IND Agent(s) ...............................................................................................10  
2.3 Other Agent: Ramucirumab (Cryamza) .................................................................16  
2.4 Rationale for the Combination of  Olaparib and Ramucirumab .............................22  
2.5 Correlative Studies Background ............................................................................23  
3. PATIENT SELECTION ....................................................................................................28  
3.1 Inclusion Criteria ...................................................................................................29  
3.2 Exclusion Criteria ..................................................................................................32  
3.3 Inclusion of Wome n and Minorities ......................................................................34  
4. REGISTRATION PROCEDURES ...................................................................................34  
4.1 Investigator and Research Asso ciate Registration with CTEP ..............................34  
4.2 Site Registration .....................................................................................................35  
4.3 Patient Registration ................................................................................................37  
4.4 General Guidelines .................................................................................................38  
5. TREATMENT PLAN ........................................................................................................38  
5.1 Agent Administration .............................................................................................38  
5.2 Dose Escalation ......................................................................................................41  
5.3 Dose Expansion: ....................................................................................................43  
5.4 General Concomitant Medication an d Supportive Care Guidelines ......................43  
5.5 Safety Monitoring ..................................................................................................44  
5.6 Duration of Therapy ...............................................................................................45  
5.7 Duration of Follow Up ...........................................................................................46  
6. DOSING DELAYS/DOSE MODIFICATIONS................................................................47  
6.1 Olaparib and Ramucirumab Do se Modification Tables ........................................47  
6.2 General Management of Adverse Events for Phase 1 and 2 ..................................47  
6.3 Management of Specific Adverse Events for Phase 1 and 2: ................................49  
7. ADVERSE EVENTS:  LIST AND RE PORTING REQUIREMENTS ............................58  
7.1 Comprehensive Adverse Events and Potential Risks Lists (CAEPRs) .................58  
7.2 Adverse Event Characteristics ...............................................................................62  
7.3 Expedited Adverse Event Reporting ......................................................................62  
7.4 Routine Adverse Event Reporting .........................................................................64  
7.5 Secondary Malignancy ...........................................................................................64  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 77.6
 Second Malignancy ................................................................................................65  
8. PHARMACEUTICAL INFORMATION ..........................................................................65  
8.1 CTEP IND Agent(s) ...............................................................................................65  
8.2 Commercial Agent .................................................................................................68  
9. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES ........................................70  
9.1 Integral Laboratory or Imaging Studies .................................................................70  
9.2 Integrated Correlative Studies ................................................................................70  
9.3 Exploratory/Ancillary Correlative Studies ............................................................71  
10. STUDY CALENDAR .......................................................................................................81  
11. MEASUREMENT OF EFFECT........................................................................................82  
11.1  Antitumor Effect ‚Äì Solid Tumors ..........................................................................82  
12. STUDY OVERSIGHT AND DATA REPORTING / REGULATORY 
REQUIREMENTS .............................................................................................................89  
12.1  Study Oversight .....................................................................................................89  
12.2  Data Reporting .......................................................................................................90  
12.3  CTEP Multicenter Guidelines ................................................................................91  
12.4  Collaborative Agreements Language .....................................................................92  
12.5  Genomic Data Sharing Plan ...................................................................................93  
13. STATISTICAL CONSIDERATIONS...............................................................................93  
13.1  Study Design/Endpoints.........................................................................................93  
13.2  Sample Size/Accrual Rate ......................................................................................95  
13.3  Stratification Factors ..............................................................................................96  
13.4  Analysis of Secondary Endpoints ..........................................................................96  
13.5  Reporting and Exclusions ......................................................................................97  
REFERENCES .................................................................................................................... ..........99  
APPENDIX A  PERFORMANCE STATUS CRITERIA ................................................104  
APPENDIX B: NEW YORK HEART ASSOCIATION CLA SSIFICATIONS .........................105  
AppendiX C  PILL DIARY FOR OLAPARIB ..............................................................106  
APPENDIX D  PATIENT DRUG INFORMATION HANDOUT AND 
WALLET CARD .............................................................................................................107  
APPENDIX E  DIARRHEA MANAGEMENT ...............................................................110  
   
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 81. OBJECTIVES 
 1.1 Primary Objectives 
 1.12     Phase 1 Primary Objective :  
To determine the safe dose of olaparib with ramuciru mab, but not to exceed olaparib dose of 
300mg twice daily (tab let formulation). 
 1.13 Phase 2 Primary Objective:
  
To determine the efficacy of ol aparib plus ramucirumab as me asured by the objective response 
rates (ORR) stratified by BROCA-HR biomar ker status. 
  1.2 Secondary Objectives 
x To estimate median progression-free survival  (PFS) stratified by BROCA-HR biomarker 
status. 
x To estimate median overall survival (OS)  stratified by BROCA-H R biomarker status.  
x To measure the prevalence of the BROCA-HR biomarker in our study population. 
x To determine toxicity of olaparib and ramucirumab combination. 
 1.3       Exploratory Objectives 
x To assess the correlation between the signatu re 3 status and muta tions in BROCA-HR 
panel.  
x To evaluate the association between findi ngs from BROCA-HR pane l with response to 
therapy. 
x To evaluate the association between fi ndings from BROCA-HR pa nel and signature 3 
results with response to therapy.  
x To determine results of i mmunoassay for poly-ADP-ribosylat ed (PAR) substrates in 
tumor tissue.  
x To create a PDX model to study DNA repair in gastric tumors treated with PARP 
inhibitors (PARPi) from both pre-treatment bi opsy and repeat biopsy after 16 weeks of 
treatment.  
x Development of a novel genomic assay for BRCAness  
x Defining T cell receptor diversity of gastric cancer patients  +/- BRCAness  
x Biobank additional tumor tissue for future genomic analysis.  
x Biobank peripheral blood for future genomic analysis and assessme nt of circulating 
tumor DNA.  
 2. BACKGROUND 
 2.1 Gastric and Gastroesophageal Adenocarcinoma  
 Despite decreased incidence, ga stric cancer remains a significant public hea lth problem in the 
state of Connecticut, US, and globally. Mo reover, the incidence of GEJ-centered 
adenocarcinomas has increased dram atically in Western countries ove r the past four decades. It 
is estimated that were will be 26,370 new case s of gastric cancer, and 16,910 new cases of 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 9esophageal cancer, the majority of which are GEJ‚Äì centered adenocarcinomas, in the United Stats 
in 2016 [1]. Global gastric cancer incidence has declined with improved sanitation, food 
preparation and infection contro l, but the most recent global  incidence remains high with 
951,600 cases in 2012 [2]. The five-year survival rate of gastroesophageal adenocarcinoma is 
<30% for all stages and < 4% for metastatic disease [3, 4].  It‚Äôs estimated that were will be 310 
deaths attributed to gastroesophageal cancer fo r Connecticut in 2016 [5]. Thus, gastric and GEJ 
adenocarcinomas remain highly lethal with earl y propensity for metastatic spread, and despite 
new therapies, improvement in su rvival has been modest [4].  
 National Comprehensive Cancer Network (NCCN) guidelines for metasta tic gastroesophageal 
adenocarcinoma recommend a platinum containing doublet or triplet in th e first line setting, but 
median survival is less than 1 year [6]. Approved second-line re gimens include ramucirumab as 
single agent or in combination with paclitaxel [ 7, 8]. Targeted therapy fo r HER2 positive disease 
with trastuzumab has been effective [9], but the role for other targeted agents remains unclear. 
Olaparib in combination with paclitaxel has shown mixed results  in gastric cancers expressing 
low levels of the ataxia telangiectasia (ATM ) protein and further study is ongoing [10]. Low 
levels of ATM protein are t hought to be a sign of defec tive double stranded DNA repair 
mechanisms through inter action with BRCA [10]. Gastric cancer  cell lines have demonstrated 
sensitivity to olaparib, which is even more pr onounced with low levels of ATM expression [11]. 
 Defective DNA repair is a widely known mechan ism for cancer devel opment. BRCA mutations 
result in defective DNA repair  by causing defects within e rror-free homology- directed double 
strand break repair. Cells must then rely on the more error prone non-homologous DNA repair, 
which results in increased mutational burden within  cells and predisposes to breast, ovarian, and 
pancreatic cancer. While the association between  BRCA mutation and gastri c cancer is weaker 
than the association with breast and ovarian can cer, recent data reveals that evidence of 
homologous recombination deficiency (HRD) ma y be present in up to 12% of non-BRCA 
mutated gastric cancers as determined by a mole cular signature for HRD. This observation is 
discussed further in Corr elative Studies Background, section 2.5.2  [12].  
 
Additional evidence supporting de fective homologous repair in the pathogenesis of gastric 
cancer relates to mutations in reported in th e DNA repair gene ATM. Mutations in ATM have 
been reported in 11% of gastric cancers, and fo und to be expressed at low levels in 14% of 
patients in a prospective study [10, 13, 14]. The BROCA-HR mutation panel developed by Dr. 
Swisher at the University of Washington is a gene  panel that has been va lidated and is available 
to assess for the presence of mutations in 84 DNA repair genes. This panel contains 17 DNA 
repair genes with actionable mutations, including ATM and BRCA. Mutations within the 
BROCA-HR panel have been reported in more th an 40% of gastric cancers reported in the 
cosmic database, and details regarding the panel are discussed further in the Correlative Studies 
Background, section 2.5.1  [15, 16]. The use of the BROCA-HR panel and the use of mutational 
signatures both present opportuni ties as biomarkers to identify tumors with defective 
homologous repair that may be more susceptible to the combination of ramucirumab and 
olaparib. The rationale for this co mbination is further described in section 2.4 . A separate test, 
the Myriad HRD assay, measures homologous recomb ination in tumor cells. Homologous repair 
is measured by three components: loss of he rozygosity, large-scale state transitions, and 
telomeric allelic imbalance [17]. The Myriad assay is currently under review for validation for 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 10 ovarian and breast cancer, but also presents an opportunity for use as a biomarker for defective 
homologous repair in gastric patients [17, 18].  2.2 CTEP IND Agent(s)  
 2.2.1 Olaparib (AZD 2281) 
 
Olaparib (AZD2281, KU-0059436) is a potent oral i nhibitor of polyadenosi ne 5‚Äôdiphosphoribose 
polymerase (PARP). PARP inhibi tion is a novel approach to targeting tumors  that have 
homologous recombination DNA repair pathway de ficiencies. In HRD tumors, single agent 
treatment with olaparib can lead to tumor regr ession by a process known as  synthetic lethality- a 
result of the accumulation of un-repaired  DNA double-strand breaks  and an unsupportable 
increase in genomic instability. In synthetic leth ality, neither the deficien cy in homologous repair 
nor PARP inhibition is cytotoxi c by itself, but the combination of both leads to cell death. 
 Olaparib is the first PARP inhibitor approved by regulatory agencies for clinical indication. In 
the US, the FDA has approved olaparib as mo notherapy for patients with deleterious or 
suspected deleterious germline BRCA mutated (as de tected by an FDA-approved test) in patients 
with advanced ovarian cancer who have been treated with three or more prior lines of 
chemotherapy. Additionally, the European Medi cines Agency (EMA) approved olaparib as 
monotherapy for the maintenance treatment of adult patients with  platinum-sensitive relapsed 
BRCA-mutated (germline and/or so matic) high grade serous epithe lial ovarian, fallopian tube, or 
primary peritoneal cancer who ar e in response (complete resp onse or partial response) to 
platinum-based chemotherapy.  The majority of completed studies were perform ed with the capsule fo rmulation of olaparib. 
However since 2012/2013 most new studies, including the phase II I registration studies, are 
being performed with the tablet formulation which was designed to  deliver the therapeutic dose 
of olaparib in fewer dose units than the capsule.   Mechanism of Action  
The mechanism of action for olaparib activity has been proposed to involve the trapping of 
inactivated PARP onto the single-strand breaks prev enting their repair and generating a potential 
block for cellular DNA replication [19, 20]. An important consequen ce of this is that processing 
of trapped PARP-DNA complexes a nd/or the stalling of replicati on forks, or collapsing of 
replication forks leads to the generation of more serious DNA double stranded breaks [19, 20]. 
Under normal circumstances thes e double stranded breaks would be  repaired by processes that 
involve ATM and additional homologous recombin ation DNA repair proteins such as RAD51, 
BRCA1, and BRCA2 (Olaparib IB v. 14). However,  when homologous repair  is not functioning 
cells must rely on the more er ror prone base-excision repair  system, which requires PARP 
function. Homologous repair dysfunc tion sensitizes cells to PARP inhibition leading to further 
chromosomal instability, cell cycle arrest and ap optosis [21]. In cases where DNA repair defects 
may not result in the same level of sensitivity as  BRCA mutations single agent olaparib may not 
be sufficient to induce cell kill through synthetic lethality. Howeve r, it may still be possible to 
induce tumor cell death through comb inations with ionizing radiat ion or chemotherapies that 
either increases DNA damage accumulation or mito tic stress. Pre-clinical  studies support these 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 11 findings, showing that other BRCA  mutant, but not wild-type, human cell lines are highly 
sensitive to olaparib [22].   
 Nonclinical Pharmacology and Efficacy  
Olaparib was developed as a PARP inhibito r from a targeted screening program of 
pharmacophores with the aim of enhancing killing actions of certain existing cancer 
chemotherapies such as topoisome rase I inhibitors and alkylating agents. Olaparib is an agent 
that has potential both as monotherapy as well as  in combination with other cancer treatments 
[22].    Multiple tumor cell lines have been  investigated using colony form ation assays for sensitivity to 
PARP inhibition with olaparib as a single ag ent. These cell lines have shown wide-ranging 
cellular activity from low nM to 10 »ùM. The effective concentration for inhibiting cellular PARP 
activity in cancer cells by >90% is approximate ly 30 nM to 100 nM olaparib in several human 
tumor cell lines including ovarian A2780, br east MCF-7, and colorectal SW620. These 
concentrations led to significant ablation of PARP activity (based on the inhibition of PAR 
formation), with maximal PARP-1 inhibition oc curring at around 100 nM. C onsistent with this, 
maximal potentiation of an a ppropriate DNA SSB-inducing chemot oxic agent (MMS) was also 
seen in vitro at 100 nM, which equates to 43.4 ng/mL. 
 Following single oral doses, absorption was ra pid (maximum plasma concentration Cmax <2 
hours in mice, rats and dogs) while  bioavailability was <60% in ma le and female mice, <20% in 
male and female rats and ~79% in male dogs (Ola parib IB v. 14). Low oral bioavailability in rats 
may have been due to poor abso rption or rapid first pa ss metabolism. Distribution of olaparib is 
in the gastrointestinal tract and in tissues as sociated with the metabo lism and elimination of 
foreign compounds. Further investig ations are still ongoing. Excreti on is primarily via the feces 
(65% to 75%) and, to a lesser exte nt, the urine (20% to 30%).  
 Investigations in human in vitro systems indicated metabolism of olaparib was CYP mediated 
and that CYP3A4 and 3A5 were the dominant me tabolic enzymes (Olaparib IB v. 14). Similar 
studies indicated flavin m ono-oxygenase-3 was not able to  metabolize ol aparib. For in vitro 
direct inhibition assays, olaparib WR»ù0ZDVDZHDNLQKLELWRURI&<3$,&
50 »ù0
2ODSDULEWR»ù0ZDVDOVR WHVWHGDJDLQVW&<3V$$ %&& 9, 2C19, 2D6, 
DQG($W»ù0  olaparib, no significant direct inhi bitor effect on CYPs 1A2, 2A6, 2B6, 
2C8, 2D6 or 2E1 was observed although more limited inhibition of CYP2C9 (22%) and 
CYP2C19 (26%) was observed. Regulatory guida nce suggested clinically meaningful drug 
interaction due to olaparib di rectly inhibiting hepatic and GI tract CYP3A4/5 cannot be 
excluded. In time dependent inhibition assays, ol aparib had only very minor effects against 
CYP3A and no effect against other CYPs.   In studies using Madin-Darby Canine Kidney (MDCK) II cells transfected with multidrug 
resistance 1 (MDR1; Pgp), BCRP or MRP-2 drug e fflux transporters, olapar ib was shown to be a 
substrate of MDR1 but not BCRP or MRP-2 (Olaparib IB v. 14). Olaparib‚Äôs ability to inhibit 
MDR1, BCRP, and MRP-2 was also investigated . MDR1 and BCRP were expressed in MDCK 
II cells while MRP-2 was prepared in isolated me mbrane vesicles. Olaparib was shown to inhibit 
MDR1 (IC
50 »ù0DQGYHU\ZHDNO\LQKL ELW%&532ODSDULEGLGQRW inhibit MRP-2. The 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 12 possibility for inhibition of hepatic uptake transporters OATP1B1, OATP1B3, OCT1 or NTCP 
was investigated. Olaparib was an  inhibitor of OTAp1B1 and the IC
50 »ù0DQG»ù0
was dependent on the substrate used. Ol aparib was an inhibitor of OCT1 (IC 50 »ù0LW
caused no significant inhibition of OATP1B3 an d was a very weak inhibitor of NTCP (IC 50 >100 
»ùM) (Olaparib Investigator‚Äôs Brochure, 2015). 
 Nonclinical Toxicology  
Non-clinical safety evaluation st udies conducted with olaparib in clude single dose oral and iv 
studies in mice and rats, repeat dosing oral studies of up to 1 m onths duration in mice, pivotal 
repeat dosing studies of up to 6 m onths duration in rats and dogs, a battery of in vitro and in vivo 
genetic toxicity studies and re productive toxicology studies in rats, which are summarized in 
section 4.3 (toxicology) of the Olaparib IB  v. 14. There were no noted effects on the 
cardiovascular or respiratory parameters of an an esthesized dog or any behavioral, autonomic, or 
motor effects in the rat. Toxicol ogy studies indicate that the target  organ of toxicity is the bone 
marrow. Ex vivo work has confirmed that olaparib is also active against human marrow. The 
cytotoxic effect becomes evident at a higher conc entration than required to fully ablate PARP 
activity. 28-day dog and rat studies demonstrate a reversible myelotoxic effect that is mild to 
moderate. Platelets are first affected, followed by white blood cells. In 26-week repeat-dose 
studies in rats, doses were well tolerated in male  rats, with hematological effects and increased 
spleen weights observed at all dosages. In fema le rats, doses of 15 mg/kg/day resulted in 
significant reduction in body weight . Hematological effects and increased spleen weights were 
again observed at all dosages. The difference between  sexes was considered to be due to the fact 
that females had greater plasma exposure levels than males. In  26-week repeat-dose studies in 
dogs, olaparib was well tolera ted. Hematological changes we re observed, characterized by 
pancytopenia.   Clinical Pharmacology ‚Äì Single-dose Tablet Data (Olaparib IB v. 14)  
Following administration of single oral doses of the tablet formulation at doses of 25, 50 and 250 
PJQ SHUFRKRUWDEVRUSWLRQZ DVUDSLGDQGVOLJKWO\PRUHUDS LGthan the capsule dose. The 
peak plasma concentration was typically achi eved at 1.5 hours. Following the peak, plasma 
concentrations declined in a biphasic manner  with an average terminal elimination t
1/2 of 12.2 
hours (Sd 5.31 hours) and 13.02 hours (Sd 4.16 hours) . The Gmean apparent oral plasma 
clearance was approximately 7.95 L/h and 6.36 L/h. The volume of distribution was greater than 
total body water indicating that olaparib was distributed into the tissues, 146.2 L and 112.1 L. 
The observed variability in e xposure was moderate to high, th e Gmean %CV for AUC and Cmax 
following 300 mg single dose olaparib ranged from 24.3% to 67.4%.  The relative bioavailabilities of the tablet formula tion (compared to capsule) at the 3 dose levels 
studied are shown in Table 10 in  the Olaparib Investigator‚Äôs Brochure, 2015. At the 2 lower 
tablet doses (25 and 50 mg), fo llowing normalization fo r dose, although the Cmax achieved after 
dosing with the tablet formulation tended to be higher than that w ith the capsule, the AUC values 
for the 2 formulations were actual ly very similar. However, at the highest tablet dose (250 mg), 
the exposure delivered by the tablet formula tion (both dose-normalized Cmax and AUC) was 
higher than that delivered by the capsule. The tablet and the capsule  formulations cannot 
therefore be considered  to be bioequivalent. 
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 13 Safety Profile: As of 15 December 2016, approximately 6558 patients are estimated to have 
received olaparib in the c linical programme including As traZeneca-sponsored studies (3923 
patients), a MAP (676 patients), ISSs and collaborative group studies (1959 patients). An 
estimated 4475 patients with ovari an, breast, pancreatic, gastric and a variety of other solid 
tumors are estimated to have received trea tment with olaparib in AstraZeneca-sponsored, 
interventional studie s (3799 patients) and the MAP (676 patients). Since 2012/2013, most new 
clinical studies have utilized th e tablet formulation which was de signed to deliver the therapeutic 
dose of olaparib in fewer dose units than the capsule. Of the 4475 patie nts, 2109 received the 
capsule formulation, 2341 receiv ed the tablet formulation, an d 25 received both capsule and 
tablet. In the AstraZeneca-sponsored, interventi onal studies, olaparib  was given either as 
monotherapy (2618 patients) or in  combination with chemotherapy or other anti-cancer agents, 
including studies where patient s received monotherapy and combination therapy sequentially 
Q    
 Data from the available pre-clinical studies a nd subsequent clinical development programme 
demonstrate that olaparib appears to be active an d generally well tolerated in patients with solid 
tumours including those with BRCA  mutated cancers. In  ovarian cancer, responses have been 
seen in all patient groups, including pl atinum resistant and refractory cancer.  
 From the available data to date in patients with advanced cancer, there is no evidence of any unexpected toxicity following long-term ol aparib (capsule) monotherapy exposure.  
 
Adverse laboratory findings and/or clinical diagnoses considered to be associated with 
administration of olaparib monotherapy include hematological effects (anemia, neutropenia, 
lymphopenia, thrombocytopenia, MCV elevation and increase in  blood creatinine), nausea and 
vomiting, decreased appetite, diarrhea, dyspepsia , stomatitis, upper abdo minal pain, dysguesia, 
fatigue (including asthenia), headach e and dizziness. Most of these events were generally mild or 
moderate in intensity.   In a relatively small number of patients, pne umonitis, MDS/AML and new primary malignancies 
have been observed. Evidence from across the development programme for olaparib does not 
support a conclusion that there is a causal relatio nship between olaparib and these events. There 
are important potential risks for olaparib and are being kept under close surveillance.  
  Data from studies of olaparib in combination with various chemothera py agents indicate an 
increase in bone marrow toxicity (anemia, neutro penia, thrombocytopenia) greater than expected 
if the agents had been administered alone. Th e effects are generally transient but treatment 
delays are common and alternative administratio n schedules/toxicity mana gement processes are 
currently being evaluated within so me of these studies. When this ty pe of toxicity has occurred it 
has been managed by routine clinical pr actice including dose de lays, dose reductions, 
intermittent dosing and/or the use of supportive care measures, including G-CSF. Currently, all 
ongoing olaparib combination studies  are being closely monitored fo r myelotoxicity. Results of a 
Phase II study in combination with carbopla tin/paclitaxel (Study D0810C0041) showed that 
addition of olaparib to carboplatin AUC 4 + paclitaxel in the chem otherapy phase had a 
generally similar tolerability profile to carbopla tin AUC 6 + paclitaxel. Th e regimen of olaparib 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 14 capsule 200 mg bd for 10 days out of 21, with ca rboplatin AUC 4 + paclitaxel had an acceptable 
and manageable tolerability profile in patients with recurrent serous ova rian cancer. Olaparib 
tolerability during the monotherapy maintenance phase was consistent with the previously 
known safety and tolerability profile. In Study D0810C00039 and Study 081BC00004, olaparib 
100 mg tablet bd in combination with weekly paclitaxel 80 mg/m
2 was well tolerated, with no 
new unexpected safety findings. In both studies, th e incidence of neutropenia was higher for the 
olaparib combination arm and this  contributed to higher rates of dose modifications for patients 
on olaparib compared to place bo. In Study D081BC00004, there was also a higher incidence of 
anemia on the olaparib + paclitaxe l combination arm than the plac ebo + paclitaxel arm and more 
dose interruptions, reducti ons and discontinuations. 
 Important potential risks  
Myelodysplastic syndrome/ acute myeloid leukemia: 
The incidence of MDS/AML in patients treated in clinical trials with olaparib monotherapy, 
including long-term survival follow-up, was <1.5 % and the majority of  events had a fatal 
outcome. All patients had potential contributi ng factors for the development of MDS/AML, 
having received previous chemotherapy with pla tinum agents. Many had also received other 
DNA damaging treatments. The majority of report s were in germline BRCA mutation carriers 
and some of the patients had a history of prev ious cancer or of bone marrow dysplasia. If MDS 
and/or AML are confirmed while on treatment with  olaparib, it is recommended that olaparib 
should be discontinued and the pa tient be treated appropriately. 
 
New Primary Malignancies other than MDS/AML: 
New primary malignancies have been reporte d in <1% of patients . There were other 
contributing factors/potential alternative explan ations for the developm ent of the new primary 
malignancy in all cases, includ ing documented BRCA mutation, tr eatment with radiotherapy and 
extensive previous chemothera py including carboplatin, taxanes, anthracyclines and other 
alkylating and DNA damaging agents.  Pneumonitis: Pneumonitis has been reported in <1.0% patients treate d with olaparib monot herapy in clinical 
studies. Reports of pneumoniti s had no consistent clinical pattern and were confounded by a 
number of pre-disposing factor s (cancer and/or metastases in lungs, underlying pulmonary 
disease, smoking history, and/ or previous chemotherapy and ra diotherapy). When olaparib was 
used in clinical studies in combination with othe r therapies there have been events with a fatal 
outcome. If patients present with new or worsening respiratory symptoms such as dyspnea, 
cough and fever, or an abnormal chest radiologic  finding is observed, olaparib treatment should 
be interrupted and prompt investigation initiate d. If pneumonitis is confir med, olaparib treatment 
should be discontinued and the patient treated appropriately. 
 Laboratory toxicities:  
From the completed studies, there are no safe ty concerns noted for the renal or hepatic 
parameters measured and no clinically signific ant changes of concern relating to coagulation 
parameters. Changes observed in the hematol ogical parameters (dec reased hemoglobin, 
neutrophils, thrombocytes and lymphocytes) ar e known to be associated with olaparib 
monotherapy and/or can be explained by co-e xisting conditions/previous chemotherapy. Mean 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 15 corpuscular volume increases have also been observe d with olaparib. The clinical significance of 
this laboratory finding is unknown. Data from Ph ase 1 and Phase 2 studies of olaparib in 
combination with various chemotherapy agen ts indicate an increase in neutropenia, 
thrombocytopenia, and anemia compared to giving these agents alone. These findings are consistent with pre-clinical fi ndings and are reflected in the mo re severe hematological events 
i.e., CTCAE Grade 4 neutropenia, febrile neutro penia and thrombocytopen ia being reported as 
SAEs.   Mild elevations in creatinine with no apparent sequelae have been observed in the absence of an 
elevation in urea or blood urea nitrogen or a reported abnormality on urinalysis. The clinical 
significance of these mild eleva tions in creatinine is unknown but  inhibition of organic cation-
transporter-2 by olaparib is considered  a plausible mechanistic explanation.  
 Clinical Efficacy:  
 The regulatory approvals of olaparib were based on study D0810C00019. This was a Phase 2, 
randomized, double-blind, multicente r study to assess the effica cy of olaparib (capsule 
formulation) in the treatment of patients with pl atinum sensitive serous ovarian cancer, following 
treatment with 2 or more plati num containing regimens [23]. Patie nts that responded to platinum 
based chemotherapy were randomly assigned to maintenance therapy with either placebo or 
olaparib at a dose of 400mg twice daily. The primary endpoint was PFS according to the 
RECIST guidelines. Of the 265 patients randomi zed into the study, all olaparib (136) and 
128/129 placebo patients received study treatment . PFS was significantly longer with olaparib 
than with placebo (median, 8.4 months vs. 4.8 months from randomiza tion on completion of 
chemotherapy; hazard ratio for progression or de ath, 0.35; 95% confidence interval [CI], 0.25 to 
0.49; P<0.001). Subgroup analyses of PFS showed that , regardless of subgroup, patients in the 
olaparib group had a lower risk of progression. The investigators concluded that olaparib as 
maintenance treatment significantly improved PF S among patients with platinum-sensitive, 
relapsed, high-grade serous ovari an cancer. Interim analysis show ed no overall survival benefit. 
The toxicity profile of olaparib in this population was consistent w ith that in previous studies.  
 Fong et al reported the result of  a phase 1 study in a study populat ion enriched in carriers of a 
BRCA1 or BRCA2 mutation [24].T he investigators enrolled and treated 60 patients; 22 were 
carriers of a BRCA1 or BRCA2 mu tation and 1 had a strong fam ily history of BRCA-associated 
cancer but declined to undergo mutational te sting. The olaparib dose and schedule were 
increased from 10 mg daily for 2 of every 3 weeks to 600 mg twice daily continuously. 
Reversible dose-limiting toxicity was seen in one  of eight patients rece iving 400 mg twice daily 
(grade 3 mood alteration and fa tigue) and two of five patients  receiving 600 mg twice daily 
(grade 4 thrombocytopenia and gr ade 3 somnolence). This led to enrollment of another cohort, 
consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olap arib at a dose of 200 
mg twice daily. Other adverse effects included mild gastrointestinal symptoms. There was no obvious increase in adverse effects seen in the mutation carriers. Pharmacokinetic data indicated 
rapid absorption and eliminati on; pharmacodynamic studies c onfirmed PARP inhibition in 
surrogate samples (of periphera l-blood mononuclear cells and pl ucked eyebrow-hair follicles) 
and tumor tissue. Objective antitumor activity wa s reported only in mutation carriers, all of 
whom had ovarian, breast, or pr ostate cancer and had received multiple treatment regimens.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 16 In an expansion phase in BRCA-de ficient ovarian cancer at a dose of olaparib 200 mg BID, fifty 
patients were treated, including 48 with BRCA-defic ient germline mutations and two patients of 
unknown status or significance. Twenty (40%) pa tients achieved comple te response (CR) or 
partial response (PR) by RECI ST and/or GCIG-CA125 criteria.  An additional three patients 
experienced stable disease (SD)  for more than four cycles [25]. A multicenter phase 2 study 
enrolled two sequential cohorts of women w ith known germline BRCA1 or BRCA2 mutations 
and recurrent advanced ovarian can cer to receive olapar ib continuously at a dose of 400 mg BID 
(Cohort 1) or 100 mg BID (Cohort 2) [26]. Responses  were observed in 33% (11 of 33) patients 
enrolled in the 400mg BID cohort an d 13% (3 of 24) patients enro lled in the 100 mg BID cohort. 
A phase 2 study of olaparib in a dvanced serous ovarian cancer a nd triple-negative breast cancer 
showed ORR of 41% in ovarian patients with  BRCA1 or BRCA2 mutations and 24% without 
mutations and no confirmed responses in  patients with breast cancer [27].  
 Kaufman et al reported the re sults from the phase 2 study of ol aparib monotherapy in patients 
with advanced solid cancer and germline BRCA1/2 mutation [28]. Olaparib was given 400mg 
twice a day and the primary endpoint was tumor response rate. A total of 298 patients received 
treatment and were evaluable. The tumor res ponse rate was 26.2% (78 of 298; 95% CI, 21.3 to 
31.6) overall and 31.1% (60 of 193; 95% CI, 24.6 to  38.1), 12.9% (eight of 62; 95% CI, 5.7 to 
23.9), 21.7% (five of 23; 95% CI, 7.5 to 43.7), and 50.0% (four of eight; 95% CI, 15.7 to 84.3) in 
RYDULDQEUHDVWSDQFUHDWLFDQGSU RVWDWHFDQFHUVUHVSHFWLYHO\ 6WDEOHGLVHDVH¬ïZHHNVZDV
observed in 42% of patients (95% CI, 36.0 to 47.4), including 40% (95% CI, 33.4 to 47.7), 47% 
(95% CI, 34.0 to 59.9), 35% (95% CI, 16.4 to 57.3), and 25% (95% CI, 3.2 to 65.1) of those with 
ovarian, breast, pancreatic, or prostate cancer, respectively.  
 Lee and Kohn and colleagues have examined olap arib with carboplatin in two schedules in 
BRCA1/2 mutation carriers with breast and/or ov arian cancer and women w ith high grade serous 
ovarian cancers[29]. They also observed clinic al activity with over 80%  of ovarian cancer 
patients attaining either SD or PR lasting up to 18+ months. Additional phase 1 and 2 trials in both BRCA-deficient and BRCA-competent ovarian cancer are currently ongoing.  
 
 
2.3 Other Agent: Ramucirumab (Cryamza) 
 Pathways that mediate angiogenesis are considered  important targets in cancer drug development 
and drugs that target this pa thway have been correlated with  multiple outcomes. Vascular 
endothelial growth factors (VEGFs; incl uding VEGF-A, VEGF-B, VEGF-C, VEGF-D, and 
placental growth factor) have emerged as key re gulators of angiogenesis and the expression of 
VEGFs has been correlated with poor prognosis in  several solid tumor types, including gastric 
adenocarcinoma.  A comprehensive clinical development program to  assess ramucirumab in the treatment of solid 
tumor malignancies was initiated following Ph ase 1 studies evaluati ng dose, schedule, and 
toxicity. The clinical development has focuse d on tumors where VEGF ligands (including 
VEGF-A) and VEGF-R2 are overexpressed and wher e the unmet medical need is high [30, 31]. 
  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 17 Mechanism of Action 
 Ramucirumab is a human receptor- targeted antibody that specifically binds VEGF Receptor 2 
(VEGF-R2). The binding of ramu cirumab to VEGF-R2 prevents it s interaction with activating 
ligands, VEGF-A, VEGF-C, and VEGF-D  [31, 32]. As a result, ramucirumab inhibits ligand-
stimulated activation of VEGF-R2, thereby inhib iting ligand-induced proliferation, downstream 
signaling components including Er k1/Erk2, and migration of human  endothelial cells [33, 34]. 
Preclinical data for DC101, a neutralizing rat anti-mouse mAB specific for murine VEGF-R2, 
demonstrate antitumor activity  in multiple tumor models. 
 Nonclinical Pharmacology, Efficacy and T oxicology (Ramucirumab Investigator‚Äôs 
Brochure 2014)  The pharmacokinetics (PK) and toxicokinetics (TK) of ramu cirumab were determined in 
cynomolgus monkeys. The PK behavior of ra mucirumab in monkeys was typical of a 
monoclonal antibody. The PK was nonlinear and showed antibody acc umulation with repeated 
doses. The formation of antidrug antibodies (ADA)  was assessed in all primate studies, and 
generally indicated the presence of ADA in indi vidual animals; however, the predictive value of 
this finding for the occurrence of immunogenicity  in humans is unclear. Formal studies to 
characterize the disposition, excretion, and metabolism of ramucirumab have not been 
conducted. As a monoclonal antibody, ramucirumab will be largely c onfined to the extracellular 
space and elimination is primarily by catabolism of the antibody.  
 
PK and TK of ramuciru mab in cynomolgus monkeys was obtai ned in 5 and 39 week repeat-dose 
toxicology studies. Animals were administered IV doses of 0, 4, 12, or 40 mg/kg ramucirumab 
DP weekly and blood samples for ramucirumab concentration anal ysis in serum were obtained 
after the first dose.   Non-compartmental analysis of  the contentration-vs-time da ta from the monkey toxicology 
studies indicated that the PK behavior of ramucirumab was n on-linear over the 4-50 mg/kg dose 
range. Ramucirumab half-life increased and clearance decreased with increasing dose. The steady-state volume of distributi on was approximately equal to th e vascular space at each dose 
level. Mean ramucirumab AUC in the 50mg/ kg group increased between the first and 39
th doses, 
indicating that drug accu mulation occurred. Antibodies against ramucirumab were detected in 
the 4, 12, and 40 mg/kg dose groups in the 5 week  study and in the 5, 16 mg/kg dose groups in 
the 39 week study. The PK behavior  of ramucirumab in monkeys is  thus nonlinear and typical of 
a monoclonal antibody.  The toxicity of IV ramucirumab was evaluated in monkeys that received 4 doses over 5 weeks, 
or weekly doses for up to 39 weeks. The effe ct of ramucirumab was also assessed in an 
incisional model of wound heali ng after a single IV dose, and no impairment in wound healing 
was observed. Focal muscle fiber degeneration and mononuclear cell  infiltration were seen in 
skeletal muscle in ramucirumab treated animals only, but were conclude d to not be treatment 
related due to the focal nature of lesions and lo w incidence in females. No ramucirumab related 
adverse events were evident in the routine toxicological assessmen ts. Treatment of monkeys with 
ramucirumab for 39 weeks resulted in renal toxic ity at doses of 16 and 50 mg/kg and thickening 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 18 and osteochondropathy of the epiphyseal growth  plate noted at 5 mg/kg and above. Thus a no 
observable adverse effect level for ramucirumab was not established when administered to monkeys once a week for 39 weeks.   Nonclinical in vitro pharmacodyna mics studies demonstrated th at ramucirumab possesses high 
affinity for VEGF receptor 2 and that picomo lar concentrations of the antibody can inhibit 
binding of VEGF in vitro. Thus ramuciru mab potently inhibits VEGF-mediated VEFR2 
activating, signaling, and biologic effects in endothelial cells. These responses include cell 
migration, proliferation, and survival. Pharmaco logical proof-of principle experiments that 
validated targeting VEGFR2 as an antiangioge nic strategy depended on the use of a surrogate 
antibody, DC101.   The preclinical pharmacodynamics da ta demonstrated that ramuci rumab binds specifically and 
with high affinity to human VEGFR2, and not to  murine VEGFR2 or the related human VEGF 
receptors, VEGF receptor 1 and VEGF Receptor 3. Additionally, ramucirumab is capable of 
inhibiting the relevant in vitro biological co nsequences of VEGF stimulated activation of 
VEGFR2. The antiangiogenic and antitumor e ffects observed in mice treated with DC101 
provide the basis to anticipate pot ent antiangiogenic effects of ra mucirumab in human cancers.   
 Clinical Pharmacology  Serum ramucirumab concentrations were determined  using either an original bioanalytical assay 
or a modified bioanalytical assay. The original PK  assay was modified and validated to meet the 
industry bioanalytical assay standards. Only data  using the modified as say are considered the 
primary source for ramucirumab PK ch aracterization and are presented.  
 For gastric cancer, trough concentr ations (or minimum concentrations) were collected in both the  
Phase 2 and 3 studies for the REGARD and RAINBOW clinical tr ials. Using the dosing regimen 
of ramucirumab 8 mg/k g every 2 weeks the observed min imum concentration values were 
similar between both REGARD and RAINBOW. The mean observed trough values were 
DSSUR[LPDWHO\»ùJP/DQGDSSUR[L PDWHO\WR»ùJP/EHIRUH WKHIRXUWKDQGVHYHQWKGRVHV
respectively.   In a pooled analysis of 11 studies involving 1639 patients across multiple cancers revealed the 
volume of distribution at  steady state (Vm) and terminal half life we re 0.0147 L/h (30.0%) and 
5.4L (15.0%) and 14 days (20.0%) resp ectively. Results from this po oled analysis indicate that 
the PK of ramucirumab followi ng 8 and 10 mg/kg dose administrat ions were linear and time 
independent. Covariate analysis indicate that ramucirumab is not affected by body weight, sex, 
age, serum albumin, race, hepati c status, and renal function. 
 Two dedicated studies were conduced to asse ss the effect of concomitant ramucirumab 
administration on the PK of paclitaxel and doc etaxel. In study 14T-IE-J VCA was demonstrated 
that concomitant administration of ramuciruma b had no effect on the dose normalized AUC and 
Cmax of paclitaxel. Similarly in study 14T-IE-JVCB dose normalized AUC and Cmax of 
irinotecan and SN-38 in cycle 2 were similar to  those when FOLFIRI wa s administered alone in 
cycle 1, which suggests that concominant admini stration of ramucirumab is unlikely to impact 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 19 the PK of irinotecan and its active metabolite SN-39. In study 14T-IE-JVCC the dose-normalized 
AUC and Cmax of docetaxel were similar whethe r docetaxel was administe red with or without 
ramucirumab, which suggests that concominant administr ation of ramuciruma b is unlikely to 
impact the PK of docetaxel.   Safety Profile  Weekly doses of ramucirumab ra nging from 2 to 16mg/kg were evaluated in the Phase 1 study 
JVBM. An MTD for weekly dosing was identified as 13 mg/kg. Every-2-week (6 to 10 mg/kg) 
and every-3-week (15 to 20mg/kg) dose regimens  were evaluated in an additional dose ranging 
study (Study JVBN). All dose re gimens in study JVBN were well tolerated and no MTD was 
identified in this study.  REGARD demonstrated a well-toler ated safety profile in the ga stric cancer monotherapy setting. 
Due to the low incidence of hypertension and neut ropenia, no safety-exp osure relationship was 
identified.  In RAINBOW, the overall safety profile was al so considered management, although increasing 
ramucirumab exposure was corre lated with increased incide nce of Grade 3 or greater 
hypertension, neutropenia, and le ukopenia. Of note, there were no Grade 4 or 5 hypertension 
events in RAINBOW. Hypertension was ma naged primarily by the use of standard 
antihypertensive medication, and th e association of neutropenia with ramicurmab exposure does 
not appear to translate to an increased risk of febrile neutropenia with higher ramucirmab 
exposure.  Laboratory Toxicities  In study 14T-MC-JVBT(ramucirumab and FOLFOX) th e overall safety profile for ramucirumab 
revealed the most common G UDGH¬ï$(UHSRU ted regardless of causality was: 
a. Neutropenia 22 patients (26.8%) in ramucirumab arm vs 29 patients (36.3%) in placebo 
arm 
b. Fatigue 15 patients (18.3%) in ramucirumab ar m vs 12 patients (15.0%) in placebo arm 
c. Neuropathy 7 patients (8.5%) in ramucirumab arm vs 9 patients (11.3%) in placebo arm 
22 patients (26.8%) in ramu cirumab arm vs 29 patients (36.3%) in placebo arm 
 In study 14T-IE-JVBD (REGARD) WKHPRVWFRPPRQ*UDGH¬ï  was: 
d. Hypertension 7.6% in ramuciruma b arm vs 2.6% in placebo arm 
 In study 14T-IE-JVBE (RAINBOW) WKHPRVWFRPPRQ*UDGH¬ïZDV  
e. Fatigue  11.9% in ramucirumab arm vs 5.5% in placebo arm 
f. Neutropenia 40.7% in ramucirumab arm vs 18.8% in placebo arm 
g. Leukopenia 17.4%% in ramucirumab ar m vs  6.7% in placebo arm 
h. Hypertension 14.1% in ramucirumab arm vs 2.4% in placebo arm 
 Clinical Efficacy  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 20 Several factors provided rationale  for further clinical development of ramucirumab in gastric 
cancer; these include co ntribution of angiogenesis to cance r pathogenesis, and preclinical 
evaluations of the rat antibody to murine VE GF-R2, DC101. Ramucirumab does not cross react 
with the murine VEGF-R2, and for this re ason DC101 was used in murine models, and 
preliminary evidence of potential activity of othe r antiangiogenic agents in gastric cancer [35, 
36].   Clinical activity was seen early in the development of ramucirumab. In Phase 1 studies, ramucirumab was generally well tolerated and e xhibited preliminary evid ence of anti-tumor 
activity in patients with solid tumors. The ma ximum tolerated dose (MTD) of ramucirumab was 
identified to be 13 mg/kg when given once w eekly in the phase 1 dose-escalation study, Study 
14T-IE-JVBM (JVBM). Preliminary activity was obs erved across a range of doses, including the 
2-mg/kg weekly dose. Every-2-week (6 to 10 mg /kg) and every-3-week (15 to 20 mg/kg) dose 
regimens were evaluated in an additional dose-ranging st udy, 14T-IE-JVBN (JVBN). No MTD 
was identified for every-2-week or every-3-week  dosing; all dose regimens  were well tolerated, 
and preliminary evidence of clinical efficacy  was observed across a range of dose/schedule 
cohorts  [7].  
 Two dose regiments, 8 mg/kg every 2 weeks and 10 mg/kg were selected in the subsequent 
phase 2 and phase 3 studies. The ramucirumab do se of 8 mg/kg every 2 weeks has demonstrated 
a statistically significant and clin ically meaningful benefit in OS  in the phase 3 REGARD study: 
ramucirumab plus BSC vs placebo plus BSC with  advanced gastric canc er. Median OS was 5.2 
PRQWKVLQWKHUDPXFLUXPDEDUP YHUVXVPRQWKVLQWKHSODFHER DUP+D]DUGUDWLR 
FRQILGHQFHLQWHUYDO> &,@S 5DPX cirumab was well tolerated in this 
patient population with similar ra tes for most adverse events (AEs) between the ramucirumab 
and placebo arms. Rates of hyperten sion were higher in the ramuci rumab arm than in the placebo 
arm (38 [16%] vs 9 [8%]), wher eas rates of other AEs were mo stly similar between arms (223 
[94%] vs 101 [88%]). Five (2%) deaths in the ramucirumab arm and 2 (2 %) in the placebo arm 
were considered to be related to study drug. Based on this benefit, ramucirumab monotherapy 
was approved as a second line treatmen t for metastatic gastric cancer.   
 The approval of ramucirumab in combination with pa clitaxel in patients with  advanced gastric or 
GEJ cancer whose disease has progressed af ter prior platinum/fl uoropyrimidine-based 
chemotherapy was based on the randomized RAINBOW Phase 3 study [8]. The primary 
endpoint of OS was met; median  OS was 9.63 months on the ramu cirumab plus paclitaxel arm 
FRPSDUHGZLWKRQWKHSODFHERSOXVSDFOLWD[HODUP+5  &,
S *UDGH¬ï$(VRFFXUULQJLQ!RISDWLHQWVRQWKHUDP XFLrumab plus paclitaxel arm 
were: neutropenia (40.7% ramuciru mab plus paclitaxel arm; 18.8% placebo plus paclitaxel arm), 
leukopenia (17.4% vs 6.7%), hypertension (14.1% vs 2.4%), anemia (9.2% vs 10.3%), fatigue 
(7.0% vs 4.0%), abdominal pain (5.5% vs 3.3 %), and asthenia (5.5%  vs 3.3%). Febrile 
neutropenia was reported in 3.1% in the ramucirumab plus paclit axel arm and 2.4% placebo plus 
paclitaxel arm.   A placebo-controlled, double-blind phase 2 study , 14T-MC-JVBT (JVBT), of ramucirumab in 
combination with mFOLFOX-6 as first line th erapy for advanced adenocarcinoma of the 
HVRSKDJXV*(-RUVWRPDFK1  VKRZHGQRLPSURYHPHQWLQWKH primary endpoint of 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 21 progression-free survival. Median PFS was 6.4 mont hs for the ramucirumab arm vs 6.7 months 
for the placebo arm VWUDWLILHG+5 &,S RUWKHVHFR QGDU\26
HQGSRLQWPHGLDQ26ZDVPRQW KVYVPRQWKVVWUDWLILHG +5 &,
S EXWGLG  lead to improved PFS rate at 3 mont hs (89.0% versus 75.3%) and an improved 
GLVHDVHFRQWUROUDWH'&5 YVS 7KHPDMRUL W\RISDWLHQWV had a primary 
tumor location involving the GEJ/ cardia/esophagus (76.8%), with nearly half of the patients 
(47.6%) with a primary tumor lo cation of esophagus. Progression-fr ee survival was similar for 
all subgroups pairings with the exception of primary tumor location. In a preplanned subgroup 
analysis, an improvement in PFS (as assessed by HR) was observed for ra mucirumab in patients 
with a primary tumor location of gastric/GE J/cardia (median PFS was 8.7 months for the 
UDPXFLUXPDEDUPYVPRQWKVLQWKHSODFHERDUP+5 FRPS DUHGWRSDWLHQWVZLWKD
primary tumor locat LRQRIHVRSKDJXVPHGLDQ3)6ZD VPRQWKVYVPRQWKV+5  $
higher rate of discontinuation fro m study treatment for reasons other than progressive disease 
(PD) in the ramucirumab arm compared with  the placebo arm was obs erved (50% vs 19%), 
which led to lower study drug e xposure in the experimental arm.  These observations may have 
had a negative impact on the results of th e PFS assessment of the entire study population. 
Overall, the safety profile for ramucirumab in this study was c onsistent with the known safety 
SURILOHRIUDPXFLUXPDE7KHPR VWFRPPRQ¬ï$(E\FRQVROLGDWHG $(UHSRUWHGZDV
neutropenia (26.8% ramucirumab arm vs 36.3% placebo arm). Fatigue (18.3% in the 
ramucirumab arm vs 15.0% in the placebo arm) and neuropathy (8.5% vs 11.3%) were the most 
FRPPRQ*UDGH¬ï$(VE\FRQVROLGDW HGWHUPUHSRUWHGDWDVLPLO DUIUHTXHQF\LQHDFKDUP7KH
following treatment-emergent adverse events (T EAEs) (by consolidated term) were reported 
PRUHIUHTXHQWO\¬ïJUHDWHU LQWKHUDPXFLUXPDEDUPWKDQLQ the placebo arm for 
thrombocytopenia (56.1% vs 38.8%), headache (23.2% vs 15.0%), hypokalemia (19.5% vs 
K\SRFDOFDHPLDYV DQGK\SRSKRVSKDWHPLD YV*UDGH¬ï
adverse events of special interest (AESIs) we re uncommon with the exception of hypertension 
(15.9% vs 3.8%).   More information about the known and expected benefits, risks, and reasonably anticipated AEs 
of ramucirumab are found in the Investigator‚Äôs Brochure (IB). Information on AEs expected to 
be related to ramucirumab may be  found in Section 7 (Development Core Safety Information) of 
the IB.   Ramucirumab has been approved by the US FDA as a single agent and in combination with 
paclitaxel for the treatment of patients with  advanced or metastatic, gastric or GEJ 
adenocarcinoma after fluoropyri midine- or platinum-contain ing chemotherapy (CYRAMZA 
package insert [PI].  The approval of ramucirumab as a single agen t was based on clinical efficacy and safety 
demonstrated in the randomized Phase 3 study, REGARD, which compared ramucirumab 
monotherapy with best supportive care in patients with advanced  gastric or GEJ adenocarcinoma 
whose disease had progressed afte r prior chemotherapy [7].   
 
In both the REGARD and RAINBO W trials, which were conducte d in the sec ond-line setting, 
ramucirumab was administered at a dose of 8mg/kg every 2 weeks (REGARD), and 8mg/kg on 
Day 1 and Day 15 using a 28-day schedule (RAI NBOW). In summary, the dosing regimen of 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 22 8mg/kg every 2 weeks is anticipated  to produce an acceptable benefit- risk profile in patients with 
metastatic gastric or GEJ adenocar cinoma as second-line treatment.  
 2.4 Rationale for the Combination of Olaparib and Ramucirumab 
 The process of DNA damage repair is complex, and additional altera tions beyond BRCA 1 and 2 
play a role in sensitivity to PARP inhibition. Th is has led to the concept of ‚ÄúBRCAness,‚Äù and we 
propose that the BROCA-HR panel can help identif y patients with the BRCAness phenotype in 
addition the more typical BRCA mutations. Preclinical work ha s shown that hypoxia may induce 
BRCAness, which can potentially be taken adva ntage of through the combined effects of 
VEGF/VEGF receptor (VEGFR ) and PARP inhibition.  
 Hypoxia has been shown to down regulate BRCA 1 expression through promoter modification 
by E2F4 complexes, which result s in decreased homologous repa ir in human cancer cell lines 
[37-39]. Subsequent work has shown that ge ne silencing of BRCA 1 can occur through 
epigenetic modification by H3K9 methylation of the BRCA 1 promoter, which is potentiated 
under hypoxic conditions [38]. These modifications result in geneti c instability, as cells then 
must rely on non-homologous DNA repair, which is more error prone. Similar findings have has 
also been reported for RAD51, another gene involved in the homologous repair pathway  [38, 40-
42].   As expected the exact opposite changes we re seen in VEGF expression under hypoxic 
conditions, which further supports  the potential synergy for PA RP and VEGF/VEGFR inhibition 
[38]. Data also exists that PARP inhibitors themselves likely inhibit tumor angiogenesis [43]. 
The argument for synergy was strengthened by evidence in cancer cell lines that revealed 
increased lethality with PARP inhibitors in  hypoxic conditions as compared to normoxic 
conditions [44]. Subsequently, VE GFR3 inhibition in ovarian cell lines has also been shown to 
result in reduced BRCA expression [45].   Based on these pre-clinical observations, a phase  2 trial comparing olaparib and cediranib to 
olaparib alone for metastatic ovarian cancer wa s recently completed. Significant improvement in 
progression-free survival was seen with the co mbination of cediranib and olaparib, and the 
benefit was observed for both BRCA mutated an d non-BRCA mutated individuals [46]. A phase 
3 study is currently ongoing to  confirm these findings.  
 These pre-clinical and clinical observations  of synergy between PARP and angiogenesis 
inhibition in BRCA-deficient tumo rs provide rationale for combin ing olaparib with ramucirumab 
in tumors characterized by de fective homologous DNA repair path way. Ramucirumab is a fully 
humanized IgG1 monoclonal antibody that binds  to VEGFR-2 and blocks VEGF-A, VEGF-C, 
and VEGF-D binding and receptor-mediated path way activation. Ramucirumab is approved for 
second-line therapy in gastroes ophageal adenocarcinoma.  In th is setting ramucirumab is well 
tolerated and has been shown to significantly extend progression-fr ee survival compared to best 
supportive care.   As noted above, the olaparib and cediranib combination resulted in high response rates 
regardless of the presence of BRCA mutations. Based on this we anticipate responses in both 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 23 biomarker positive and negative cohorts given the proposed synergy with this combination 
therapy. Thus, we propose an open-label single arm study of olaparib in combination with 
ramucirumab for metastatic gastric adenocarcino mas with the use of the BROCA-HR integrated 
biomarker, which is described in further detail below in section 2.5.1 . 
 
2.5  Correlative Studies Background 
 2.5.1 BROCA-HR Panel 
Aim: To determine whether mutations in HRD ge nes confer sensitivity to ramucirumab and 
olaparib. 
 BRCA1 and BRCA2 (BRCA1/2 ) are tumor suppressor genes, in which inherited loss-of-function 
mutations confer a high lifetime risk  of breast and ovarian carcinoma. BRCA1/2  are key 
components of the BRCA-Fanconi anemia (FA) pathway, which is critical to homologous 
combination-mediated DNA repair. Other genes in this pathway ( BRIP1/FANCJ, 
PALB2/FANCN, RAD51C/FANCO, RAD51D ) also contribute to hereditary breast and ovarian 
cancer [47-51], and as our sequenc ing efforts have increased mutati ons in these same genes have 
been recognized in other cancers, including ga stric cancer. The Cancer  Genome Atlas Network 
(TCGA) suggested that up to half of serous  ovarian carcinomas have  homologous recombination 
defects (HRD), but that estimate was based on a variety of molecula r findings, many with 
uncertain impact on DNA repair fu nction[52]. PARP inhibitors (P ARPi) demonstrate synthetic 
lethality in cells with HRD, including cells deficient in BRCA1/2 [21, 53] . Recurrent ovarian 
carcinomas in BRCA1/2  mutation carriers have an approximate 40% response rate to PARPi and 
also have an increased response to pla tinum-based chemotherapy [54]. Importantly, 
approximately 25% of serous ovari an cancers that are wildtype for BRCA1/2  also respond to 
PARPi [27].  Germline BRCA1/2 mutations are the prototype molecular alterations that confer HRD [21, 53]. 
BRCA1 and BRCA2  somatic mutation occur in approximate ly 6% of ovarian cancer cases and 
also appear to confer sensitivity to PARPi [ 55]. Of note, PARPi also selectively kill cells in vitro  
that are deficient in ot her homologous recombina tion (HR) genes including RAD51D, NBN, 
ATM, and CHEK2 [47, 56] .  Germline and somatic mutations in BRCA1/2  and other BRCA-FA 
genes in ovarian carcinomas are associated with improved respons e to primary platinum therapy 
and longer overall survival [57]. Germline a nd somatic BRCA-FA mutations are not limited to 
high-grade serous ovarian carcinom as, but can be found in all hist ological sub-types with the 
exception of mucinous carcinomas [57].   In order to respond to a PARPi, can cer cells need to be deficient in  HR but also proficient in the 
alternative error prone non-homol ogous end joining (NHEJ) DNA repair pathway [58, 59]. Thus, 
loss of HR is not, by itself, sufficient for PARP i sensitivity, and an accur ate predictor of PARPi 
responsiveness could require as sessment of many component s of both the HR and NHEJ 
pathways. A more efficient assay, which would not require a prior knowle dge of the critical 
elements in these DNA repair pathways, woul d instead measure DNA repair capacity. Recent 
evidence suggests that BRCA1/2  deficient cancers exhibit gl obal DNA alterations termed 
‚Äúgenomic scarring‚Äù that are cons istent with their reliance on the NHEJ pathway [60-62]. This 
genomic scar could serve as a downstream functiona l output to measure DNA repair capacity, 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 24 indicative of both HR deficiency and NHEJ profic iency. Therefore, mutations in NHEJ and other 
pathways that could affect HR as well as genomi c scarring will also be evaluated as exploratory 
biomarkers.    Relevance  
 
The marked susceptibility of patients with BRCA-mutated cancers has validated germline BRCA 
mutations as a predictive biom arker for PARPi response [63]. Other mechanisms of HRD may 
be a functional biomarker for response to DNA damaging agents and PARPi. Thus, it is 
important to identify the subset  of patients have germline or somatic mutations in HRD genes 
and to examine their potential as predictive bi omarkers. Additional expl oratory biomarkers for 
HRD will include BRCA1  methylation, BRCA1  protein expression, and genomic scarring. We 
hypothesize that the BROCA-HR test will identify subsets of gastri c cancer patients with HRD, 
and may yield biomarkers with potential to guide  administration of this combination regimen. 
Preliminary Data 
BROCA-HR and genomic scarring 
BROCA is a targeted capture and massively pa rallel sequencing assay that is capable of 
identifying all classes of mu tations including gene rearrange ments [51, 64]. Using BROCA, 
Walsh et al demonstrated that  nearly one-fourth of women with ovarian carcinoma have 
germline loss of function mutations in at least 12 genes [51]. Furthermore,  most of these genes 
are in the BRCA-FA pathway. After BRCA1/2 , the most common genes mutated in women with 
ovarian cancer are BRIP1 (FANCJ), RAD51D, RAD51C (FANCO), and PALB2 (FANCN) [51, 
65].  Pennington et al applied BROCA to dete ct somatic mutations in tumor DNA from 363 
women with ovarian carcinoma. Combining germline and somatic mutations increased the fraction of cases identified with HRD to 31%, in cluding 23% with germline  and 9% with somatic 
mutations in FA/HR genes (and 1%  with both somatic and germline  mutations). The presence of 
either a germline or somatic FA/HR mutation is highly predictive of an improved primary response to platinum chemotherapy (p <0.0005) and longer overall survival (p  3HQQLQJWRQ
Swisher et al manuscript in progress). Germline  and somatic loss of function mutations were 
identified in all of the 13 FA/HR genes evaluated.  
Dr. Swisher‚Äôs laboratory has developed a new version of BROCA (BROCA-HR) that includes 
many additional DNA repair genes (84 total gene s), and 3000 single nucl eotide polymorphisms 
(SNPs). Similar sequenci ng accuracy and sensitivity sequenci ng DNA is obtained from formalin 
fixed paraffin embedded (FFPE), fresh blood a nd flash frozen specimens. BROCA-HR includes 
genes that are targets of both somatic and germline mutations . The BROCA-HR includes genes 
that regulate HR or NHEJ that , if mutated, could mediate re sistance to PARPi such as 
TP53BP1[66-68]  . The BROCA design is flexible and can be altered to incl ude any genes of 
research interest. The current design for BROCA-HR includes the following genes: 
 
BROCA-HR gene list (n=84)  
a. FA-BRCA HR pathway: ATM, ATR, BABAM1, BAP1, BARD1, BLM, BRCA1, BRCA2 
(FANCD1), BRIP1 (FANCJ), BRCC3, BRE, CHEK1, CHEK2, C11ORF30 (Emsy), ERCC1, 
ERCC4 (FANCQ), FAM175A (abraxas), FANCA, FANCB, FANCC, FANCD2,  FANCE, FANCF, FANCG (XRCCC9), FANCI, FANCL, FAMCM, GEN1, MRE11A, NBN, PALB2 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 25 (FANCO), RAD50, RAD51, RAD51C (FANCO), RA D51D, RBBP8 (CtIP), SLX4 (FANCP), 
UIMC1 (RAP80), XRCC2   
b. DNA mismatch repair MLH1, MSH2 ( and EPCAM), MSH6, PMS2   
c. Other DNA repair, surveillance genes, or modifier genes : CDK12 , CDH4 , HELQ, NEIL1, 
PPM1D, POLD1, POLE, POLQ, RIF1,TP53, ID 4, PARP1, PAXIP1, POLQ, RINT1, TP53BP1, 
USP28, WRN, XRCC3   
d. NER genes: ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, DDB1, XPA, XPC   
e. NHEJ genes: DCLRE1C, LIG4, PRKDC, TOBP1, XRCC4, XRCC5, XRCC6   
f. PI3K pathway: PTEN, PI3KCA  
 
2.5.2 Signature 3 
Aim: To determine whether a mutational signatur e characteristic of HRD confers sensitivity to 
ramucirumab and olaparib. 
 Evidence of defective homologous repair has be en reported in up to 12% of Gastric Tumors 
based on mutational signature an alysis. Alexandrov et al. ut ilized whole genome sequencing, 
followed by frequency of single base  substitutions to describe 21 distinct mutational signatures 
across 30 cancer types [69]. Cancer genomes generally carry a larg e number of somatic 
mutations, which for the most part are passe nger mutations [70]. However the frequency and 
distribution of these single ba se somatic mutations creates an imprint on the cancer genome, 
which can provide insight into th e pathogenesis of a particular tu mor [71]. For example, previous 
work has shown that C:G > A:T substitutions occur at higher frequencies for smoking-associated lung cancers [72]. Alexandrov‚Äôs work has taken th is a step further by an alyzing the frequencies 
of the 6 classes of base substitutions (C:G > A:T, C:G > G:C, C:G > T:A, T:A > A:T, T:A > 
C:G, T:A >G:C), which including the 5‚Äô and 3‚Äô  bases yields 96 possi ble combinations [69]. 
Whole exome sequencing data from more than  7000 tumors across 30 different cancer types 
were analyzed, which resulted in approximately  5 million somatic substi tutions as well as 
insertions and deletions.   After analyzing the frequency for the 96 possible combinations of base substitution it was noted 
that the number of somatic muta tions was variable amongst the di fferent cancer classes. This 
sequencing data allowed for the identification of  21 distinct mutational signatures across the 30 
cancer types through the applica tion of validated mathematical  algorithms [61, 69, 71]. This 
same mathematical modeling allows for the quan tification of each signature in a particular 
cancer genome as multiple signatures may contri bute to a different propo rtion of the mutations 
detected in a specific tumor [70, 71]. Helleday et  al. uses the analogy of a human face to help 
explain; the aggregate of all the somatic substitu tions would represent the face, while the facial 
features such as the eyes, nose,  and mouth would represent the extracted individual mutational 
signatures [71]. Some signatures we re notable for a very specific  base substitution, and others 
had a more homogenous distributi on of the 96 possible combina tions. While an individual 
signature can be seen across multi ple cancers, several signatures were discovered to have strong 
associations to specific cancer s and known driver muta tions [70]. In additi on to the distribution 
of the 96 somatic substitutions large insertions and deletions  were found to have a strong 
association with signature 3, which was strongly associated with BRCA1 and BRCA2 mutations 
[12, 69].   Signature 3 was observed in BRCA-mutated ovari an, breast, and pancre atic cancers and was 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 26 characterized by a homogenous distribution of ba se substitutions [69]. Additionally, increased 
numbers of indels with overlapp ing microhomologies at break points were identified in signature 
3 tumors [12, 69]. These findings st rongly suggest that signature 3 is  characteristic of a defective 
homologous DNA repair pathway. Subsequently, signa ture 3 has been described in 7-12% of 
gastric cancers with the major ity being non-BRCA mutated, which i ndicates a separate defect in 
the homologous DNA repair pathway or additiona l mechanisms of BRCA silencing [12]. This 
offers a novel biomarker to identify tumors with defects in the homologous double-stranded 
DNA repair pathway that may benefit from agents  targeting DNA repair pathways, specifically 
PARP inhibitors.  2.5.3 Immunoassay for poly-ADP-ribosylated (PAR) products:  
 Aim: To assess the effectiveness for olaparib and ramucirumab to  inhibit DNA repair in gastric 
carcinoma.  
 Because the product of the PARP enzyme is  poly-ADP-ribosylated (P AR) molecules, an 
immunoassay to quantify the amount of cellular PAR was developed as a clinical biomarker of 
PARP inhibition. Abbott Laboratories and the NC I-Frederick laboratorie s developed and cross-
validated a quantitative immunoassay for PAR [ 73].  The validated assay is a sandwich enzyme 
chemiluminescence immunoassay em ploying commercially obtaine d antibodies to PAR, and 
pure PAR as a standard. Assay dynamic range is  31 to 2000 pg/ml PAR, with a lower limit of 
quantitation of approximately 15 pg/ml PAR. Th e standard curve is linear throughout the range 
(with an adjusted R2 typically better than 0.98) . The assay uses high, midr ange, and low controls 
produced from the human melanoma line Colo8 29. Specimen handling was optimized for both 
PBMCs and tumor needle biopsies (18 ga), and ha rmonized for use with the same standards and 
controls. Specimens could be subjected to at leas t 3 freeze-thaw cycles wi thout a detectable loss 
of antigen binding. Assay precision was determined at both Abbott and the NCI-Frederick, to be 
better than 80% (estimated total imprecision at A bbott, 7% or less). Accuracy, as assessed by 
spike recovery of pure PAR into PBMC lysates,  was 100% +/- 20%. Assay dilution linearity was 
established for the Colo829 controls and tumor lysates, although deviations from linearity are 
observed in some tumor homogenates, and assay condi tions are controlled to compensate for that 
lack of linearity. The validate d assay was used to measure PA R levels in PBMCs of healthy 
donors, in animal models after administration of  a single and multiple  dosing of ABT-888, and 
will be used to measure PAR in PBMCs and tumor biopsies in the proposed protocol.  
2.5.4 Novel Genomic assay for ‚ÄúBRCAness‚Äù 
Aim: To build a genomic assay for identifying BRCAness in clinical samples to identify 
genomically-driven mechanisms of sensitivity to PARP inhibition. 
 Homologous recombination pathways have been  described in great detail, both in model 
organisms as well as in human cancer. However, despite the gr owing list of gene products 
responsible for or involved in hom ologous recombination-based repair , assays that reliably detect 
homologous recombination repair deficiency are still lacking. Therefore we will develop and 
perfect a sensitive DNA sequencing-based diagnostic of HR defects. Towards this goal, we will 
obtain whole-exome sequencing (WES) in various cancer that harbor mutations (germline or bialleleic somatic) in key DNA-repair genes.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 27 Samples will be obtained as part of this clinic al trial with the PARP inhibitor olaparib in 
gastroesophageal cancers. Exome wide patterns of break and repair in  HR-deficiency cancers 
will be defined and then we will attempt to packag e this in a compact targeted footprint, ideally 
less than 100kb, so that it can be adapted to mul tiplexed and cell free applic ations in the clinic. 
2.5.5 Factors demonstrating synthetic lethality wi th PARP inhibitors in gastric cancers. 
Aim 1: Investigate the role of key signal tran sduction pathways in regulating the DNA damage 
response pathway in gastric cancer cell line models. Aim 2: Unbiased iden tification of modifier s of responsiveness to  PARP inhibitors.  
Aim 3: Test effects of PARP i nhibitors alone or in combinatio n with other agents (based on 
results of Aims 1 and 2) in pa tient-derived xe nograft models. 
 It has become clear that signaling through onc ogenic pathways result  in activation of DNA 
damage checkpoint response pathways. For exampl e, acute expression of  oncogenic RAS results 
in activation of DNA damage response (DDR) pa thways, which is mediated by the ATR protein 
kinase and checkpoint kinases, CHK 1/2 [74, 75]. In agreement with this, inhibition of CK1 
activation results in enhanced  sensitivity to DNA-damaging cy totoxic agents [76]. Emerging 
evidence demonstrates that components of th e DNA damage checkpoint response are regulated 
through RAS effector pathways. In particular the PI3 kinase pathway has been demonstrated to 
regulate ATM activity. This effect  was enhanced by dual-inhibition of MEK and PI3 kinase in a 
melanoma model [77]. A possibl e role of the RAF-MEK-ERK pa thway in regulating DDR is 
further supported by our findings  demonstrating regulation of ATM protein expression by MEK 
as determined by Reverse-Phase Pr otein Analysis. In contrast to other cancers of the GI system, 
RAS oncogenes are rarely mutated in gastric cancer s and the role and regulation of specific DDR 
components through oncogenic signal transduction pr ocesses in this disease is poorly understood 
[14]. Therefore, in Aim 1, we will investigate th e role of key signal transduction pathways in 
regulating the DNA damage response pathway in gastric cancer cell line models. We will further 
seek to identify new markers of sensitivity to PA RP inhibition in gastric cancer in an unbiased 
fashion. Previous work performed by Dr. Ashw orth and colleagues identified such markers 
(including NBS1, TDG, XPA, and MK2 ) in breast cancer models using a multi-dimensional set of 
genomic and RNA expression data [78] . Since this correlative approach  is limited in its ability to 
predict causality, we will focus in Aim 2 on identifying so far unknown mediators of 
responsiveness to PARP inhibitors  in gastric cancer using a CRIS PRi screening approach. In aim 
3 we will test the effects of PARP inhibitors al one or in combination with other agents in PDX 
models. These models overcome limitation of  cell line derived in vivo models (loss of 
characteristics of the parent tumor, lack of clin ical annotation, and the limited representation of 
genotypes and subtypes) and closely resemble co nditions in human tumors. As part of an 
ongoing effort, Dr. Janjigian‚Äôs gr oup at Memorial Sloan Ketteri ng Cancer Center (MSKCC) has 
been able to implant 131 tumor samples from patients with esopha gogastric cancers in mice were 
so far, with 32 resulting in established PDX tu mors. Engraftment rates were 46% (orthotopic) 
and 26% (subcutaneous). Both normal and tu mor patient DNA from patients and PDX tumor 
DNA are being analyzed by next generation DNA sequencing. Data so  far demonstrate 
consistently that primary and PDX tumors exhibit similar hist ology, mutational profile, and copy 
number plots, suggesting that P DXs represent the tumo rs from which they are derived. To date, 
10 of the 32 PDXs have been analyzed with tumo rs clustering with the CIN subtype, 1 with the 
MSI subtype and 2 were genomically stable. We  are planning on obtaining fresh tumor biopsies 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 28 from selected patients with olaparib and ramucirumab to generate additional PDX models 
representing BRCAness genotypes.  2.5.6 T Cell receptor diversity. 
Aim: To define the T cell receptor diversity of gastric cancer patients with and without BRCAness.  
Humans generate T cells with a circulating divers ity of > 100 x 10
6. Persistence of antigen-
specific T cells is dependent on the presence of the specific antigens. If BRCAness is associated 
with a greater number of neoantig ens, then the repertoire of T cells within these patients should 
reflect this increased antigenic diversity. We therefore hypothesize that patients with the 
BRCAness phenotype will have a higher diversity  of T cell clonotypes. Moreover, if PARPi 
induced tumor cell lysis, this will lead to releas e of antigens, which could in turn be associated 
with treatment induced T cell repert oire diversification. To test this hypothesis, we will perform 
next-generation T-cell receptor sequencing on bot h fresh tumor samples and blood from patients 
with gastric cancer to assess both  of these compartments. T cells see antigen through their TCR, 
which is comprised of two subunits, ƒÆand a »ï. Each is generated by a VDJ recombination event 
resulting in a broad range of T cell cl ones with different specificities. The »ï subunit has greater 
clonal diversity. We have used next-gen eration sequencing of the T cell receptor »ï chain (TCR »ï) 
to define the diversity and frequency of T cell cl ones in the blood of cancer patients. The Fong 
lab has demonstrated that CTLA -4 blockade induces global rem odeling of the T cell repertoire 
[79]. We found that anti-CTLA -4 administration promotes active turnover in the T cell 
repertoire, which increases with sequential treatments, and a net result of increased repertoire diversity overall. These change s occurred both in na√Øve and non-na √Øve T cells, the latter of which 
includes the antigen-exper ienced effector T cell population. In terestingly, maintenance of high-
frequency clonotypes (greater than 1 in 1000) wa s associated with cl inical response and 
improved overall survival foll owing ipilimumab. We have sin ce sequenced blood from patients 
with localized prostate cancer, metastatic castr ation resistant prostate  cancer, or age-matched 
healthy men without cancer. We find  that men with prostate can cer have a significantly more 
diverse T cell repertoire (i.e. lowe r clonality index). This finding would indicate that cancer can 
induce the diversification of the pool of circulating T cell clon es in these patients. In this study, 
TCR diversity will be measured by the numbe r of unique TCR, the distribution of TCR 
frequency, and the Shannon‚Äôs diversity index [79]. We will also determin e through these studies 
whether the circulating T cell repertoire is reflective of the T cells within the tumor 
microenvironment. 
 
3. PATIENT SELECTION 
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 29 3.1 Inclusion Criteria 
3.1.1 The patient must have histologically c onfirmed, gastric carcinoma, including GEJ 
adenocarcinoma (patients with adenocarcinoma of the distal esophagus are eligible if the 
primary tumor involves the GEJ). 
3.1.2 The patient has metastatic disease or local ly recurrent, unresectable disease.  
3.1.3 The patient must have measurable disease by RECIST v1.1. Please see Section 11  for the 
definition of measurable disease. 
3.1.4 The patient must have experienced disease pr ogression during or w ithin 4 months after 
the last dose of chemotherapy for metastatic disease, during or within 6 months after the 
last dose of adjuvant chemothe rapy, or have been intolerant  of previous chemotherapy. 
3.1.5 The patient must have experienced disease progression or intolerance as outlined above 
after treatment with 1 or more prior chemotherapies. 
3.1.6 All previous treatments are acceptable as long as they did not contain bevacizumab, 
ramucirumab or PARP inhibitors. 
3.1.7 Elevation in tumor markers without radiograp hic evidence of disease progression is not 
satisfactory for progressi on on previous treatment. 
3.1.8 7KHSDWLHQWLV¬ï\HDUVRIDJH  
3.1.9 7KHSDWLHQWKDVDOLIHH[SHFWDQF\RI¬ï 6 weeks. 
3.1.10  ECOG performance status score of 0-1 (Karnofsky ¬ï60%). 
3.1.11  Patients must have normal organ and ma rrow function within 28 days prior to 
administration of study treat ment as defined below: 
 
 Hemoglobin ¬ï10 g/dL with no blood transfusi ons (packed red blood cells and 
platelet transfusions) in the past 28 days. 
 
 White blood cells (WBC) > 3 x 109/L 
 
 $EVROXWHQHXWURSKLOFRXQW$1&¬ï  1.5 109/L 
 
 3ODWHOHWFRXQW¬ï  100 X 109/L 
 
 No features suggestive of MDS/AML on peripheral blood smear or bone marrow 
biopsy, if clinically indicated. 
 
 Total bilirubin ¬î[WKHLQVWLWXWLRQDOXSSH UOLPLWRIQRUPDO8/1  
 
 AST (SGOT) / ALT (SGPT) ¬î 2.5 √ó institutional ULN unl ess liver metastases are 
present in which case they must be ¬î 5 x ULN 
 
 Calculated serum creatinine clearance ¬ï 60 mL/min/1.73 m2  
 
 Proteinuria with urinary protein ¬î on dipstick or routine urinalysis, or a 24-
hour urine collection for protein < 1000 mg of protein in 24 hours. 
 
 Coagulation parameters (INR, aPTT) ¬î1.25 x institutional limits, except where a 
lupus anti-coagulant has been confirmed or the patient is on warfarin. Patients on 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 30 full dose anticoaugulation must be on a stable dose for at least 14 days. If 
receiving warfarin, the patie nt must have an INR ¬î 3.0 without any evidence of 
active bleeding within 14 days prior to first dose of study treatment or a 
pathologic condition that car ries a high risk of bleedi ng (tumor involvement with 
major blood vessels or varicies).  
 
3.1.12  Postmenopausal or evidence of non-childbear ing status for women of childbearing 
potential a negative urine or serum pregnancy test within 28 days of study treatment and 
confirmed prior to treatment on day 1. Postmenopausal is defined as: 
 
Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments. 
 Luteinizing hormone (LH)and Follicle stimula ting hormone (FSH) levels in the post 
menopausal range for women under 50.  Radiation-induced oophorectomy with last menses > 1 year ago.  Chemotherapy-induced menopause with > 1 year interval since last menses. 
 Surgical sterilization (bilateral oophorectomy or hysterectomy). 
3.1.13  The effects of olaparib and ramucirumab on the developing fetus are unknown. For this 
reason, women of child-bearing potential and men must agree to use adequate 
contraception including hormona l, barrier, or abstinence. C ontraception must be started 
prior to study enrollment. Female patients of  childbearing potential must have a negative 
serum pregnancy test within 7 days prior to  treatment. Should a woman become pregnant 
or suspect she is pregnant while she or he r partner is participa ting in this study, she 
should inform her treating phys ician immediately. Both men and women treated or 
enrolled on this protocol must also agree to  use adequate contraception prior to the study, 
for the duration of the study pa rticipation, and for 3 months after completion of olaparib 
and ramucirumab administration. Male patien ts and their partners, who are sexually 
active and of childbearing potential, must agree to the use of two highly effective forms 
of contraception in combination , throughout the period of ta king study treatment and 
for 3 months after last dose of study dr ug(s) to prevent pregnancy in a partner.  
3.1.14  Ability to understand and the willingness to sign a written informed consent document. 
3.1.15  The patient must be willing to undergo a biopsy prior to treatment, an on treatment 
biopsy at week 16 is optional if felt to be safe in the opinion of the investigator.   
3.1.16  For inclusion into optional exploratory gene tic and biomarker rese arch, patients must 
fulfill the following criteria: 
x Provision of informed cons ent for genetic research 
x Provision of informed consen t for biomarker research 
If a patient declines to participate in the optional exploratory genetic research or the 
optional biomarker research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other parts of the study.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 31 3.1.17  Patients must be able to tolerate or al medications by m outh, and not have a 
gastrointestinal illness that woul d preclude absorption of olaparib. 
3.1.18  Adequately controlled blood pressure (BP) <140 mmHg (sys tolic) and <90 mmHg 
(diastolic) taken in the clinic  setting by a medical professi onal within 2 weeks prior to 
starting study. Patients with hypertension may be managed with up to a maximum of 3 
antihypertensive medications. A cardiologist or blood pressure  specialist must evaluate 
patients who are on 3 antihypertensive medi cations within 4 we eks of enrollment. 
3.1.19  Patients who have the following risk factors are considered to  be at increased risk for 
cardiac toxicity and must have documente d LVEF by Echocardiogram greater than 
institution‚Äôs lower limit of nor mal (or 55% if threshold for no rmal not otherwise specified 
by institutional guidelines) obtained within 3 months. 
x Prior treatment with anthracyclines 
x Prior treatment with trastuzumab 
x A New York Heart Association (NYHA) cl assification of II  controlled with 
treatment (See Appendix B ) 
x Prior central thoracic radiation ther apy (RT), including RT to the heart. 
x History of myocardial infa rction within 12 months (patients with history of 
myocardial infarction within 6 months are excluded) 
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 32 3.2 Exclusion Criteria 
3.2.1 Patients with untreated brain metastases are ex cluded from this clinic al trial because of 
their poor prognosis and because they often develop progressive neurologic dysfunction 
that would confound the evaluation of neurolog ic and other adverse events. A scan to 
confirm the absence of brain metastases is not required. The patient can receive a stable 
dose of corticosteroids before a nd during the study as long as these were started at least 4 
weeks prior to treatment. Patients with spinal  cord compression are also excluded unless 
considered to have received definitive treatmen t for this and evidence of clinically stable 
disease for 28 days. 
3.2.2 Patients who have not recovere d from adverse events due to  prior anti-cancer therapy 
(i.e., have residual toxicities > CTCAE Grad e 1 or baseline, with the exception of 
alopecia). 
3.2.3 Patients unable to swallow orally admin istered medication and patients with 
gastrointestinal disorders lik ely to interfere with absorp tion of the study medication. 
3.2.4 The patient has experienced any grade 3-4 gast rointestinal bleeding within 3 months prior 
to randomization. 
3.2.5 The patient has experienced any arterial thro mbotic events, includi ng but not limited to 
myocardial infarction, transient ischemic at tack, cerebrovascular accident, or unstable 
angina, within 6 months  prior to enrollment. 
3.2.6 The patient has an ongoing or active infecti on, symptomatic conges tive heart failure, 
unstable angina pectoris, symptomatic or  poorly controlled cardiac arrhythmia, 
uncontrolled thrombotic or hemorrhagic diso rder, or any other serious uncontrolled 
medical disorder in the opinion of the investigator. 
3.2.7 The patient has an ongoing or active psychiatri c illness or social situation that would 
limited compliance with  study requirements. 
3.2.8 Clinically significant peripheral vascular disease or vascular  disease (abdominal aortic 
aneurysm >5cm) or aortic dissection). If know n history of abdominal aortic aneurysm 
ZLWK¬ïFPLQGLDPHWHUDOORI WKHIROORZLQJPXVWEHPHW  
x An ultrasound within the last 6 months required to document that it is ¬î5cm 
x Patient must be asymptomatic from the aneurysm 
x Blood pressure must be well controlled as defined in this protocol (see section 6 ). 
3.2.9 The patient has uncontrolled or poorly contro lled hypertension despite standard medical 
management as defined in this protocol (see section 6 ). 
3.2.10  NYHA classification of III or IV.  
3.2.11  A resting EK *ZLWKD47&¬ï 70 msec detected on 2 or more time points within a 2 hour 
period or family history of long QT syndrome. If the EK *GHPRQVWUDWHV47&¬ï 70 
msec, the patient will only be eligible if a repeat EK *GHPRQVWUDWHV47&¬î  470 msec. 
3.2.12  History of hypertensive cr isis or hypertensive encepha lopathy within 3 years. 
3.2.13  Major surgery within 28 days of starti ng study treatment and patients must have 
recovered from any effect s of any major surgery.  
3.2.14  An open biopsy, non-healing wound, ulcer or sign ificant traumatic inju ry within 28 days 
prior to starting treatment (percutaneous, endobronchial, and endoscopic biopsies are 
allowed).  
3.2.15  The patient has received chemotherapy, radi otherapy (except for palliative reasons), 
immunotherapy, or targeted therapy for gastri c cancer within 3 w eeks of study treatment.  
3.2.16  The patient has received any investigationa l therapy within 4 weeks of enrollment. 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 33 3.2.17  The patient has received prior therapy w ith bevacizumab, ramucirumab or any PARP 
inhibitor, including olaparib. 
3.2.18  Patients must not have evidence of coagul opathy or bleeding diat hesis. Therapeutic 
anticoagulation for prior thromboembolic events  is permitted. The clinical indication for 
therapeutic anticoagulation must be clearly doc umented prior to enrollment and must be 
discussed with the PI. Due to risk of se rious bleeding with ramucirumab, patients on 
greater than or equal to 2 an ti-thrombotic agents, including bu t not limited to anti-platelet 
agents (NSAIDS/aspirin, clopidogrel), hepari n, low molecular weight  heparin, warfarin 
and a direct thrombin in hibitor will be excluded.  
3.2.19  The patient has elective or pl anned major surgery to be pe rformed during the course of 
the clinical trial.  
3.2.20  History of allergic reactions attributed to compounds of si milar chemical or biologic 
composition to olaparib and ramucirumab.  
3.2.21  Patients with a known hypersensitivity to olaparib  or any of the excipients of the product. 
3.2.22  Patients with a known hypersensitivity to  the combination/co mparator agent. 
3.2.23  Pregnant or breast feeding women are excluded from this study because olaparib and 
ramucirumab have the potential for teratogenic or abortifacient effects.  
3.2.24  Immunocompromised patients, this include s HIV-positive patients, because of the 
potential for interaction with antiretroviral therapy and ramucirumab and/or olaparib. In 
addition, these patients are at increased risk  of lethal infections when treated with 
marrow-suppressive therapy. 
3.2.25  Patients with a known history of Hepatitis B (defined as Hepatitis B surface antigen 
[HBsAg] reactive) or known ac tive Hepatitis C virus (defined as detectable HCV RNA) 
infection. Note: no testing for Hepatitis B a nd Hepatitis C is required unless mandated by 
local health authority.  
3.2.26  The patient has known and active alcohol or drug dependency. 
3.2.27  The patient has a concurrent active malignancy other than  treated non-melanoma skin 
cancers or in situ neoplasm. A patient with a prior history of ma lignancy is eligible, 
provided that they have been free of disease for ¬ï 5 years. 
3.2.28  Patients may not have featur es suggestive of myelodysplas tic syndrome (MDS) or acute 
myelogenous leukemia (AML) on peripheral bl ood smear or bone marrow biopsy, if 
clinically indicated. 
3.2.29
 Patients may not have had a prior allogeneic bone marrow transplant  or double umbilical 
cord blood transplantation (dUCBT).  
3.2.30  Patients may not have current signs and/or symptoms of bowel obstruction within 1 
month prior to starting study drugs, except if  it was a temporary incident (improved 
within <24 hr with medical management).  
3.2.31  History of hemoptysis w ithin the last 1 month. 
3.2.32  History of abdominal fistula,  intra-abdominal abscess, or  gastrointestinal perforation 
within the last 3 months. 
3.2.33  Dependency on IV hydration > 1 day per week within the screening period.  
3.2.34  Participants receiving any medica tions or substances that are strong inhibitors or inducers 
of CYP3A4/5 are ineligible. The required washout period prior to starting treatment is 2 weeks for CYP3A inhibitors, 3 weeks for CYP3A inducers, and 5 weeks for 
enzalutamide. Dihydropyridine calcium-channel blockers ar e permitted for management 
of hypertension.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 34 3.2.35  Whole blood transfusions in the last 120 da ys prior to entry to the study (packed red 
blood cells and platelet transfusions are accep table, for timing please refer to inclusion 
criteria 3.1.12). 
3.2.36  Involvement in the planning and/or conduct of the study  (applies to both AstraZeneca 
staff and/or staff at the study site). 
3.2.37  Previous enrollment in  the present study. 
3.2.38  Current use of natural herb products or ot her complementary alternative medications. If 
used previously, patients must have at leas t 1-week washout and mu st stop using them 
while participating in this study. 
  3.3 Inclusion of Women and Minorities 
 NIH policy requires that women and members of minority groups  and their subpopulations be 
included in all NIH-supported bi omedical and behavioral res earch projects involving NIH-
defined clinical research unless a clear and comp elling rationale and justif ication establishes to 
the satisfaction of the funding Inst itute & Center (IC) Director that inclusion is inappropriate 
with respect to the health of the subjects or th e purpose of the researc h.  Exclusion under other 
circumstances must be designated by the Dire ctor, NIH, upon the recommendation of an IC 
Director based on a compelling rationale and justif ication.  Cost is not an acceptable reason for 
exclusion except when the study would duplicat e data from other sources.  Women of 
childbearing potential should not be  routinely excluded from particip ation in clinical research.  
Please see http://grants.nih.gov/gran ts/funding/phs398/phs398.pdf . 
 
4. REGISTRATION PROCEDURES 
 4.1 Investigator and Research Asso ciate Registration with CTEP 
 Food and Drug Administration (FDA) regulations require IND sponsors to  select qualified 
investigators.  NCI policy requires all persons par ticipating in any NCI-sponsor ed clinical trial to 
register and renew their registra tion annually.  To register, all individuals must obtain a CTEP 
Identity and Access Management (IAM) account ( https://ctepcore.nci.nih.gov/iam ).  In addition, 
persons with a registration type of Investigator (IVR),  Non-Physician Inves tigator (NPIVR), or 
Associate Plus (AP) (i.e., clinical site staff re quiring write access to OPEN or RAVE or acting as 
a primary site contact) must  complete their annual regist ration using CTEP‚Äôs web-based 
Registration and Credential Repos itory (RCR) (https://ctepcore.nc i.nih.gov/rcr).  Documentation 
requirements per registration type are outlined in the table below. 
 
Documentation Required  IVR NPIV
R AP A 
FDA Form 1572 D D   
Financial Disclosure Form D D D  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 35 Documentation Required  IVR NPIV
R AP A 
NCI Biosketch (education, training, 
emplo yment, license, and certification) D D D  
HSP/GCP trainin g D D D  
Agent Shipment Form (if applicable) D    
CV (optional) D D D  
 
An active CTEP-IAM user account and appropria te RCR registration is required to access all 
CTEP and CTSU (Cancer Trials Su pport Unit) websites and applic ations.  In addition, IVRs and 
NPIVRs must list all clinical practice sites a nd IRBs covering their practice sites on the FDA 
Form 1572 in RCR to allow the following: 
x Added to a site roster 
x Assigned the treating, credit, consenting, or  drug shipment (IVR only) tasks in OPEN 
x Act as the site-protocol PI on the IRB approval 
 
Additional information can be f ound on the CTEP website at < 
https://ctep.cancer .gov/investigatorResources/default.htm  >.  For questions, please contact the 
RCR  Help Desk  by email at < RCRHelpDesk@nih.gov  mailto: >. 
 
4.2 Site Registration 
 This study is supported by the NCI Ca ncer Trials Support Unit (CTSU). 
 
Each investigator or group of i nvestigators at a clinical site must obtain IRB approval for this 
protocol and submit IRB approval and supporting documentation to the CTSU Regulatory Office 
before they can be approved to enroll patients.   Assignment of site re gistration status in the 
CTSU Regulatory Support System (R SS) uses extensive data to ma ke a determination of whether 
a site has fulfilled all regulatory criteria in cluding but not limited to the following:  
x An active Federal Wide Assurance (FWA) number 
x An active roster affiliation with the Lead  Network or a participating organization 
x A valid IRB approval 
x Compliance with all protoc ol specific requirements 
In addition, the site-protocol Pr incipal Investigator (PI) must meet the following criteria: 
x Active registration status 
x The IRB number of the site  IRB of record listed  on their Form FDA 1572 
x An active status on a participating roster at the registering site 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 36 Sites participating on the NCI CI RB initiative that are approv ed by the CIRB for this study are 
not required to submit IRB a pproval documentation to the CTSU  Regulatory Office. For sites 
using the CIRB, IRB approval info rmation is received from the CI RB and applied to the RSS in 
an automated process.  Signatory Institutions mu st submit a Study Specif ic Worksheet for Local 
Context (SSW) to the CIRB via IRBManager to i ndicate their intent to open the study locally.  
The CIRB‚Äôs approval of the SSW is then communi cated to the CTSU Regulatory Office.  In 
order for the SSW approval to be processed, th e Signatory Institution must inform the CTSU 
which CIRB-approved institutions aligned with the Signatory Institution are participating in the 
study. 
 
4.2.1 Downloading Regulatory Documents 
 
Site registration forms may be downloaded from the 10066  protocol page located on the 
CTSU Web site.  Permission to view and download this protocol  is restricted and is based 
on person and site roster data housed in the CT SU RSS.  To participate, Investigators and 
Associates must be associated with th e Corresponding or Participating protocol 
organization in the RSS.   
x Go to https://www.ctsu.org  and log in using your CTEP-IAM username and 
password. 
x Click on the Protocols tab in the upper left of your screen.  
x Either enter the protocol # in  the search field at the to p of the protocol tree, or 
x Click on the By Lead Organization fold er to expand, then select LAO-CT 018, 
and protocol #10066.  
x Click on LPO Documents, select the Site Registration documents link, and 
download and complete the forms provi ded.  (Note: For sites under the CIRB 
initiative, IRB data will load to RSS as described above.)  
4.2.2 Requirements For 10066 Site Registration: 
 
x IRB approval (For sites not particip ating via the NCI CIRB; local IRB 
documentation, an IRB-signed CTSU IRB Ce rtification Form, Protocol of Human 
Subjects Assurance Identification/IRB Ce rtification/Declaration of Exemption 
Form, or combination is accepted)  
4.2.3 Submitting Regulatory Documents 
 
Submit required forms and documents to the CTSU Regulatory Office, where they will be entered 
and tracked in the CTSU RSS.   
Regulatory Submission Portal: www.ctsu.org   (members‚Äô area) √Ü Regulatory Tab √ÜRegulatory 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 37 Submission  
When applicable, original documents should be mailed to: 
CTSU Regulatory Office 
1818 Market Street, Suite 3000 Philadelphia, PA 19103 
 
Institutions with patients waiting that are unable  to use the Portal should alert the CTSU 
Regulatory Office immediately at 1-866-651-2878 in  order to receive further instruction and 
support. 
 
4.2.4 Checking Site Registration Status 
 
You can verify your site re gistration status on the memb ers‚Äô section of the CTSU 
website.   
 
x Go to https://www.ctsu.org and log in to  the members‚Äô area using your CTEP-IAM 
username and password 
x Click on the Regulatory tab at  the top of your screen 
x Click on the Site Registration tab 
x Enter your 5-character CTEP Institution Code and click on Go 
 
Note: The status given only reflects comp liance with IRB documentation and institutional 
compliance with protocol-speci fic requirements as outlined by  the Lead Network. It does 
not reflect compliance with pr otocol requirements for indi viduals participating on the 
protocol or the enrolling invest igator‚Äôs status with the NCI or their affiliated networks. 
 
4.3 Patient Registration 
 4.3.1 OPEN / IWRS 
 
Patient enrollment will be fa cilitated using the Oncology Patient Enrollment Network 
(OPEN).  OPEN is a web-based registration syst em available to users on a 24/7 basis.  It 
is integrated with the CTSU Enterprise System  for regulatory and ro ster data interchange 
and with the Theradex Interactive Web Respons e System (IWRS) for retrieval of patient 
registration/randomization assignment.  Patient enrollment data entered by Registrars in 
OPEN / IWRS will automatically transfer to the NCI‚Äôs clinical data management system, 
Medidata Rave.  For trials with slot reservation requirement s, OPEN will connect to IWRS at enrollment 
initiation to check slot availa bility.  Registration staff s hould ensure that a slot is 
available and secured for the patient  before completing an enrollment.  
 The OPEN system will provide the site with a printable confirmati on of registration and 
treatment information.  Pl ease print this confirmati on for your records.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 38  
4.3.2 OPEN/IWRS User Requirements 
 
OPEN/IWRS users must meet the following requirements: 
x Have a valid CTEP-IAM account ( i.e., CTEP username and password). 
x To enroll patients or request slot rese rvations:  Be on an ETCTN Corresponding 
or Participating Organization roster with the role of Registrar. Registrars must 
hold a minimum of an AP registration type. 
x To approve slot reservati ons or access cohort manageme nt:  Be identified to 
Theradex as the ‚ÄúClien t Admin‚Äù for the study.  
x Have regulatory approval for the co nduct of the study at their site. 
 
Prior to accessing OPEN/IWRS, site staff should verify the following: 
x All eligibility criteria have been met w ithin the protocol st ated timeframes.   
x If applicable, all patients have signed an appropriate  consent form and HIPAA 
authorization form. 
 4.3.3 OPEN/IWRS Questions? 
 
Further instructional inform ation on OPEN is provided on the OPEN tab of the CTSU 
website at https://www.ctsu.org  or at https://open.ctsu.org .  For any additional questions 
contact the CTSU Help Desk at 1-888-823-5923 or ctsucontact@westat.com .  
 
Theradex has developed a Slot Reservations  and Cohort Management User Guide, which 
is available on the Theradex website http://www.theradex.com/clinic alTechnologies/?National-
Cancer-Institute-NCI-11 . This link to the Theradex website  is also on the CTSU website 
OPEN tab. For questions about the use of IWRS for slot reservations, contact the 
Theradex Helpdesk at 609-619-7802 or  Theradex main number 609-799-7580; 
CTMSSupport@theradex.com . 
 
4.4 General Guidelines 
 Following registration, patients should begin prot ocol treatment within 10 days. Issues that 
would cause treatment delays should be discusse d with the Principal Investigator.  If a patient 
does not receive protocol thera py following registration, the pa tient‚Äôs registration on the study 
may be canceled.  The Study Coordinator should be  notified of cancellations as soon as possible. 
 5. TREATMENT PLAN 
 5.1 Agent Administration 
 Treatment will be administered on an outpatient basis.  Reported adverse events and potential 
risks are described in Section 7 .  Appropriate dose modifi cations are described in Section 6 .  No 
investigational or commercial agents or ther apies other than those described below may be 
administered with the intent to treat the patient's malignancy. 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 39  
Dose Escalation Schedule 
Dose Level Dose* 
Olaparib 
(mg) Ramucirumab 
(mg/kg) N/A 
-2 100 mg twice daily, 
orally (tablet) 8 mg/kg every 2 
weeks, intravenous  
-1 150 mg twice daily, 
orally (tablet) 8 mg/kg every 2 
weeks, intravenous  
1 (starting dose) 200 mg twice daily, 
orally (tablet) 8 mg/kg every 2 
weeks, intravenous  
2 300 mg twice daily, 
orally (tablet) 8 mg/kg every 2 
weeks, intravenous  
 
 
Regimen Description 
Agent Premedications; 
Precautions Dose Route Schedule Cycle 
Length 
Olaparib Swallow whole, do 
not chew or crush. Take AM and PM dose 12 hours apart, doses can be taken with or without food. The patient will be requested to maintain a medication diary of each dose medication. This medication diary will be returned to clinic staff at the end of each course (Appendix C ). 
 Up to 300mg 
(tablet formulation) Oral Twice 
daily 
14 days  
(2 weeks)    
Ramucirumab  Intravenous 
antihistamine (H1 receptor antagonist); for grade 1-2 infusion reactions dexamethasone and acetaminophen are added. 8mg/kg Through 
intravenous line Day 1 
every 2 weeks  
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 40  
5.1.1 CTEP IND Agent(s)  
 
5.1.2 Olaparib 
 
For the phase 1 dose escalation, olaparib dosing will be increased in a 3+3 dose 
escalation with doses of 200mg and 300mg twic e daily (See 6.0). In phase 2, after biopsy 
for the BROCA-HR panel patients will receiv e olaparib dose TBD within 14 days of 
biopsy. The olaparib will be gi ven at the appropriate dose le vel orally continuously twice 
daily, with doses taken at the same times ea ch day 12 hours apart. The olaparib tablets 
can be taken with or without food and shoul d be swallowed whole with water and never 
chewed, crushed, dissolved or divided. The olapar ib will be dispensed at the start of each 
cycle. Patients will be provided with a pill  diary. Patients will be  advised to avoid 
grapefruit juice while on st udy due to P450 interactions.  
 If difficulty tolerating oral me dications and vomiting occurs  the vomited dose should not 
be made up. Should an enrolled patient miss a scheduled dose the patient will be allowed 
to take the dose up to a maximum of 2 hours after that normally scheduled dose time, but 
if greater than 2 hours the patient should wait until their next allotted dose time. 
  Dose Reductions 
For guidance on dose reductions for management of AEs refer to section 6 .  
 
Renal Impairment If subsequent to study entry and while still on study therapy, a pati ent‚Äôs estimated CrCl 
IDOOVEHORZWKHWKUHVKROGIR UVWXG\LQFOXVL RQ¬ïPOPLQ 1.73 m
2), retesting should be 
performed promptly. In the instances wh ere the CrCl falls to between 31 and 50 
ml/min/1.73 m2 the olaparib dose will be reduced by one dose level (see section 6 ).  
 
5.1.3 Ramucirumab 
 
For both the phase 1 dose escalation and the phase 2, ramucirumab will be dosed at 8 
mg/kg on day 1 of each 2-week cycle. Ramuciru mab at the appropriate dose level will be 
delivered intravenously over 60 minutes (+/- 15 minutes) through either  a peripheral IV 
or central line. (Please refer to the ramucirumab package insert). 
 5.1.4 Premedication for Ramucirumab 
 Premedication is required for all patients prior to each infusion of ramucirumab. The 
recommended agents are hista mine (H1) antagonist s, such as diphenhydramine chloride. 
Additional premedication may be  given at the inve stigator‚Äôs discretion (please refer to 
ramucirumab package insert). All premedicati on administered must be  documented in the 
case report forms.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 41 5.1.5 Other Modality or Procedures 
 N/A 
 5.2  Dose Escalation 
 A 3+3 dose escalation scheme will be used for olap arib in phase 1 with a plan to only escalate by 
one dose level. A definition of adverse events is included at the bottom of this section. 
Management and dose modifications  associated with adverse ev ents are outlined further in 
Section 6 . With a 3+3 dose escalation design if no dos e-limiting toxicity (DLT) is observed a 
total of 9 patients would be enrolled. However,  if DLTs are observed during dose escalation 9-12 
patients could be enrolled dependi ng on whether DLTs were seen at one or both dose levels. If 2 
or more DLTs are observed in the first cohort the study would de-escalate the dose. There are 2 
dose levels below the starting dose (dose level -1  and dose level -2), and this could take a 
maximum of 18 patients if DLTs were seen at all dose levels. A schema for the 3+3 design is 
provided below, and the starting dose of olap arib is 200 mg twice daily as outlined in Section 6.  
The maximum dose of olaparib tested in this st udy will be an increase of one dose level to 
olaparib 300 mg twice daily, which is the maximu m tolerated dose per the olaparib IB. Even if 
no DLTs are observed, the dose of olaparib wi ll not be increased be yond 300 mg twice daily 
(dose level 2) in this study.   The DLT evaluation period is 28 days and dose escalation will proceed according to the 
following scheme and DLT definitions are define d below. A patient is evaluable for DLT if 
he/she receives 2 doses (100%) of  ramucirumab and 45 doses (80%) of olaparib within the first 
28 days OR he/she experiences a DLT. If this minimum amount of treatment is not reached due 
to treatment related AEs, this is considered a DLT. However, patients who fail to achieve this minimum amount of treatment  due to reasons that are clearly unr elated to treatment (e.g. error on 
part of patient or outside physician) would be replaced. 
 Due to the non-overlapping toxicity profiles of olaparib and ramucirumab the likelihood for DLT 
is estimated at 15 to 25%. The doses of olaparib and ramuciru mab will not be increased beyond 
the previously established maxima lly tolerated doses as described in the respective investigator 
brochures. In the REGARD study, which evaluated ramucirumab mono therapy in gastric cancer, 
it was well tolerated with no increase in  ¬ïgrade 3 AEs as compared to placebo. Similarly in 
Study 19, which evaluated olaparib  monotherapy in ovarian cancer  it was well tolerated with ¬ï 
grade 3 AEs 15% higher than the placebo group. 
 
Number of Patients with DLT at a 
Given Dose Level Escalation Decision Rule 
0 out of 3 Enter 3 patients at the next dose level. The dose of 
olaparib will not be increased beyond dose level 2. If 0 out of 3 DLTs are observed at dose level 2 an additional 3 patients will be enrolled  at this dose level. 
¬ï Dose escalation will be stoppe d.  This dose level will be 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 42 declared the maximally administered dose
1 (highest 
dose administered).  Three (3) additional patients will be entered at the next lowest  dose level if 3 or fewer 
patients were treated prev iously at that dose.  
1 out of 3 Enter at least 3 more patients at this dose level. 
x If 0 of these 3 patients experience DLT, proceed to 
the next dose level. 
x If 1 or more of this group suffer DLT, then dose 
escalation is stopped, and th is dose is declared the 
maximally administered dose1. Three (3) additional 
patients will be entered at the next lowest dose level if only 3 patients were treate d previously at that dose. 
¬îRXWRIDW  dose level 2 or at the 
highest dose level below the maximally administered dose  This is generally the recommended phase 2 dose
2. At 
least 6 patients must be entered at the recommended phase 2 dose. The olaparib dose will not be escalated beyond dose level 2. If 0 out of 3 DLTs are observed at dose level 2, an additional 3 patients will be enrolled. 
1 Maximum administered dose: Th e highest dose level of olapar ib that 2 or more patients 
suffers a DLT (or 300 mg twice daily of  olaparib if no DLTs are observed). 
2 Recommended phase 2 dose: The highe st dose level of olaparib that ¬î1 out of 6 patients 
suffers a DLT. 
 Definition of Dose Limiting Toxicities  Non-Hematologic: Any grade 3-4 non-hematologic toxic ity at least ‚Äúpossibly related‚Äù to the combination of olaparib 
and ramucirumab occurring from cycle 1 day 1 through cycle 2 day 2 during phase 1 will be 
considered a DLT with the following exceptions:  
1. *UDGHWR[LFLW\WKDWODVWV¬î GD\VIRUQDXVHDYRPLWLQJIDWL JXHGLDUUKHDFRQVWLSDWLRQRU
anorexia will not be considered a DLT.  
2. *UDGHK\SHUWHQVLRQZLOOQRWEHFR QVLGHUHGD'/7XQOHVVLWSHU VLVWVIRU¬ïGD\V
despite optimal medical management. 
3. 7UDQVLHQW¬îGD\V*UDGH¬ïH OHYDWLRQVLQ$67DQGRU$/7ZLW KRXWRWKHUHYLGHQFHRI
hepatic injury will not be considered a DLT.  
4. A subject did not receive at least 45 doses (80%) of olaparib or 2 doses (100%) of 
ramucirumab up to and including cycle 2 day 1 (i.e., other AEs not attributed as DLTs 
and/or dosing lab eligibility not met) will be considered a DLT. 
 Hematologic:  $Q\JUDGHKHPDWRORJLFWR[LFLW\ H[FHSWO\PSKRSHQLDWKDWODVW V¬ïGD\VDWOHDVW¬≥SRVVLEO\
related‚Äù to the combination of  olaparib and ramucirumab oc curring from cycle 1 day 1 through 
cycle 2 day 2 during phase 1 will be consid ered a DLT with the following exceptions: 
1. 7KURPERF\WRSHQLDJUDGH¬ïZLWKF OLQLFDOO\VLJQLILFDQWEOHHGLQJ  will be considered a 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 43 DLT.  
2. Febrile neutropenia (a single temperature of 38.3¬∞C (101¬∞F)  or more orally) or 38.0¬∞C 
(100.4¬∞F) or more over one hour and ANC < 1.0 x 10
9 / L will be considered a DLT. 
3. Grade 3 neutropenia WKDWODVWV¬ï  days will be considered a DLT. 
  5.3 Dose Expansion: 
 After completion of the phase 1 portion of the study the maximum safe dose of olaparib will be 
used for phase 2. An additional 40 patients will be enrolled for phase 2 for treatment with combined olaparib (dose TBD) and ramuciruma b 8 mg/kg. During phase 2 patients will continue 
to be monitored for o ccurrence of DLT.  If ¬ï 2 of the first 6 patients RU¬ï of patients 7-12 
experience a DLT, the Principal Investigator wi ll discuss with all study investigators and with 
CTEP whether further addition of patients is ne eded to re-assess the recommended phase 2 dose.  
Monitoring of all safety and toxicity data is done by the Principal Investigator and the 
corresponding organization on a real-time basis as da ta are entered into Medidata Rave using the 
Web Reporting Module. The adverse event CRF is used for routine AE re porting in Rave. All 
participating sites are expected to notify the Principal Investigator wh en a DLT has occurred. 
 5.4 General Concomitant Medication and Supportive Care Guidelines 
 Because there is a potential for interaction of olaparib and ramucirumab with other 
concomitantly administered drugs , the case report form must capt ure the concurrent use of all 
other drugs, over-the-counter medi cations, or alternative therapie s. The Principal Investigator 
should be alerted if the patient is taking any agent known to affect  or with the potential for drug 
interactions. In vitro studies de monstrate that olaparib is pr imarily metabolized by CYP 3A4/5 
enzymes. Potent inhibitors or  inducers of CYP 3A4/5 are pr ohibited. The study team should 
check a frequently-updated medical  reference for a list of drugs to avoid or minimize use of.  
Appendix D (Patient Drug Information Handout and Wallet Card) should be provided to patients 
if available. 
 Patients who are taking warfarin ma y participate in this trial; however, it is recommended that 
international normalized ratio (INR)  be monitored carefully at le ast once per week for the first 
month, then monthly if the INR is stable. Subcutaneous hepa rin and low molecular weight 
heparin are permitted.  Palliative radiotherapy  Palliative radiotherapy may be used for the treatment of pain at the site of bony metastases that 
were present at baseline, provide d the investigator does not feel that these are indicative of 
clinical disease progression dur ing the study period.  Study treatme nt should be discontinued for 
a minimum of 3 days before a pati ent undergoes therapeuti c palliative radiati on treatment.  Study 
treatment should be restarted within 4 weeks as lo ng as any bone marrow toxicity has recovered.  
 Administration of ot her anti-cancer agents 
Patients must not receive any other concurrent  anti-cancer therapy, including investigational 
agents, while on study treatment. Patients ma y continue the use of bisphosphonates or 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 44 denosumab for bone disease and co rticosteroids for the symptomatic control of  brain metastases 
provided the dose is stable before and during th e study and they were started at least 4 weeks 
prior to beginning study treatment.   Subsequent therapies for cancer  Details of first and subsequent th erapies for cancer and/or details of surgery for the treatment of 
the cancer, after discontinuation of treatment, will  be collected.  Reasons for starting subsequent 
anti-cancer therapies including access to other PARP inhibitors or investigational drugs will be collected and included in the exploratory assessments of OS.  Medications that may NOT be administered No other chemotherapy, immunoth erapy, hormonal therapy or ot her novel agent is to be 
permitted while the patient is  receiving study medication. 
  5.5 Safety Monitoring 
 
x Laboratory safety assessment:  Full hematology assessments for safety (hemoglobin, red 
blood cells [RBC], placelets, mean cell volume [MCV], mean cell hemoglobin 
concentration [MCHC], mean cell hem oglobin [MCH], white blood cells [WBC], 
absolute differential white cell count (neu trophils, lymphocytes, monocytes, eosinophils 
and basophils) and absolute neutrophil coun t or segmented neutrophil count and Band 
forms should be performed at each treatment  visit and when clinically indicated. If 
absolute differentials are not available, please provide % differentials. Coagulation 
[activated partial thromboplastin time {APTT} and international normalized ratio {INR}] 
will be performed at baseline and if clinically  indicated unless the patient is receiving 
warfarin. Patient taking warfarin may partic ipate in this study; however, it is 
recommended that prothrombi n time (INR and APTT) be monitored carefully at least 
once per week for the first month, th en monthly if the INR is stable. 
 
x Biochemistry assessment for safety (sodium , potassium, calcium, magnesium, glucose, 
creatinine, total bilirubin, gamma glutamy ltransferase [GGT], alkaline phosphatase 
[ALP], aspartate transaminase [AST], alanine transaminase [ALT], urea or blood urea 
nitrogen [BUN], total protein, albumin and l actic dehydrogenase [LDH]). All should be 
performed at each treatment visit.  
 
x Urinalysis by dipstick should be performed at baseline. A urine dipstick for protein 
should be performed for on treatment  visits or full urinalysis may be obtained if clinically 
indicated. Microscopic analysis  should be performed by the hospital‚Äôs local laboratory if 
required.   
x Bone marrow or blood cytogenetic samples should be collected for patients with 
prolonged hematologic toxicities. 
 
These tests will be performed by the hospital‚Äôs local laboratory. Additional analyses may be 
performed if clinically indicated. Any clinical  significant abnormal laboratory values should 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 45 be repeated as clinically indicated.  
 
x In case a subject shows an  AST or ALT please refer to section 6  for management 
considerations.  
 
x Resting 12-lead EKG: 
 
EKGs are required within 7 days prior to starting study treatment and when clinically 
indicated. 
 
Twelve-lead EKGs will be obtained after the pati ent has been rested in a supine position for 
at least 5 minutes in each case.  The investigator or designate d physician will review the paper 
copies of each of the timed 12-lead EKGs on each  of the study days when they are collected. 
 
EKGs will be recorded at 25 mm/sec. All EKGs  should be assessed by the investigator as to 
whether they are clinically sign ificantly abnormal / not clini cally significantly abnormal. If 
there is a clinically significan t abnormal finding, the Investigator will reco rd it as an AE. The 
original EKGs must be stored in the patient medical record as source data. 
 
x Serum or urine pregnancy test: 
 
Two pregnancy tests on blood or urine samp les will be performed for pre-menopausal 
women of childbearing potential, one within 28 days pr ior to the start of  study treatment, and 
the other on Day 1 of the study prior to comm encing treatment. Tests will be performed by 
the hospital‚Äôs local laboratory. If results are positive the patient is ineligible/must be discontinued from the study. In the event of a suspected pregnancy dur ing the study, the test 
should be repeated.  
 
x Bone marrow or blood cytogenetic analysis:  
 
Bone marrow or blood cytogenetic analysis may be performed according to standard 
hematological practice for patients with prol onged hematological t oxicities. Bone marrow 
analysis should include an aspirate for cel lular morphology, cytogeneti c analysis and flow 
cytometry, and a score biopsy for bone marrow cellularity. If it is not possible to conduct 
cytogenetic analysis or flow cy tometry on the bone marrow aspi rate, then attempts should be 
made to carry out the tests on a blood sample . If findings are consistent with MDS/AML, 
study drug should be discontinued a nd a full description of findi ngs should be submitted with 
an SAE report. Presence or absence of blood  cytogenetic abno rmalities and flow cytometry 
will be documented on the clinical database. 
 
x Thyroid Function: 
 
Thyroid function should be monitored per th e ramucirumab (CYRAMZA ) package insert.  
 5.6 Duration of Therapy 
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 46 In the absence of treatment delays due to adverse event(s), treatment may continue until one of 
the following criteria applies:  
x Disease progression 
 
x Concurrent illness that prevents further administration of treatment 
 
x Unacceptable adverse event(s) 
 
x Patient decides to withdraw from the study 
 
x General or specific changes in the patient's  condition render the patient unacceptable 
for further treatment in the judgment of the investigator 
 
x Pregnancy 
 
o All women of child bearing potential s hould be instructed to contact the 
investigator immediately if  they suspect they might  be pregnant (e.g., missed 
or late menstrual period) at any time during study participation. 
 
o The investigator must immediately notif y CTEP in the event of a confirmed 
pregnancy in a patient pa rticipating in the study. 
 
x Termination of the study by sponsor 
 
x The drug manufacturer can no l onger provide the study agent 
 
x Severe non-compliance with the study protocol. 
 
x Bone marrow findings consistent with myelodysplastic syndrome (MDS) / acute 
myeloid leukemia (AML). 
 The reason(s) for protocol therapy discontinua tion, the reason(s) for st udy removal, and the 
corresponding dates must be documented in the Ca se Report Form (CRF). 
  5.7 Duration of Follow Up 
x Patients who are off study treatment due to disease progression will be seen at 4 
weeks for a post treatment vi sit, and will continue to be followed for survival. 
x Patients who discontinue the study treatme nt for reasons other than disease 
progression will be seen at 4 weeks af ter discontinuing study treatment and 
continue to undergo radiographic tumor assessment until radiographic 
documentation of disease progression ever y 6 weeks, or earl ier if clinically 
indicated, or until overall study completion, whichever comes first.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 47 x Patients who discontinue the study treatme nt for unacceptable adverse event(s) 
will be followed until resolution or stabi lization of the adverse event or until 
radiographic documentation of diseas e progression as noted above.  
x Patients who are discontinued from study drugs will be followed for survival 
every 3 months. 
 
6. DOSING DELAYS/DOSE MODIFICATIONS 
 
The dose levels and general approach to dos e modification of olap arib and ramucirumab 
combination is described in the tables below. Ramucirumab will be maintained at standard dose 
of 8 mg/kg, and olaparib will be decreased in the event of AEs. The recommended phase 2 dose 
for olaparib is TBD based on phase 1 of the study.  6.1 Olaparib and Ramucirumab Dose Modification Tables 
 Olaparib Dosing for Phase 1 and Phase 2: 
Dose Level Olaparib Dose Dose Reduction 1 Dose Reduction 2 
-2 100 m g, twice dail y Off stud y treatment -- 
-1 150 m g, twice dail y 100 m g, twice dail y Off stud y treatment 
 1 200 m g, twice dail y 150 m g, twice dail y 100 m g, twice dail y 
 2 300 m g, twice dail y 200 m g, twice dail y 150 m g, twice dail y 
 
 Ramucirumab Dosing for Phase 1 and Phase 2: 
Dose Level Ramucirumab Dose 
1 (startin g dose for both phase 1 and phase 2) 8 m g/kg, ever y 2 weeks 
 
General Management of Adverse Events: 
 Patients experiencing ongoing clinical benefit w ho experience a related AE where continuation 
of one of the drugs is considered, in the judgm ent of the treating investigator AND study PI, to 
be potentially life-threatening or with the potenti al for long-term harm to  the patient, may be 
allowed to continue on the unrelated drug after discussion with the study PI. 
   6.2 General Management of Advers e Events for Phase 1 and 2  
 The DLT definitions are provided in section 5.2  and the DLT period for phase 1 is specified 
to be 28 days. Patients that miss > 11 doses of  olaparib in the 28 day DLT period for drug 
related AEs despite appropriate supportive care and causality investigation will be 
permanently discontinued from ol aparib and ramucirumab therapy.  
 
Patients experiencing ongoing cl inical benefit who experien ce a related AE that would 
necessitate stopping study treatment may be allowed to continue on the unrelated drug if felt to 
be in the best interest of the patient by the tr eating investigator after di scussion with the study PI 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 48  
General Management of Non Hematologic A dverse Events (see below for specific AE 
management tables for select toxicities). 
 
Observation  Action  
Grade 1 AE resolves promptly with 
supportive care No change in dose 
Any grade 2 non-hematologic AE related to 
olaparib or ramucirumab that resolves within 
5 days with appropriate supportive care (excluding hypertension or other AEs with specific management instructions outlined below, or easily correctable asymptomatic 
grade 2 abnormalities).  Hold study drugs1 until toxicity resolves to ¬î
grade 1. Treatment may be restarted at the 
same dose without dose reduction. 
Any grade 2 non-hematologic AE related to olaparib or ramucirumab that persists more than 5 days despite appropriate supportive care (excluding hyperten sion or other AEs 
with specific management instructions outlined below, or easily correctable asymptomatic grade 2 abnormalities). Hold study drugs
1 for up to 14 days until 
toxicity resolves to ¬îJUDGH  1. Treatment may 
be restarted at one dose level lower for olaparib as per dose reduction levels above
2. 
The overall PI of the study should be informed regarding all dose modifications. Patients whose toxicity has not resolved after 14 days will be permanently discontinued from olaparib and ramucirumab therapy.  Patients experiencing persistent grade 2 fatigue that is felt to be acceptable by both patient and treating inve stigator may continue 
on study drug without do se hold or reduction 
at the treatin
g investi gator‚Äôs discretion. 
$Q\¬ïJUDGHQRQ -hematologic AE 
(excluding grade 3 hypertension or easily correctable grade 3 abnormalities IRU¬îGD\V
as outlined in section 5.2 ). Refer to section 
5.2 for DLT criteria. Hold study drugs1 for up to 14 days until 
WR[LFLW\UHVROYHVWR¬îJUDGH Treatment may 
be restarted at one dose level lower for olaparib, as per the dose reduction levels above
2. The overall PI of the study should be 
informed re gardin g all dose modifications.   
x Grade 3 or 4 non-hematologic AE 
related to olaparib or ramucirumab 
lasting >14 days despite maximum supportive care and treatment being held
 3. Refer to section 5.2  for DLT 
lcriteria. 
x Grade 3 or 4 non-hematologic AE 
related to olaparib and ramucirumab 
that occurs at the lowest reduced dose level. The patient will be permanently discontinued 
from olaparib and ramucirumab therapy
4.  
1At the discretion of the investi gator, the stud y drugs may be held or dose modified 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 49 independently if the observed toxi city is attributed to only one of the drugs, while the patient 
continues to receive the drug not associated w ith the observed toxicity. The time a given drug 
is held should not exceed 14 days. 
2Patients who are at the lowest dose reduced le vel may have their drug resumed at that dose 
level after discussion with overall PI. 
3Excluding hypertension. For thromboembolic ev ents, treatment may be resumed at the 
discretion of the investigator once patient is asymptomatic.  
4At the discretion of the inve stigator the patient may con tinue to receive the drug not 
associated with the observed toxicit y as monotherap y after a discussion with the overall PI. 
 6.3 Management of Specific Adverse Events for Phase 1 and 2: 
 Please refer to section 5.2  for a definition of DLTs in the 28 day DLT period for phase 1.  
 
No routine prophylactic anti-emetic treatment is required at the st art of study treatment, however, 
patients should receive appropriate anti-emetic treat ment at the first onset of nausea or vomiting 
and as required thereafter, in accordance with lo cal treatment practice guidelines.  Alternatively, 
olaparib tablets can be taken with a light meal/snack (ie 2 pieces of  toast or a couple of biscuits). 
 Events of nausea and vomiting ar e known to be associated with  olaparib treatment. In study 
D0810C00019 nausea was reported in 71% of the olaparib treated patients and 36% in the 
placebo treated patients and vomi ting was reported in 34% of the olaparib treated patients and 
14% in the placebo treated patients. These events  are generally mild to moderate (CTCAE grade 
1 or 2) severity, intermittent and manageable on continued treatment. Th e first onset generally 
occurs in the first month of treatment for nausea  and within the first 6 months of treatment for 
vomiting. For nausea, the inciden ce generally plateaus at around 9 months, and for vomiting at 
around 6 to 7 months.  As per international guidance on anti-emetic use in cancer patients (ESMO, NCCN), generally a 
single agent antiemetic should be considered. 
 
Nausea  
Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
¬î*UDGH  No chan ge in dose. No chan ge in dose 
Grade 2 If it lasts ¬î 5 days, hROGXQWLO¬î
grade 1 and resume at same dose level. If it lasts ¬ï 6 days hold* up 
to 14 days until ¬î grade 1 and 
treatment may be restarted at one dose level lower. No change in dose
** 
Grade 3 Hold* until ¬î Grade 1.  Resume at 
one dose level lower. No change in dose** 
 
Grade 4 N/A N/A 
*Patients requiring a delay of >2 weeks shoul d be permanently discontinued from olaparib. 
**At the discretion of the investigator the patient may continue to receive ramucirumab if it is 
not associated with the observed toxicit y. 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 50 Nausea  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
Recommended management:  Daily serotoni n (5-HT3) antagonists are recommended for 
nausea management with break through trea tment options includi ng prochlorperazine, 
benzodiazepines, steroids, cannabinoids, and at ypical antips ychotics. 
  
Vomiting  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucriumab 
¬î*UDGH  No chan ge in dose No chan ge in dose 
Grade 2 If it lasts ¬î 5 days, hROGXQWLO¬î
grade 1 and resume at same dose level. If it lasts ¬ï 6 days hold* up 
to 14 days until ¬î grade 1 and 
treatment may be restarted at one dose level lower. No change in dose
** 
Grade 3 Hold* until ¬î grade 1. Resume at 
one dose level lower. No change in dose** 
Grade 4 Hold* until ¬î grade 1.  Resume at 
one dose level lower. No change in dose** 
*Patients requiring a delay of >2 weeks shoul d be permanently discontinued from olaparib. 
**At the discretion of the investigator the patient may continue to receive ramucirumab if it is 
not associated with the observed toxicit y. 
Recommended mana gement:  antiemetics. 
 
 
Diarrhea  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
¬î*UDGH  No chan ge in dose. No chan ge in dose 
Grade 2 If it lasts ¬î 5 days, hROGXQWLO¬î
grade 1 and resume at same dose level. If it lasts ¬ï 6 days hold* up 
to 14 days until ¬î grade 1 and 
treatment may be restarted at one dose level lower. No change in dose
** 
Grade 3 Hold* until ¬î grade 1.  Resume at 
one dose level lower. No change in dose** 
Grade 4 Hold* until ¬î grade 1.  Resume at 
one dose level lower. No change in dose** 
*Patients requiring a delay of >2 weeks shoul d be permanently discontinued from olaparib. 
**At the discretion of the investigator the patient may continue to receive ramucirumab if it is 
not associated with the observed toxicit y. 
Recommended management:  Loperamide antidiarrheal therapy Dosage schedule:  4 mg at first onset, followed by 2 mg with each loose motion until diarrhea-
free for 12 hours (maximum dosa
ge:  16 m g/24 hours) 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 51 Diarrhea  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
Adjunct anti-diarrheal therapy is permit ted and should be recorded when used. 
Appendix E  includes instructions fo r diarrhea management for the patient, and should be 
provided to the patient. 
 
 
Leukopenia  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab   
¬î*UDGH  No chan ge in dose No chan ge in dose 
Grade 2 No chan ge in dose No chan ge in dose** 
Grade 3 Hold* until ¬î grade 2.  Resume at 
one dose level lower. No change in dose** 
Grade 4 Hold* until ¬î grade 2.  Resume at 
one dose level lower. No change in dose** 
*Patients requiring a delay of >2 weeks desp ite appropriate supportiv e care and causality 
investigation should permanently discontinue ol aparib. Check weekly differential blood counts 
including reticulocytes and peri pheral blood smear. If any blood pa rameters remain clinically 
abnormal after 4 weeks of dose in terruption, the patient should be referred to he matologist for 
further investigations. Bone marrow analysis and/or blood cytogenetic analysis should be 
considered at this stage according to standard  hematological practice.  Olaparib should be 
discontinued permanently if bl ood counts do not recover to CTC grade 1 or better within 4 
weeks of dose interruption.  
**At the discretion of the investigator the patient may continue to receive ramucirumab if it is 
not associated with the observed toxicit y. 
Insert an y recommended mana gement guidelines, i f appropriate.  
 
 
Neutropenia ( Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab   
¬î*UDGH  No chan ge in dose No chan ge in dose 
Grade 2 No chan ge in dose No chan ge in dose** 
Grade 3 Hold* until ¬î grade 2.  Resume at 
one dose level lower. No change in dose** 
Grade 4 Hold* until ¬î grade 2.  Resume at 
one dose level lower. No change in dose** 
*Patients requiring a delay of >2 weeks desp ite appropriate supportiv e care and causality 
investigation should be discont inued from olaparib. Check w eekly differential blood counts 
including reticulocytes and peri pheral blood smear. If any blood pa rameters remain clinically 
abnormal after 4 weeks of dose in terruption, the patient should be referred to he matologist for 
further investigations. Bone marrow analysis and/or blood cytogenetic analysis should be 
considered at this stage according to standard  hematological practice.  Olaparib should be 
discontinued permanently if bl ood counts do not recover to CTC grade 1 or better within 4 
weeks of dose interruption.  
**At the discretion of the investi gator the patient ma y continue to receive ramucirumab if it is 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 52 Neutropenia ( Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab   
not associated with the observed toxicit y. 
Insert an y recommended mana gement guidelines, i f appropriate.  
 
Febrile Neutropenia  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab   
¬î*UDGH  N/A N/A 
Grade 2 N/A N/A 
Grade 3 Off protocol therap y. No chan ge in dose** 
Grade 4 Off protocol therap y. No chan ge in dose** 
*Patients requiring a delay of >2 weeks shoul d be permanently discontinued from olaparib. 
**At the discretion of the investigator the patient may continue to receive ramucirumab if it is 
not associated with the observed toxicit y. 
Primary prophylaxis with Granulocyte colony-s timulating factor (G-CSF)  is not recommended, 
however, if a patient develops  febrile neutropenia, study tr eatment should be stopped and 
appropriate management incl uding G-CSF should be given according to local hospital 
guidelines. Please note that G-C SF should not be used within at least 24 h (7 days for pegylated 
G-CSF) of the last dose of study tr eatment unless absolutely necessary.  
 
 
Anemia  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab   
+HPRJORELQ¬ï  
 No change in dose No change in dose 
Hemoglobin < 10 but 
¬ïJGO&7&$(Grade 2) First occurrence: 
Give appropriate supportive treatment and investigate causality.  Investigator judgment to continue olaparib with supportive treatment (e.g. transfusion) or interrupt dose for a maximum of 4 weeks. Study treatment can be restarted if hemoglobin has recovered to > 9 g/dl.  Subsequent occurrences:* ,IKHPRJORELQEXW¬ïJGOinvestigator judgment to continue olaparib with supportive treatment (e.g. transfusion) or dose interrupt (for a maximum of 4 weeks) and upon recovery dose reduction may be considered b
y 1 dose level as a No change in dose** 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 53 Anemia  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab   
first step and 2 dose levels as a 
second step.  
,I+HPRJORELQEXW¬ïJGO
dose interrupt (for max of 4 weeks) and continue with supportive treatment (e.g. transfusion) until KHPRJORELQ¬ïDQGXSRQUHFRYHU\dose reduction may be considered by 1 dose level as a first step and 2 dose levels as a second step. 
Hemoglobin < 8 g/dl (CTCAE Grade 3)* Give appropriate supportive 
treatment (e.g. transfusion) and investigate causality.  Interrupt olaparib for a maximum of 4 weeks until improved to KHPRJORELQ¬ïJGO  
 Upon recovery dose reduce by one 
dose level as a first step and 2 dose 
levels as a second step. No change in dose
** 
*Patients requiring a delay of > 4 weeks and/or  red blood cell transfusion dependence despite 
appropriate supportive care and causality investigation should  be permanently discontinued 
from olaparib. Check weekly di fferential blood counts including reticulocytes and peripheral 
blood smear. If any blood parameters remain cl inically abnormal af ter 4 weeks of dose 
interruption, the patien t should be referred to hematologist  for further inve stigations. Bone 
marrow analysis and/or blood cytoge netic analysis should be consid ered at this stage according 
to standard hematological practice.  
**At the discretion of the investigator the patient may continue to receive ramucirumab if it is 
not associated with the observed toxicit y. 
Packed red blood cell transfusions, if indicate d, should be done according to local hospital 
guidelines.  
 
Thrombocytopenia  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
¬î*UDGH  No chan ge in dose No chan ge in dose 
Grade 2 +ROGXQWLO¬î*UDGH Resume at 
same dose level. No change in dose** 
Grade 3 Hold* until ¬î grade 1.  Resume at 
one dose level lower. No change in dose** 
Grade 4 Hold* until ¬î grade 1.  Resume at 
one dose level lower. No change in dose** 
*Patients requirin g a dela y of >2 weeks and/or platelet  transfusion dependence despite 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 54 Thrombocytopenia  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
appropriate supportive care and causality investigation should  be permanently discontinued 
from olaparib. Check weekly di fferential blood counts including reticulocytes and peripheral 
blood smear. If any blood parameters remain cl inically abnormal af ter 4 weeks of dose 
interruption, the patien t should be referred to hematologist  for further inve stigations. Bone 
marrow analysis and/or blood cytoge netic analysis should be consid ered at this stage according 
to standard hematological pr actice. Olaparib should be di scontinued permanently if blood 
counts do not recover to CTC gr 1 or be tter within 4 weeks of dose interruption.  
**At the discretion of the investigator the patient may continue to receive ramucirumab if it is 
not associated with the observed toxicit y. 
Platelet transfusions, if i ndicated, should be done accordin g to local hospital guidelines. 
 
Hypertension: 
 Only modifications in ramuciru mab will be modified for hyperte nsion, and olaparib doses will 
not be reduced unless other toxicities are experienced.   
Hypertension  
Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
¬î*UDGH  No chan ge in dose No chan ge in dose 
Grade 2 No chan ge in dose No chan ge in dose 
Grade 3 No change in dose** No change in dose, but if SHUVLVWV¬ï
14 days after initiation of optimal medical management, hold* until ¬î 
grade 1. If ramucirumab discontinued the treating physician and study PI will discuss continuin
g olaparib monotherap y.   
Grade 4 No change in dose** Discontinue ramucirumab and 
discussion between treating physician and PI continuing on olaparib monotherap
y. 
*Patients requiring a delay of >4 we eks should discontinue ramucirumab. 
**At the discretion of the investigator the patient may continue to receive olaparib if it is not 
associated with the observed toxicit y after discussion with the overall stud y PI. 
If hypertension grade 2: Initiate blood pressure  (BP) medication for first-line treatment. 
Escalate dose of medication in stepwise fashion until BP is controlled or at a maximum dose. If 
BP is not controlled to <140/90 mmHg with one drug regimen, then add a second agent.  
If hypertension grade 3: Maximize 2 drug regime n. Suggestions: ACE inhibitor plus beta 
blocker. Escalate doses of existing medication un til BP is controlled or at a maximum dose. If 
BP is not controlled to <140/90 with two drug regimen then add a third agent. Additional BP 
meds up to 4 may be maximized to control BP. If hypertension grade 4: Initiate tr eatment as inpatient hospital admission for ICU management, 
IV therap y as necessar y. 
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 55  
Proteinuria  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
1+ Proteinuria No chan ge in dose No chan ge in dose 
¬ï2+ Proteinuria No change in dose Continue as scheduled, and 
conduct a 24-hour urine collection prior to subsequent treatment. If <2 g/24 hours continue without dose interruption, if 2-3 g/24 hours hold until proteinuria ¬î+ or < 2 g/24 
hours..  Resume at same dose level.** 
Grade 4 N/A N/A 
*Patients requiring a delay of >2 we eks should discontinue ramucirumab. 
**For patients with 2+ proteinuria on urine dipstick a 24 hour urine collection will be 
conducted. If the protein level is < 2 g/24 hour s the patient will con tinue on the same dose 
without interruption. If the protein level is 2-3 g/24 hours, ramucirumab w ill be held for up to 2 
weeks and a 24 hour urine protein will be re peated. The patient will be discontinued 
permanentl y from ramucirumab if the 24 hour  urine protein level is > 3 g/24 hours.  
If SURWHLQXULDJUDGH¬ï consider consultation with nephrologist. 
 
 
Decrease in LVEF: 
Patients who have any of the following should u ndergo an echocardiogra m (ECHO) at baseline 
and every 4 cycles while on study: 
x Prior treatment with anthracyclines 
x Prior treatment with trastuzumab 
x NYHA classification of II cont rolled with treatment (see Appendix B ) 
x Prior central thoracic radiation 
x History of myocardial infarcti on within the prior 12 months 
x Prior history of impaired cardiac function 
 
The decision to continue to hold olaparib/ramuc irumab is based on the LVEF compared to the 
institutional lower limit of nor mal and change in ejection frac tion from screening, according to 
the following table. If the institution‚Äôs lower limi t of normal is not spec ified, an LVEF of 55% 
should be considered the threshold.  
Decreased Left 
Ventricular 
Ejection Fraction  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
<10% from screenin
g* No change in dose. No change in dose. 
10-19% from 
screening* No change in dose. No change in dose and repeat 
echocardiogram after 2 additional c
ycles.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 56 Decreased Left 
Ventricular 
Ejection Fraction  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
¬ï20% from 
screening* No change in dose. Hold treatment and repeat 
echocardiogram  in 10-14 days. If 
decrease in EF remains ¬ï 20% 
from screening, discontinue ramucirumab and discussion between treating physician and PI about continuing olaparib monotherap
y.** 
*If no screening ECHO the change should be calc ulated from prior pati ent ECHO or if not 
available, the institutiona l lower limit of normal. 
**Repeatin g ECHO will be at disc retion of the treatin g physician. 
If baseline cardiac dysfunction or decreased ejection fraction: Ho ld treatment as outlined and 
consider consultation with a cardiologist.  
 
 Decrease in Creatinine Clearance   
Creatinine 
Clearance  Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
&U&O¬î  Hold* until CrCl > 30 Hold* until CrCl > 30 
CrCl 31-50 Decrease b y one dose level Continue at same dose level 
CrCl 51-59 No chan ge in dose. No chan ge in dose. 
&U&O¬ï  No chan ge in dose. No chan ge in dose. 
*Patients requiring a delay of >2 weeks shoul d be discontinued from both olaparib and 
ramucirumab. 
 Infusion Reaction  
Infusion Reaction  
Management/Next Dose for 
Olaparib Management/Next Dose for 
Ramucirumab 
Grade 1-2 No change in dose Reduce the infusion rate of 
ramucirumab b y 50%. 
Grade 3-4 No change in dose. Permanently discontinue 
ramucirumab.  
*Patients requirin g a dela y of >2 weeks should be di scontinued from ramucirumab. 
 
Gastrointestinal Perforation.  Gastrointestinal perforations have been obs erved in patients recei ving ramucirumab, most 
commonly related to the primary tumor. Ramuci rumab should be permanently discontinued in 
those patients who experience a gastro intestinal perforation or fistula. 
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 57 Hemorrhage and arterial thromboembolic events (ATEs) 
Hemorrhage and arterial thromboembolic even ts have been observed with ramucirumab. 
Ramucirumab will be permanently discontinued in  patients who experience these types of 
events.  Management of new or worsening pulmonary symptoms   If new or worsening pulmonary symptoms (e.g., dys pnoea) or radiological abnormalities occur in 
the absence of a clear diagnosis , an interruption in study treatme nt dosing is recommended and 
further diagnostic workup (including a high resolution CT scan ) should be performed to exclude 
pneumonitis. Following investigation, if no evidence of abno rmality is observed on CT imaging and symptoms 
resolve, then study treatment ca n be restarted, if de emed appropriate by the investigator. If 
significant pulmonary abnor malities are identified, these need  to be discussed with the Study 
Physician.‚Äù  Olaparib adverse events of special interest  Adverse events of special interested [AESI] are events of scientific and medical interest specific to the further understanding of ol aparib‚Äôs safety profile and re quire close monitoring and rapid 
communication by CTEP to AstraZeneca. An AESI  may be serious or non-serious. Adverse 
Events of Special Interest for olaparib are the Important Potential Risks of MDS/AML, new 
primary malignancy (other than MDS/AML) and pneumonitis.  
 ANY event of MDS/AML, new primary malignanc y, or pneumonitis should be report to CTEP 
whether it is concered a non-se rious AE [eg non-melanoma skin cancer] or SAE, and regardless 
of investigator‚Äôs assessment of causal ity or knowledge of the treatment arm. 
 A questionnaire may be sent to any investigator reporti ng an AESI, as an aid to provide further 
detailed information on the even t. During the study th ere may be other events identified as 
AESIs that require the use of a questionnaire to help characte rize the event and gain a better 
understanding regarding the relationship between the event and study treatment. 
 There are currently no identified OAEs for olaparib.   Overdose of olaparib  There is currently no specific treatment in th e event of overdose with olaparib and possible 
symptoms of overdose are not established.  Olaparib must only be used in accordance with  the dosing recommendations in this protocol. 
Any dose or frequency of dosing that exceeds the dosing regimen specified in this protocol 
should be reported as an overdose. Adverse reacti ons associated with overdose should be treated 
symptomatically and should be managed appropri ately. An overdose with associated AEs should 
be recorded.   
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 58  
    Interruptions for intercurrent non-toxicity related events 
 Study treatment dose interruption fo r conditions other than toxicity  resolution should be kept as 
short as possible. If a patient cannot started study treatment within 4 weeks for resolution of 
intercurrent conditions not related to disease progression or toxici ty, the case should be discussed 
with the principal investigator and CTEP.  All dose reductions and interruptions (includi ng any missed doses), and the reasons for the 
reductions/interruptions are to be recorded. Study  treatment should be stopped at least 3 days 
prior to planned surgery. Afte r surgery study treatment can be  restarted when the wound has 
healed. No stoppage of study treatment is re quired for any needle biopsy procedure. 
 Study treatment should be discon tinued for a minimum of 3 days  before a patient undergoes 
radiation treatment. Study treatme nt should be restarted within  4 weeks as long as any bone 
marrow toxicity has recovered.   Because the AEs related to olaparib may include asthenia, fatigue and dizziness, patients should 
be advised to use caution while driving or using machinery if thes e symptoms occur.  
   7. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  
 Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of AEs ( Section 7.1 ) and the characteristics of an observed AE ( Sections 7.2 and 
7.3) will determine whether the event requires ex pedited reporting via the CTEP Adverse Event 
Reporting System (CTEP-AERS) in  addition to routine reporting.  
 7.1 Comprehensive Adverse Events and Potential Risks Lists (CAEPRs)  
 The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of reported and/or potential adverse events (AE)  associated with an agent using a uniform 
presentation of events by body system.  In additi on to the comprehensive list, a subset of AEs, 
the Specific Protocol Exceptions to Expedited Re porting (SPEER), appears in a separate column 
and is identified with bold and italicized text.  The SPEER is a list of  events that are protocol-
specific exceptions to expedited reporting to NCI (except as noted below).  Refer to the 'CTEP, 
NCI Guidelines: Adverse Event Reporting Requirements' http://ctep.cancer.gov/protocolDev elopment/adverse_effects.htm for further clarification.  
 
NOTE :  The highest grade currently reported is no ted in parentheses next to the AE in the 
SPEER.  Report ONLY AEs higher than this grade expeditious ly.  If this CAEPR is part of a 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 59 combination protocol using multiple investigat ional agents and has an AE listed on different 
SPEERs, use the lower of the grades to de termine if expedited reporting is required.  
 7.1.1 CAEPRs for CTEP IND Agent(s) 
 
7.1.1.1  CAEPR for Olaparib 
 
Comprehensive Adverse Events and Potential Risks list (CAEPR) 
for 
Olaparib (AZD2281, NSC 747856)
 
 
The Comprehensive Adverse Events and Potential Risk s list (CAEPR) provides a single list of reported 
and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by 
body system. In addition to the comprehensive list, a subset, the Specific Protocol Exceptions to 
Expedited Reporting (SPEER), appears in a separate co lumn and is identified with bold and italicized 
text. This subset of AEs (SPEER) is a list of events that are protocol specific exceptions to expedited 
reporting to NCI (except as noted below).  Refer to  the 'CTEP, NCI Guidelines: Adverse Event Reporting 
Requirements' http://ctep.cancer.gov/protocolDevelopment/e lectronic_applications/docs/aeguidelines.pdf  
for further clarification. Frequency is provided based on 3449 patients. Below is the CAEPR for Olaparib 
(AZD2281). 
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses next to 
the AE in the SPEER.  If this CAEPR is part  of a combination protocol using multiple 
investigational agents and has an AE listed on diffe rent SPEERs, use the lower of the grades to 
determine if expedited reporting is required. 
 
Version 2.5, July 1, 20211 
 
 Adverse Events with Possible  
 Relationship to Olaparib (AZD2281) 
 (CTCAE 5.0 Term) 
[n= 3449]  
 
 Specific Protocol 
Exceptions to Expedited 
Reporting (SPEER)  
Likel y (>20% ) Less Likel y (<=20% ) Rare but Serious (<3%)  
BLOOD AND LYMPHATIC SYSTEM DISORDERS   
Anemia    Anemia (Gr 4)  
  Febrile neutropenia   
GASTROINTESTINAL DISORDERS   
 Abdominal distension    
Abdominal pain    Abdominal pain (Gr 3)  
 Constipation   Constipation (Gr 2)  
Diarrhea    Diarrhea (Gr 3)  
 Dyspepsia   Dyspepsia (Gr 2)  
                                                     
Mucositis oral    
Nausea    Nausea (Gr 3)  
Vomiting    Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINI STRATION SITE CONDITIONS   
 Edema limbs    
Fatigue    Fatigue (Gr 3)  
IMMUNE SYSTEM DISORDERS   
  Allergic reaction   
INFECTIONS AND INFESTATIONS   
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 60  
 Adverse Events with Possible  
 Relationship to Olaparib (AZD2281) 
 (CTCAE 5.0 Term) 
[n= 3449]  
 
 Specific Protocol 
Exceptions to Expedited 
Reporting (SPEER)  
Likel y (>20% ) Less Likel y (<=20% ) Rare but Serious (<3%)  
 Upper respiratory infection    
 Urinary tract infection    
INVESTIGATIONS   
 Creatinine increased    
 Neutrophil count decreased   Neutrophil count decreased 
(Gr 4)  
  Platelet count decreased   
 White blood cell decreased    
METABOLISM AND NUTRITION DISORDERS   
Anorexia    Anorexia (Gr 2)  
MUSCULOSKELETAL AND CONN ECTIVE TISSUE DISORDERS   
 Arthralgia    
 Back pain   Back pain (Gr 2)  
 Muscle cramp    
 Myalgia    
 Pain in extremity    
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS )   
  Leukemia secondary to 
oncology chemotherapy   
  Myelodysplastic syndrome   
NERVOUS SYSTEM DISORDERS   
 Dizziness   Dizziness (Gr 2)  
 Dysgeusia   Dysgeusia (Gr 2)  
 Headache   Headache (Gr 2)  
RESPIRATORY, THORACIC AN D MEDIASTINAL DISORDERS   
 Cough   Cough (Gr 2)  
 Dyspnea   Dyspnea (Gr 2)  
  Pneumonitis   
SKIN AND SUBCUTANEOUS TISSUE DISORDERS   
 Rash maculo-papular    
  Skin and subcutaneous tissue 
disorders - Other (angioedema)   
  Skin and subcutaneous tissue 
disorders - Other (erythema 
nodosum)   
 
NOTE: New Primary Malignancies other than MDS/AML  
New primary malignancies have been reported in <1 % of patients. There were other contributing 
factors/potential alternative explanations for the deve lopment of the new primary malignancy in all cases, 
including documented BRCA mutation, treatment with radiotherapy  and extensive previous chemotherapy 
including carboplatin, taxanes, anthracyclines and ot her alkylating and DNA damaging agents. Most are 
not attributed to olaparib.  
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all 
Principal Investigators at the time of revision.  The current version can be obtained by contacting 
PIO@CTEP.NCI.NIH.GOV.   Your name, the name of the investigator, the protocol and the agent should 
be included in the e-mail. 
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 61  
Adverse events reported on olaparib (AZD2281) trials, but for which there is insufficient evidence 
to suggest that there was a reasonable possibility that olaparib (AZD2281) caused the adverse 
event:  
 
CARDIAC DISORDERS  - Atrial fibrillation; Cardiac disorders - Other (nodal rhythm); Chest pain - cardiac; 
Sinus bradycardia; Sinus tachycardia 
EAR AND LABYRINTH DISORDERS  - Tinnitus 
ENDOCRINE DISORDERS  - Hypothyroidism 
GASTROINTESTINAL DISORDERS  - Ascites; Colitis; Colonic obst ruction; Dry mouth; Dysphagia; 
Enterocolitis; Esophageal stenosis; Flatulence; Gast roesophageal reflux disease; Gastrointestinal 
disorders - Other (gastrointestinal hemorrhage); Gastro intestinal disorders - Other (intestinal obstruction); 
Gastrointestinal disorders - Other (intestinal perforati on); Ileus; Jejunal perforation; Obstruction gastric; 
Pancreatitis; Periodontal disease;  Rectal hemorrhage; Small intestinal obstruction; Stomach pain 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  - Death NOS; Fever; Malaise; 
Non-cardiac chest pain 
IMMUNE SYSTEM DISORDERS  - Immune system disorders - Other (systemic inflammatory response 
syndrome) INJURY, POISONING AND PR OCEDURAL COMPLICATIONS  - Dermatitis radiation; Fracture; 
Gastrointestinal anastomotic leak; Injury, poisoning and procedural complications - Other (vena cava 
injury); Wound dehiscence INVESTIGATIONS  - Alanine aminotransferase increased; Aspartate aminotransferase increased; Blood 
bilirubin increased; GGT increased; Hemoglobin increased; Lipase increased; Lymphocyte count 
decreased; Serum amylase increased; Weight loss METABOLISM AND NUTRITION DISORDERS  - Dehydration; Hyperglycemia; Hypermagnesemia; 
Hypocalcemia; Hypokalemia; Hypomagnesemia; Hyponatremia 
MUSCULOSKELETAL AND CONN ECTIVE TISSUE DISORDERS  - Avascular necrosis; Bone pain; 
Generalized muscle weakness; Muscle weakness lo wer limb; Muscle weakness upper limb; Neck pain; 
Rotator cuff injury; Soft ti ssue necrosis lower limb 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)  - Treatment 
related secondary malignancy; Tumor pain 
NERVOUS SYSTEM DISORDERS  - Amnesia; Ataxia; Cognitive dist urbance; Concentration impairment; 
Encephalopathy; Intracranial hemorrhage; Peripheral sensory neuropathy; Reversible posterior 
leukoencephalopathy syndrome; Stroke; Syncope; Transient ischemic attacks 
PSYCHIATRIC DISORDERS  - Anxiety; Confusion; Deliriu m; Hallucinations; Insomnia 
RENAL AND URINARY DISORDERS  - Acute kidney injury; Renal and urinary disorders - Other 
(decreased glomerular filtration rate); Renal and urin ary disorders - Other (hydronephrosis); Urinary tract 
obstruction REPRODUCTIVE SYSTEM AND BREAST DISORDERS  - Vaginal hemorrhage 
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS  - Bronchopulmonary hemorrhage; 
Hypoxia; Oropharyngeal pain; Pleural effusion; Respirat ory failure; Respiratory, thoracic and mediastinal 
disorders - Other (chronic obstructive pulmonary disease) 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  - Alopecia; Erythema multiforme; Pruritus 
VASCULAR DISORDERS  - Arterial thromboembolism; Flushing; Hot flashes; Hypertension; Hypotension; 
Peripheral ischemia; Thromboembolic event 
 
 
 
 Note : Olaparib (AZD2281) in combination with other ag ents could cause an exacerbation of any adverse 
event currently known to be caused by the other agen t, or the combination may result in events never 
previously associated with either agent.  
 
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 62  
7.1.1.2  Please see the October 2016 FDA-approved p ackage insert for ramucirumab for a list 
of the associated AEs. 
  7.2 Adverse Event Characteristics  
 
x CTCAE term (AE description) and grade:  The descriptions and grading scales found 
in the revised NCI Common Te rminology Criteria for Advers e Events (CTCAE) version 
5.0 will be utilized for AE reporting. All appr opriate treatment areas should have access 
to a copy of the CTCAE version 5.0. A copy of the CTCAE version 5.0 can be 
downloaded from the CTEP web site https://ctep.cancer.gov/pro tocolDevelopment/electroni c_applications/ctc.htm  
 
x For expedited reporting purposes only:   
- AEs for the agent that are bold and italicized  in the CAEPR ( i.e., those listed in the 
SPEER column, Section 7.1.1 ) should be reported thr ough CTEP-AERS only if the 
grade is above the grade provided in the SPEER. 
- Other AEs for the protocol that do not requ ire expedited reporting are outlined below. 
 
x Attribution  of the AE: 
- Definite ‚Äì The AE is clearly related  to the study treatment. 
- Probable ‚Äì The AE is likely related to the study treatment. 
- Possible ‚Äì The AE may be related  to the study treatment. 
- Unlikely ‚Äì The AE is doubtfully related to the study treatment. 
- Unrelated ‚Äì The AE is clearly NOT related  to the study treatment. 
 
7.3 Expedited Adverse Event Reporting 
 7.3.1 Expedited AE reporting for this study mu st use CTEP-AERS (CTEP Adverse Event 
Reporting System), accessed via the CTEP Web site ( https://eapps-
ctep.nci.nih.gov/ctepaers ).  The reporting procedures to be followed are presented in the 
‚ÄúNCI Guidelines for Investigators: Adve rse Event Reporting Requirements for DCTD 
(CTEP and CIP) and DCP INDs and IDEs‚Äù which can be downloaded from the CTEP Web site (http://ctep.cancer.gov/protoco lDevelopment/electronic_app lications/adverse_events.htm
).  These requirements are briefl y outlined in the tables below ( Section 7.3.3 ). 
 
In the rare occurrence when In ternet connectivity is lost, a 24-hour notification is to be 
made to CTEP by telephone at 301-897-7497.  On ce Internet connectivity is restored, the 
24-hour notification phoned in must be ente red electronically into CTEP-AERS by the 
original submitter at the site.  
7.3.2 Distribution of Adve rse Event Reports 
 
CTEP-AERS is programmed for automatic el ectronic distribution of reports to the 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 63 following individuals:  Principal Investigat or and Adverse Event Coordinator(s) (if 
applicable) of the Correspondi ng Organization or Lead Orga nization, the local treating 
physician, and the Reporter and Submitter.  CTEP-AERS provides a copy feature for 
other e-mail recipients.  
 
7.3.3 Expedited Reporting Guidelines 
 
Use the NCI protocol number and the protocol-specific patie nt ID assigned during trial 
registration on all reports. 
 
Note:  A death on study requires both rout ine and expedited reporting, regardless of 
causality.  Attribution to treatment or other cause must be provided. 
 Death due to progressive diseas e should be reported as Grade 5 ‚ÄúDisease progression‚Äù in 
the system organ class (SOC) ‚ÄúGeneral diso rders and administration site conditions.‚Äù 
Evidence that the death was a manifestation of underlyi ng disease (e.g., radiological 
changes suggesting tumor growth or progression : clinical deterioration associated with a 
disease process) should be submitted.  
 Phase 1 and Early Phase 2 Studies:  Expedi ted Reporting Requirements for Adverse 
Events that Occur on Studies under an IND/IDE within 30 Days of the Last Administration 
of the Investigationa l Agent/Intervention 
1, 2 
FDA REPORTING REQUIREMENTS FOR SERIOU S ADVERSE EVENTS (21 CFR Part 312) 
NOTE:   Investigators MUST  immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or not 
they are considered related to the investigational agent(s)/intervention (21 CFR 312.64) 
An adverse event is considered serious if it results in ANY  of the following outcomes:   
1) Death 
2) A life-threatening adverse event  
3) $QDGYHUVHHYHQWWKDWUHVXOWVLQLQSDWLHQWKRVSLWDOL]DWLRQRUS URORQJDWLRQRIH[LVWLQJKRVSLWDOL]DWLRQIRU¬ï
hours  
4) A persistent or significant incapacity or substantial di sruption of the ability to conduct normal life functions  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in  death, be life threatening, or require hospitalization 
may be considered serious when, based upon medical judgment, they may jeopardize the patient or 
subject and may require medical or surgical interv ention to prevent one of the outcomes listed in this 
definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6). 
 
ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the NCI via electronic 
submission within the timeframes detailed in the table below.  
Hospitalization Grade 1 and Grade 2 Timeframes Grade 3-5 
Timeframes  
Resulting in 
Hospitalization  
¬ïKUV  10 Calendar Days 
24-Hour 5 Calendar 
Days Not resulting in 
Hospitalization  ¬ïKUV  Not required 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 64 NOTE:   Protocol specific exceptions to expedited reporting of serious adverse events are found in the Specific 
Protocol Exceptions to Exp edited Reporting (SPEER) portion of the CAEPR. 
Expedited AE reporting timelines are defined as:  
o ‚Äú24-Hour; 5 Calendar Days‚Äù - The AE must initially be submitted electronically within 24 hours of learning 
of the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour report. 
o ‚Äú10 Calendar Days‚Äù - A complete expedited report on the AE must be submitted electronically within 10 
calendar days of learning of the AE. 
1Serious adverse events that occur more than 30 days after the last administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:  
Expedited 24-hour notification followed by complete report within 5 calendar days for: 
x All Grade 3, 4, and Grade 5 AEs 
Expedited 10 calendar day reports for: 
x Grade 2 AEs resulting in hospitalization or prolongation of hospitalization 
2For studies using PET or SPECT IND agents, the AE reporting period is limited to 10 radioactive half-lives, 
rounded UP to the nearest whole day, after the agent/intervention was last administered.  Footnote ‚Äú1‚Äù above applies after this reporting period. 
Effective Date:  May 5, 2011  
 
7.4 Routine Adverse Event Reporting 
 All Adverse Events must  be reported in routine study data submissions.  AEs reported 
expeditiously through CTEP-AERS must al so be reported in routine study data 
submissions. 
 Adverse event data collection and reporting, which are required as part  of every clinical trial, are 
done to ensure the safety of patients enrolled in the studies as well as  those who will enroll in 
future studies using similar agen ts.  AEs are reported in a routine manner at scheduled times 
during the trial using Medidata Rave.  For this trial the Adverse Event CRF is used for routine 
AE reporting in Rave.  7.5 Secondary Malignancy 
 
A secondary malignancy  is a cancer caused by treatment for a previous malignancy ( e.g., 
treatment with investigationa l agent/intervention, radiation or chemotherapy). A secondary 
malignancy is not considered a meta stasis of the initial neoplasm. 
 CTEP requires all secondary mali gnancies that occur fo llowing treatment with  an agent under an 
NCI IND/IDE be reported expeditiously via CT EP-AERS.  Three options are available to 
describe the event:   
x Leukemia secondary to oncology chemotherapy ( e.g., acute myelocytic leukemia 
[AML])  
x Myelodysplastic syndrome (MDS)  
x Treatment-related secondary malignancy  
 Any malignancy possibly related to cancer trea tment (including AML/MDS) should also be 
reported via the routine reporting mechanisms outlined in each protocol.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 65  
7.6 Second Malignancy 
 A second malignancy is one unrelated to th e treatment of a prior malignancy (and is NOT a 
metastasis from the init ial malignancy).  Sec ond malignancies require ONLY routine AE 
reporting unless otherwise specified.   8. PHARMACEUTICAL INFORMATION  
 A list of the adverse events and potential risks as sociated with the investigational or commercial 
agents administered in this study can be found in Section 7.1 . 
 
8.1 CTEP IND Agent(s) 
 8.1.1 CTEP IND Olaparib (NSC 747856) 
 
Chemical Name:  4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-
fluorophenyl)methyl]phthalazin-1(2 H)-one  
 Other Names:  AZD2281; KU-0059436; CO-CE 42 
 
Classification:  PARP inhibitor 
 CAS Registry Number:  763113-22-0 
 Molecular Formula:  C
24H23FN 4O3  M.W.: 434.46  
 Approximate Solubility:  0.1 mg/mL pH independent sol ubility across physiologic range 
 Mode of Action:  Olaparib is an inhibitor of subcla sses 1, 2, and 3 of polyadenosine 5‚Äô 
diphosphoribose polymerase (PARP- 1, PARP-2, and PARP-3). In tumo rs that are deficient in the 
homologous recombination DNA repa ir pathway (example, BRCA muta nts), inhibition of PARP by 
olaparib causes accumul ation of DNA double-stra nd breaks and ge nomic instability. Olaparib may 
also enhance the effects of DNA damage cause d by ionizing radiatio n and chemotherapy.  
 Description:  crystalline solid 
 How Supplied: AstraZeneca supplies and the CTEP, DCTD  distributes olaparib as green, film-
coated tablets in 100 mg and 150 mg strengths.  
 
x 100 mg tablets are 14.5 mm x 7.25 mm oval-shaped 
x 150 mg are 14.5 mm x 7.25 mm oval-shaped 
 
Tablets are packaged in inducti on-sealed high-density polyethyl ene (HDPE) bottles with child-
resistant closures. Each bottle contai ns 32 tablets with desiccant.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 66  
Tablet core components include active drug substance, copovid one, colloidal s ilicon dioxide, 
mannitol and sodium stearyl fuma rate. Film coating contains hydroxypropyl methylcellulose 
(hypromellose), macrogol 400 (polyethylene glycol  400), titanium dioxide,  iron oxide yellow and 
iron oxide black.  Storage: Store in a secure locatio n below 30¬∞ C (86¬∞ F).  
 
If a storage temperature excursion is identified, promptly return olaparib (AZD2281) to room 
temperature and quarantine the supplies.  Provide  a detailed report of th e excursion (including 
documentation of temperatur e monitoring and duration of the excursion) to 
PMBAfterHours@mail.nih.gov  for determination of suitability.  
 
Stability:  Shelf-life studies are ongoing. Sites are not permitted to re-package tablets. Sites are 
not permitted to re -package tablets. Once the bottle is opene d, olaparib tablets must be used 
within 3 months of the opening date; unused tablet s should be discarded. Inst ruct patients not to 
open a bottle until they are ready to use it.  Route  and Method  of Administration:   Oral. Take tablets with out regard to meals.  
 Potential Drug Interactions:  In vivo  data indicate that CYP3A4/5  is important for olaparib 
metabolism and clearance in  humans. For this reason, avoid co ncomitant administr ation of strong 
and moderate CYP 3A4/5 inducers and inhibitors .  Consult the protocol document or study 
investigator prior to making a ny dose adjustments related to potential drug-drug interactions. 
 In vitro data shows olaparib is a substrate for P-glyc oprotein (P-gp), but not for organic anion-
transporting polype ptides (OATP1B1 and OA TP1B3), organic cation transporter 1 (OCT1), multi-
drug resistance protein 2 (MRP-2) efflux transporte r or breast cancer resi stance protein (BCRP). 
Administration of strong P-gp inhibitors and indu cers should be avoided wi th concurrent olaparib.   
 
Based on in vitro  data, olaparib inhibits CYP 3A4 and UGT1A1 enzyme systems and induces CYP 
1A2, 2B6, and 3A4 and potentially induces CY P 2C9, 2C19 and P-gp . Therefore, avoid 
concomitant administration of se nsitive substrates, particularly those with narrow therapeutic 
ranges.   
 
Olaparib is also an inhibito r of P-gp, OATP1B1, OCT1, OCT 2, OAT3, multi-drug and toxin 
extrusion proteins (MAT E1 and MATE2K) and a w eak inhibitor of BRCP, but  not an inhibitor of 
OATP1B3 or MRP-2. In vitro  studies suggest that olaparib may increase exposure of substrates of 
these transport systems, although the clinical relevance is not clear. The manufacturer recommends 
that statins, in particular, sh ould be administered with caution when given concomitantly with 
olaparib.  Live virus and live bacterial vacc ines should not be administered whilst the patien t is receiving 
study medication and during the 30 day follow up pe riod. An increased risk of infection by the 
administration of live virus a nd bacterial vaccines has been observed with conventional 
chemotherapy drugs and the effects with olap arib are unknown. The efficacy of hormonal 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 67 contraceptives may be reduced if co administered with olaparib. 
 Patient Care Implications: Pre-clinical data indicate that olap arib adversely affects embryofetal 
survival and development. Therefore,  women of child-bearing  potential and their partners should 
agree to use two (2) highly effect ive forms of contraception throug hout study participation and for 
at least one (1) month after the last  dose of olaparib.  It is not kn own whether olaparib is found in 
seminal fluid, so as a precaution,  male study participants must use a condom during treatment and 
for three (3) months after the last  dose and should avoid fathering a child or donating sperm during 
this same time period. Th e study investigator shou ld discuss the most appropriate forms of highly 
effective contraceptive me thods for each patient.  
 Lactation is a protocol exclusion criterion and not advised since there is potential for serious adverse 
reactions in breastfed in fants. Advise lactating women to not breastfeed during study treatment and 
for one (1) month after receiving the last dose of olaparib.  
 Because the adverse events related to olaparib  may include asthenia, fatigue and dizziness, 
patients should be advised to use cau tion while driving or using machinery. 
 
There are no data on the effect of olaparib  on wound healing, therefore as a precaution, 
olaparib treatment should be stopped at least 3 days prior to planned surgery. After surgery 
olaparib can be restarted when the wound has heale d. No stoppage of olapar ib is required for any 
needle biopsy procedure. 
 
Study treatment should be discon tinued for a minimum of 3 days  before a patient undergoes 
therapeutic or pal liative radiation treatment. Study treatment should be restarted within 4 weeks 
as long as any bone marrow  toxicity has recovered. 
 8.1.2 CTEP IND Olaparib (NSC 747856) 
 
 8.1.3 Agent Ordering and Agent Accountability 
 
8.1.3.1  NCI-supplied agents may be requested by the Principal Investigator (or their 
authorized designee) at each  participating institution.  Pharmaceutical Management 
Branch (PMB) policy requires that agent be shipped directly to the institution where 
the patient is to be treated.  PMB does no t permit the transfer of agents between 
institutions (unless prior approval from PMB is obtained).  The CTEP-assigned 
protocol number must be used for orderi ng all CTEP-supplied inve stigational agents.  
The responsible investigator at each particip ating institution must be registered with 
CTEP, DCTD through an annual submission of FDA Form 1572 (Statement of Investigator), Curriculum Vitae, Suppleme ntal Investigator Da ta Form (IDF), and 
Financial Disclosure Form (FDF).  If ther e are several participa ting investigators at 
one institution, CTEP-supplied i nvestigational agents for the study should be ordered 
under the name of one lead inve stigator at that institution. 
 
Sites may order olaparib supplies when a patient is enrolled onto the study. 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 68  
Active CTEP-registered investigators and i nvestigator-designated shipping designees 
and ordering designees ca n submit agent requests through the PMB Online Agent 
Order Processing (OAOP) application.  Acce ss to OAOP requires the establishment 
of a CTEP Identity and Access Management  (IAM) account and the maintenance of 
an ‚Äúactive‚Äù account status and a ‚Äúcurrent‚Äù pa ssword.  For questions about drug orders, 
transfers, returns, or acc ountability, call or email PMB a ny time.  Refer to the PMB‚Äôs 
website for specific policies and guidelines related to agent management.    
8.1.3.2  Agent Inventory Records ‚Äì The investigator, or a responsible part y designated by the 
investigator, must maintain a careful record of the receipt, dispensing and final disposition of all agents received fr om the PMB using the appropriate NCI 
Investigational Agent (Drug) Accountability  Record (DARF) available on the CTEP 
forms page.  Store and maintain separate  NCI Investigational Agent Accountability 
Records for each agent, strength, formul ation and ordering investigator on this 
protocol.  
8.1.3.3  Investigator Brochure Availability 
 
The current versions of the IBs for the agents  will be accessible to site investigators 
and research staff through the PMB Online Agent Order Processing (OAOP) 
application. Access to OAOP requires the establishment of a CTEP Identity and 
Access Management (IAM) account and the maintenance of an ‚Äúactive‚Äù account 
status and a ‚Äúcurrent‚Äù password. Questions above IB access may be directed to the 
PMB IB coordina tor via email. 
 
8.1.3.4  Useful Links and Contacts 
x CTEP Forms, Templates, Documents:  http://ctep.cancer.gov/forms/  
x NCI CTEP Investigator Registration:  RCRHelpDesk@nih.gov  
x PMB policies and guidelines: 
http://ctep.cancer.gov/branche s/pmb/agent_management.htm   
x PMB Online Agent Order Processing (OAOP) application: https://eapps-
ctep.nci.nih.gov/OAOP/pages/login.jspx 
x CTEP Identity and Access Management (IAM) account: 
https://ctepcore.nci.nih.gov/iam/index.jsp 
x CTEP IAM account help:  ctepreghelp@ctep.nci.nih.gov  
x PMB email:  PMBAfterHours@mail.nih.gov  
x PMB phone and hours of service: (240) 276-6575 Monday through Friday 
between 8:30 am and 4:30 pm (ET) 
x IB Coordinator: IBCoordinator@mail.nih.gov  
 
8.2 Commercial Agent  
 Ramucirumab (CYRAMZA
¬Æ) is commercially available and will be dosed at 8 mg/kg every 2 
weeks as described above, please see the October 2016 FDA- approved package insert for 
additional details.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 69  
Product description :  Ramucirumab is a recombinant human IgG1 monoclonal antibody that 
specifically binds to vascular  endothelial growth factor re ceptor 2. Ramucirumab has an 
approximate molecular weight of  147 kDa. Ramucirumab is produ ced in genetically engineered 
mammalian NS0 cells. Ramucirumab is  a sterile, preservative-free, clear to slightly opalescent 
and colorless to slightly yellow solution fo r intravenous infusion following dilution and 
preparation.   How supplied: Ramucirumab is supplied at a concentra tion of 10 mg/mL in either 100 mg (10 
mL) or 500 mg (50 mL) single-dose vials. Ramucirumab is formulat ed in glycine (9.98 mg/mL), 
histidine (0.65 mg/mL), hi stidine monohydrochloride (1.22 mg/mL), polysorbate 80 (0.1 
mg/mL), sodium chloride (4.383 mg/mL), and Water for Injection, USP, pH 6.0. 
 Storage and handling: Store vials in a refrigerat or at 2¬∞C to 8¬∞C (36¬∞F to 46¬∞F) until time of 
use. Keep the vial in the outer ca rton in order to pr otect from light. DO NOT FREEZE OR 
SHAKE  the vial. 
 
 
Solution preparation  (how the dose is to be prepared):  
Inspect vial contents for particul ate matter and discolor ation prior to dilution. Discard the vial, if 
particulate matter or disc olorations are identified. Store vials in a refrigerat or at 2¬∞C to 8¬∞C (36¬∞F 
to 46¬∞F) until time of use. Keep  the vial in the outer carton in  order to protect from light.  
‚Ä¢ Calculate the dose and the requ ired volume of ramucirumab n eeded to prepare the infusion 
solution. Vials contain either 100 mg/10 mL or 5 00 mg/50 mL at a concentration of 10 mg/mL 
solution of ramucirumab.  ‚Ä¢ Withdraw the required volume of ramucirumab and further d ilute with only 0.9% Sodium 
Chloride Injection in an intravenous infusion co ntainer to a final volum e of 250 mL. Do not use 
dextrose containing solutions.  ‚Ä¢ Gently invert the container to ensure adequate mixing.  
‚Ä¢ DO NOT FREEZE OR SHAKE the infusion solution. DO NOT dilute with other solutions or 
co-infuse with other elect rolytes or medications.  
‚Ä¢ Store diluted infusion for no more than 24 hours at 2¬∞C to 8¬∞C (36¬∞F to 46¬∞F) or 4 hours at 
room temperature (below 25¬∞C [77¬∞F]).  ‚Ä¢ Discard vial with any unus ed portion of ramucirumab. 
 Route of administration:  Visually inspect the diluted solu tion for particul ate matter and 
discoloration prior to administration. If particulate matter or discolorations  are identified, discard 
the solution. Administer diluted ramucirumab infusion via infusion pump over 60 minutes (+/- 
15 minutes) through a separate in fusion line. Use of a protein sparing 0.22 micron filter is 
recommended. Flush the line with sterile sodium ch loride (0.9%) solution for injection at the end 
of the infusion.  Prior to each ramucirumab infusion, premedicate a ll patients with an intr avenous histamine H1 
antagonist (e.g., diphenhydramine hydrochloride). Fo r patients who have experienced a Grade 1 
or 2 infusion-related reaction, also premedi cate with dexamethasone (or equivalent) and 
acetaminophen prior to e ach ramucirumab infusion. 
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 70 Agent Ordering:  Commercially available through Eli Lilly and Company. 
 9. BIOMARKER, CORRELATIVE , AND SPECIAL STUDIES 
 9.1 Integral Laboratory or Imaging Studies 
Not applicable  
 9.2 Integrated Correlative Studies 
 9.2.1 BROCA-HR  (Integrated Biomarker) 
To assess correlation of response and effect of  homologous recombination deficiency (HRD) 
status, the BROCA-HR assay, esta blished by the Swisher laboratory  will be applied. In addition 
to testing the tumors, a blood sample will be  obtained at baseline for germline BROCA-HR 
testing. Somatic BROCA-HR testing will be done using the baseline tumor biopsy tissue on all 
pre-treatment biopsy specimens. The prevalence of biomarkers and correlation with response 
will be used to plan subsequent study as described in section 13 . 
 
One hypothesis for response to a PA RP inhibitor is that cancer ce lls need to be deficient in 
homologous repair, but also proficient in the al ternative error prone non-homologous end joining 
DNA repair pathway. Thus, loss of HR is not by it self, sufficient for sensitivity to a PARP 
inhibitor, and an accurate predictor of res ponsiveness could require assessment of many 
components of both the HR and non-homologous end joining pathwa ys. A more efficient assay, 
which would not require a prior knowledge of the critical elements of these DNA repair 
pathways, would instead measure DNA repair  capacity. Recent ev idence suggests that 
BRCA1/BRCA2 deficient cancers exhibit global DNA alterations termed ‚Äúgenomic scarring‚Äù 
that are consistent with their reliance on non-homologous end joining. Th is genome scar could 
serve as a downstream functiona l output to measure DNA repair capacity, indicative of both HR 
deficiency and non-homologous end joining profic iency. The BROCA-HR panel will be applied 
to the tumor samples as an integrated biomarker to  evaluate if ‚Äúgenomic scarring‚Äù is present in 
the tumor samples. Additiona l detail is provided in 2.4.1. 
 DNA will be extracted from peri pheral blood mononuclear cells and FFPE archived tumor tissue 
containing at least 30% tumor nuclei. A target ed capture and massively  parallel sequencing 
approach called BROCA-HR will be applied to sa mples. For the proposed study, the most recent 
version of BROCA-HR panel with 84 genes that  serves as a single as say for germline and 
somatic mutations that influence response to therapy will be u tilized. Library preparation has 
been fully automated to increase sample turn around and lower cost. Paired-end libraries with 
ESLQVHUWVZLOOEHSUHSDUHGIURP»ùJRIFRQVWLWXWLRQDORUQ HRSODVWLF'1$DQGK\EULGL]HWRD
custom pool of oligonucleotides targeting genomic regions as pr eviously described using the 
SureSelectXT enrichment system on a Bravo liq uid-handling instrument (Agilent). Following 
capture, samples will be barcoded with 48 diff erent indexed primers. The pooled samples are 
sequenced on a single lane of a HiSeq flowcel l (Illumina) with 2x101bp paired end reads and a 
7bp index read to allow for de-multiplexing a nd binning of individual samples. Single agent 
variants and insertions and deleti ons will be detected as previous ly described with some updates 
in the bioinformatics pipeline. Deletions and duplications of exons will be detected by a 
combination of depth of coverage and split read analysis as previously described, supplemented 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 71 with additional alignments generated by SLOPE. All germline loss of function mutations in 
cancer susceptibility genes will be confirmed with PCR amplification and Sanger sequencing. 
Cases will be identified as HR proficient or  deficient based on sequencing data of known 
Fanconi anemia (FA)-BRCA genes and then corr elate HR proficiency with response to PARPi 
on the trial.  9.2.1.1  Collection, handling, and shipping of speci mens. Details for specimen collection, 
preparation, and shipping will be outlined in  a lab manual that will be provided to the 
sites. In short, tumor samples will be co llected at each study site. Tissue will be 
formalin-fixed and paraffin embedded. The samples will then be shipped to the Yale 
STS laboratory for further proc essing. Slides with cut tumo r sections will be shipped 
from Yale to Dr. Swisher‚Äôs lab at University  of Washington for the analysis described 
above. In addition, 7ml of blood is require d for germline sequencing, which will be 
shipped to Dr. Swisher‚Äôs laboratory directly. 
 9.1.1.2 Site(s) Performing Correlative Study:  Dr. Elizabeth M. Swisher, MD  University of Washington  1959 NE Pacific St  Health Sciences Building K154  Seattle, Washington 98195-6460  
Phone: 206-543-3669  
swishere@uw.edu  
 9.3 Exploratory/Ancillary Correlative Studies 
 9.3.1 Immunoassay for Poly-ADP-Ribosylated (PAR) Substrates 
 The immunoassay for PAR substrates will be pe rformed on all 16 week post treatment biopsy 
specimens. The PARP enzyme creates poly- ADP-ribosylated (PAR) molecules, thus an 
immunoassay was developed to measure PAR as  a surrogate for PARP inhibition. Abbot 
Laboratoies and the NCI-Frederick developed a cross-validated quantitative immunoassay for 
poly-ADP-ribosylated (PAR) substrate. The assa y dynamic range is 31-2000 pg/ml PAR with a 
lower limit of quantitati on of 15 pg/ml PAR. The assay uses high, midrange, and low controls 
produced from the human melanoma line Colo8 29. Specimen handling was optimized for both 
PBMCs and tumor needle biopies (18 gauge), and harmonized for use with the same standard 
and controls. Specimens could be subjected to at least 3 freeze-thaw cycles without a detectable 
loss of antigen binding. Assay preci sion was determined at both A bbott and the NCI-Frederick to 
be better than 80%. Accuracy, as assessed by spike recovery of pure PAR into peripheral blood 
mononuclear cell lysates was 100% +/- 20%. Assay dilution linearity was established for the 
Colo829 controls and tumor lysa tes, although deviations from linearity are observed in some 
tumor homogenates, and assay conditions are contro lled to compensate for the lack of linearity. 
The validated assay has been used to measure PA R levels in peripheral blood mononuclear cells 
in healthy donors, and will be used to measur e PAR in peripheral blood mononuclear cells and 
tumor biopsies in the proposed protocol.   
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 72 9.3.1.1  Collection of Specimen(s) 
9.3.1.2  Handling of Specimens(s) 
9.3.1.3  Shipping of Specimen(s) 
9.3.1.4  Site Performing Correlative Study:  
Dr. Joann Sweasy Laboratory 
 15 York Street  Hunter Building 308  New Haven, CT 06520   Joann.sweasy@yale.edu   
 203-785-2981 
 9.3.2 Signature 3  
Collection, Handling, and Shipping of Specimens: 
 Signature 3 testing will be done on all pre-trea tment biopsies for anal ysis as a potential 
biomarker. The results of signatu re 3 testing will be correlated  with ORR, and other potential 
biomarkers including the BROCA-H R panel and signature 3 testi ng The following description of 
the biomarker testing for this was prepared at the recommendation of Drs. James Tricoli and Tracy Lively at the NCI, who were consulted about the form this part of th e protocol should take.  
Because much of the DNA-Based Mutation Assay Template does not fit next generation sequencing (NGS) of tumor DNA, they suggested that  a separate, full desc ription of the proposed 
testing be submitted along with a copy of th e DNA-Based Mutation Assay Template competed to 
the extent possible for a study involving NGS. 
 
Whole exome screening of DNA from gastric tumors  for the signature 3 mu tational pattern will 
be performed in the Yale Clinical Molecu lar Pathology Laboratory (YCMP Lab) on tissue 
microdissected from histologic sect ions of gastric tumor specimens. These sections will be cut 
from formalin-fixed, paraffin-embedded (FFPE ) blocks and mounted unstained on glass 
microscope slides.  One of the se ctions adjacent to those cut fo r microdissection will be stained 
with hematoxylin and eosin and ex amined by a pathologist (Dr. Sklar) to assess tumor content, 
location of the tumor cells within the section, and the extent, if pr esent, of necrosis, hemorrhage, 
or any other potentially interfer ing features or conditions.  Th e areas containing concentrated 
tumor cell populations in the stained slide will be circled and the corresponding regions in the 
unstained slides manually microdiss ected with a sterile scalpel blad e.  In cases for which manual 
microdissection is not ade quate, for instance, due to small cl usters of tumor cells distributed 
within stroma or other non-malignant tissue, la ser-capture microdissection will be carried out.  
The goal for this pre-analytic part  of the testing is to obtain, ei ther by manual or laser-capture 
microdissection, starting material th at is enriched for tumor cells to the level of at least 70% 
tumor.  Enrichment of tumor prior to sequencing increases th e sensitivity of the sequencing, 
which will be important because of the reduced read depth inherent in whole exome sequencing 
(WES). 
 
DNA will be extracted from these tissues using the Qiagen FFPE DNA Tissue Kit.  Additionally, 
normal DNA from the patient will be obtained from buccal swabs or  from histologically normal 
tissue, free of tumor.  WES of tumor and normal DNA will be conducted in parallel using the Ion 
Torrent whole exome platform.  Libraries of DNA fragments for sequenci ng will be constructed 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 73 by highly multiplexed PCR of tumor and nor mal DNA using AmpliSeq Exome primers.  
Libraries for tumor and normal DNA will be built separate ly incorporating s hort oligonucleotide 
sequences at the end of the fragments to ‚Äúbar code‚Äù the DNA fragments from the two sources.  
(Since the libraries generate d from tumor and normal DNA w ill be mixed and sequenced 
together, barcoding is necessary to disambiguate  the results for tumor and normal DNA when the 
sequence results are analyzed.)  Input for the initial amplification dur ing library building (18 
cycles of PCR) will be 60 ng of genomic tumor DNA and 20 ng of normal DNA (lower for 
normal DNA because of less need for read depth and analytic sensitivity ), distributed among 12 
primer pools in 12 different tubes. Amplicons fr om the library builds will be reamplified and 
attached to sequencing microbeads in aqueous dr oplets within water-oil em ulsions (all performed 
using the Ion Chef instrument), su ch that the great majority of beads are decorated with a pure, 
clonal population of amplicons.  Sequencing of the DNA amplicons on beads will be carried out 
with P1 v3 sequencing chips (each containing >165 million sensor well s each capable of 
sequencing amplicons attached to a single bead) on a Proton sequencer, or with Ion 540 chips on 
a S5 XL sequencer.  Both instruments are available in the lab for this project; however, the greater likelihood is that the P1/P roton system will be used becau se it is cheaper.  With highly 
efficient sequencing chip loading that achieved in the YCMP Lab (occupation of ~90% of wells 
in the P1 chip), the mean read depth is expected to exceed 200x for the tumor DNA and 
proportionately lower for the norma l control.  Using the newer HiQ chemistry, average fragment 
lengths should be about 250 nucleotides for a bout 3.2 megabases of total DNA, covering about 
98% of the exome.   
 
The raw sequencing results will be aligned to  the hg19 reference genom e and variants called 
using Torrent Suite, Ion Reporter,  and custom software develope d at Yale.  Those variants 
deemed somatic by virtue of their absence from  the matched normal DNA of  the patient, will be 
evaluated for signature 3 sequences, using an algo rithm designed in house,  specifically for this 
purpose.  Mutations in critical genes and a sa mpling of signature 3 mu tations (a sampling only 
because of the high volume of such mutations e xpected per case) will be manually checked as a 
quality control, in addition to review of overall quality metrics produced by Ion Torrent software 
for each sequencing run.  
 
The Ion Platform system affords a particular a dvantage relative to Illu mina sequencing for the 
research proposed in this LOI. Ion Torrent ha s pioneered the use of highly multiplex PCR to 
select regions of genomic DNA for targeted se quencing (for instance,  ~24,,000 amplicons per 
primer pool to cover the entire exome).  This approach generally  means that smaller amounts of 
starting DNA are needed for sequencing, includi ng for WES‚Äîa critical consideration when 
dealing with clinical samples, which often consis t of core needle biopsy or aspiration specimens 
that must also be utilized fo r a variety of diagnostic tests and analyses.  The theoretical 
disadvantage of Ion Torrent is lo wer throughput.  To increase read  depth and horizontal coverage 
across the exome, an entire sequenci ng chip will be used for each ca se (tumor plus paired normal 
control from the same patient).  Illumina flow cells accommodat e more cases per run, but this 
difference is negated by th e fact that cases for th e proposed trial will come  in one at a time and 
batching will not be possible, to achieve a turnaround time for returning sequencing results 
within 10 days of receipt of the specimen in th e YCMP Lab, which is the intent for biomarker 
analysis in this trial.  Both Illumina and Ion Torrent sequencing are asso ciated with systematic 
sequencing errors‚ÄîIllumina related to CG-ri ch regions and Ion Torrent related to 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 74 homopolymeric regions of seque nce.  The YCMP Lab has ex tensive experience with the 
bioinformatics to interpret Ion Torrent sequencing and the identifi cation of artifacts, both through 
the development out of the Yale Tumor Profil ing Lab (see below), from which the YCMP Lab 
was spun off, and through the NCI-MATCH trial for which the YCMP Lab is one of the four 
national sequencing centers.  Furthermore, the pa rallel sequencing of nor mal paired DNA permits 
discrimination and elimination of many of th ese artifacts encountered with Ion Torrent 
sequencing. 
 
Validation for feasibility, clinical sensitivity, sp ecificity, limit of detec tion, reproducibility, and 
fit for purpose will be carried out using control samples that are available to the YCMP Lab from 
the Yale Tumor Profiling Lab, which was founde d by Dr. Sklar six years ago, and performs 
routine clinical NGS of tumor DNA using a variet y of gene panels, including a 409-gene panel 
that contains analyzes most known cancer-rela ted genes. Among the cases that have been 
sequenced and are available as controls, ar e a sizable number that contain verified BRCA1/2  
mutations or lack mutations in BRCA1/2  and other genes in the hom ologous repair pathway.  
DNA samples from cases that have b een previously analyzed by WE S are also available, as are 
DNA from cell lines that have been previously subjected to WES. 
 
Feasibiilty testing will carried out on six cases of FFPE tissue with known sequences.  The 
primary purpose of this activity will be to insu re that the coverage and depth of sequencing 
described above can be achieved on a routine basis.   
 
Following feasibility testing, va lidation for clinical sensitiv ity will be performed on 20 DNA 
samples.  The vast number of potential varian ts that are possible within the human genome 
presents a problem for validati on of biomarker detection by NGS, compared, for instance, to 
validation of a single variant or small set of vari ants located within one or two genes.  We will 
take two approaches to this problem.  One will be to sequence the DNA from 12 FFPE samples 
(preferably gastric carcinomas), the DNA of which has either been large gene panel sequenced or 
undergone WES.  We will select these cases to cont ain a variety of differe nt types of mutations: 
VLQJOHQXFOHRWLGHYDULDQWV619V VPDOOLQVHUWLRQVDQGGHOHWLR QVLQGHOV¬îEDVHSDLUVODUJHU
indels (>4 basepairs), and gene am plifications.  However, for this  validation and trial, the most 
relevant variants will be SNVs because signat ure 3 mutations represent a subset of SNVs.  
Additionally, six of the FFPE cases will be ones that contain mutations of BRCA1  or 2, both to 
confirm that mutations in these genes can be detected in FFPE tissues and that the signature 3 
pattern of mutation normally associated with muta tions of BRCA1/2 can be  accurately discerned. 
 
The second approach will be to perform WES on DNA of eight from established HAPmap cell 
lines in which all single nucleotide polymorphisms (SNPs) have been determined previously and 
are available from commercial and other sources.  Some of them have been used in the NCI-
MATCH sequencing validations and ar e already in the lab.  These cel ls lines will be prepared as 
cell pellets, fixed in 10% buffere d formalin, and embedded in paraff in, to simulate FFPE tissue.  
The rationale for using HAPmap cell lines is to evaluate the sequenc ing system being utilized as 
efficiently and thoroughly as pos sible for its ability to detect  variants thro ughout the exome. 
 
Validation for specificity will be combined with sensitivity testing to show that false negative 
variants are detected at a minimum  in the 20 samples studied for cl inical sensitivity by WES.  A 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 75 sampling of apparent false negative varian ts that cannot be eliminated by adjusting 
bioinformatics filters used in variant calling will be analyzed by Sanger sequencing to resolve the 
ambiguity and help to es tablish the true rate of false negative results. 
 
Limit of detection will be pe rformed by performing WES on se rially diluting four FFPE DNA 
samples into HAPmap DNA (e.g., 50%, 25%, 12.5% , 6.25%, and 3.12%) to determine the lowest 
concentration at which confirme d variants within the FFPE D NA can still be detected.  The 
expected level is 5-10%, given th e mean average read depth of 200x. 
 
Validation of reproducibility will be conducted by perfor ming WES three times each on DNA 
four FFPE samples to determine whether each sequence analysis produces the same results.  
These three repetitions will be performed on differ ent days, which is required due to the capacity 
of the Proton sequencer, but also serves as a tr uer test of reproducibilit y.  Additionally, over the 
course of the trial, DNA from th e same HAPmap sample will be analyzed after every twentieth 
case to check for cont inued reproducibility.  
 
Fit for purpose validation of the entire biomarker workflow will be carried out by having two centers other than Yale mail samples to the YCMP lab and performing WES to insure that 
samples can be processed efficiently within the 10-day window.  Optimally, we will try to have 
this performed on samples that have been extens ively sequenced elsewhere.  Alternatively, we 
can mail to ourselves samples from which the DNA has previously  been sequenced at Yale. 
 
Please also see the NCI template for ‚ÄúDNA-based  Mutation Assays‚Äù and the ‚ÄúStandard Operating 
Procedures‚Äù for WES by the Yale Clinical Mo lecular Pathology Laboratory, which are provided 
as separate documents.   Site Performing Correlative Study: Dr. Jeffrey Sklar in the Yale Molecular Pathology Lab PO Box 208023 310 Cedar St. LH 215 New Haven CT 06520 203-785 4492  9.3.3 Genomic assay for ‚ÄúBRCAness‚Äù 
 Through our involvement in the PanCancer genomic s project, we have direct access to the 
combined germline and somatic data form 3,299 TCGA tumors from 12 cancer types [80] [81] . 
These are exome data derived from TCGA. A pproximately 150 of th ese exomes are form 
germline carriers of mutant BRCA 1/ 2 alleles. Since our goal is to build a diagnostic test that can 
identify not only germline variants in BRCA family genes, but to also identify genomic scarring 
based on LOH/HRD we need a test with suffic ient coverage to do both. We will run three 
algorithms on the TCGA germline BRCA 1/2 de ficient and disease-matched controls: The 
number of telomeric allelic im balances (NtAI), large scale transition (LST), and homologous 
recombination deficiency score (HRD-LOH) [82-84].  We will run all three assays on SN P data from the aforementioned  300 case / control sets and 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 76 assess diagnostic sensitivity, specificity and acc uracy, using germline BRCA status as the gold 
standard. AUC curves will be calculated and the top performing test(s) will then be brought 
forward first to the down sampling set, described below.  The most ideal scenario would be  if we had enough sequence data in  the panels that we use for 
allocation to clinical trials, such as that c onduced herein. This tria l will use the BROCA-HR 
panel, and whole exome sequencing data will be available for the signature 3 correlative 
analysis. We will then rerun the NTAI, LST, and HRD-LOH assays described above using the down sampled exome data as the input.  AUC curves will be calculated and the top perfor ming test(s) will then be validated by analyzing 
archival cases of gastric cancer available through the UCSF HDFCCC Tissue Core. DNA 
extracted from tissue sample s will be analyzed for the HR defe ct signature iden tified through the 
work described above and mutations in the BRCAness-associated genes identified by us 
(BRCA1, BRCA2, ATM, ATR, PTEN, PARP1,  MRE11A, PALB2, CDK12, BAP1, PRKDC, 
BARD1, BACH1, FANCD2, FANC E, CHEK1, CHEK2, PMS2, FA NCA, FANCC, FANCF, 
XPA, NBN, BLM, BRIP1, RAD51B, RAD51C, RAD51D, and RAD50) by next generation 
DNA sequence analysis using a capture approach a nd the Illumina Myseq instrument (available 
at the UCSF Gladstone Genomics Core). Subseq uently, the signature will be applied in a 
systematic manner to the data produced in the clinical trial with one of these assays. The 
validation studies will be perform ed in Dr. Ashworth‚Äô laboratory at  UCSF. Prior work in gastric 
cancer estimates that around 20% of  samples will score in the upper quartile of all three of these 
assays [85]. These estimates will then be availa ble for further analysis  such as supervised 
analytics looking at response to PARP, platinum , and other clinically observed characteristics. 
 Expected results: This aim will determine the ap plicability of clinically deployed sub-exome 
sequencing panels for the assessment of BRCAness using genomic measurements. 
 Pitfalls/alternative appr oaches: It is possible that the DNA footprint generate d by the commercial 
assays fails to reliably detect BRCANess in TCGA exomes. In particul ar, the NtAI may not 
perform well because it requires telomeric seque nces, which are not well captured on sub-exome 
panels. If this were the case, and further fundi ng were obtained we coul d begin work on building 
a targeted addition to these tests, but that w ould increase costs and not be ideal for large 
population screening at major cancer centers.  
 Site(s) Performing Correlative Study:  Dr. Michael Korn (UCSF) Box 1705, UCSF San Francisco, CA 94143-1705 Michael.Korn@ucsf.edu   9.3.4 Factors demonstrating synthetic lethality with  PARP inhibitors in  gastric cancers.  
 Aim 1. Elucidating the role of key si gnal transduction processes in  mediating responsiveness to 
PARP inhibitors in gastric cancer.  We will expand our panel of gast ric cancer cell lines to a total 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 77 of 20 cell lines. These lines that are genomically well characterized as part of the Cancer Cell 
Line Encyclopedia (Broad Institute). Cell lines will be selected harboring mutations conferring 
BRCAness and to represent chromosomally instab le and mismatch repair deficient subtypes of 
gastric cancer. We will profile ce ll lines for their responsivene ss to DNA damaging agents and 
PARP inhibitors, either alone or  in combination. These include bl eomycin (a dir ect inducer of 
DNA double-strand breaks) and cisplatin as well as  temozolomide (both i ndirect inducers of 
DNA double- VWUDQGEUHDNV&HOOOLQHVZLOO EHWUHDWHGZLWKEOHRP\FLQ »ùJPOFLVSODWLQ
»ù0RUWHPR]RORPLGH»ùJPO RU3$53LQKLELWRUVRODSDULEW DOD]RSDULERUUXFDSDULEDOO
compounds are available at the Ashworth and Korn  labs from commercial sources) for up to 5 
days and analyzed for cell viability (Cell TiterG lo assay), alterations in  cell cycle distribution, 
and apoptosis (fluorescence activat ed cell sorting, FACS). To a ssess the extent of DNA damage 
we will measure intra-nuclear »ñH2AX focus formation by conf ocal microscopy. Cells will be 
grown and treated on cover-slips in  6-well dishes and, after fixati on, stained using a rabbit anti- 
»ñ+$;DQWLERG\7KHQXPEHURIIRF LLQDWOHDVWFHOOVSHUFR YHUVOLSZLOOEHGHWHUPLQHG7R
assess PARP activity, poly-ADOP-ri bolyzation will be determined  using a chemiluminescence 
detection approach (Universal  Chemiluminescent PARP Assay Kit, Trevigen). Based on the 
results of this initial screen, a subset of cel ls with low and high DNA repair response to DNA 
damaging agents as well as low and high sensitivity  to PARP inhibitors will be selected.  Cells 
will be treated with increasing doses of inhib itors of key oncogenic pathways, including PI3K 
(BKM120, BYL719), RAF-MEK-ERK (GSK1120212, PD- 7*)»ï/<
WNT (PRI-724), Notch (LY-3039478), Hedghog (vismo degib), JAK-STAT (ruxolitinib). Based 
on these results of this initial screening, drug co mbinations will be test ed. For example ,if we 
reproduce down-regulation of DNA repair activity by PI3 kinase inhibitors, we will assess 
efficacy of these inhibitors in combination wi th PARP inhibitors +/- DNA damaging agents.  
 Aim 2.  Unbiased identification of modifiers of responsiveness to PARP inhibitors. We will 
utilize a pooled shRNA library (D ECIPHER, Cellecta) to identify potential modifiers of response 
to PARP inhibitors. The library contains 27,500 sHRNAs targeting 5,046 signaling components. 
We will select gastric cancer cell lines with intermediate sensitivity to the highly potent and 
selective PARP inhibitor talazoparib based on the results obtained in Aim 2A. Cells will be 
infected with lentiviruses expressing th e sHRNA library and s ubjected to selection. 
Subsequently, cells will be treated with talazopa rib or with vehicle control. Abundance of each 
barcoded hairpin will be quantified to identify shRNAs that were selectively depleted during 
treatment with talazoparib, but not  vehicle. TO assess the total population of transduced shRNAs 
for control purposes, genomic DNA will also be is olated and shRNAs iden tified from cells just 
after transduction but before drug treatment. Analysis of abundance shRNA species, next-
generation DNA sequencing will be utilized in collaboration w ith the UCSF Genome Analysis 
Core. Hits will be validated experimentally using multiple shRNA species or specific inhibitors 
if available.  Aim 3. Establishment of PDX tumors from patient sa mples and assessment of target inhibition 
and efficacy of novel drug combi nations involving PARP inhibitors. Fresh biopsies will be 
obtained from selected patients, and on repeat bi opsy at 16 weeks for elig ible patients. We will 
aim at capturing tumors harbor ing a diverse spectrum of mu tations conferring BRCAness. We 
will rest target inhibition and efficacy of nove l combination therapies in these PDX models. 
Based on our preliminary data, we expect that this will include a combination of MEK and 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 78 PARP inhibitors. Before testing this combinati on or new combination resulting from the work in 
aims 1 and 2, in mice harboring xenograft tumors, we will assess treatment t oxicity in NOD scid 
mice. Groups of three mice will be treated wi th solvent (DMSO), single inhibitors (e.g. 
talazoparib or PD0325901), or the co mbination of both at three diffe rent dose levels. In the case 
of talazoparib and PD0325901, mice will be treated at dose levels 0.1, 0.22, and 0.33 mg/kg of 
talazoparib and 5, 7.5, and 10 mg/kg of PD0325901 resu lting in a 4 x 4 matrix requiring 32 mice 
per study. The maximum doses of both inhibitors that can be administere d without occurrence of 
severe toxicity will be chosen for subse quent studies. We will then proceed with 
pharmacodynamics studies to va lidate target inhibition by the PARP and MEK inhibitor 
combination in the PDX models. Per individual tumor model, subcutaneous tumors will be 
generated in 6 mice and allowed to grow to a volume of 300 mm
3. Animals will be dosed with 
the compounds (for example tala zoparib and PD0325901) or vehicle control buffer fo r three days 
at doses that were found to be safe in the toxi city studies. Animals will be sacrificed for hours 
following the last drug administration. Tumors a nd adjacent normal tissue will be harvested and 
snap-frozen in liquid nitrogen or fixed in buffe red formalin. Proteins will be extracted from 
frozen tissues using protocols esta blished at our laboratory. Phosphor ylation of effector proteins, 
including pERK, pAKT, and pPRAS40 will be dete rmined by quantitative Western blot analysis 
using fluorescence based imaging system (Odyssey, Licor). PARP inhibition will be assessed 
using the PARP in vivo PD Assay II kit (Trevige n). If no evidence of target inhibition is 
observed in any model for a given inhibitor, the respective experi ment will be repeated at a 
modified dose based on the toxicity study. Othe rwise, apoptosis induction will be evaluated by 
TUNEL assay. A Student t-test will  be used to determine statisti cal significance of differences 
between treated and control groups. Efficacy stud ies in primary PDA xenograft tumors will also 
be conducted. Having established optimal doses for efficient target inhibi tion, we plan efficacy 
studies in the selected PDX models. Endpoints for these studies will be tumor response rate and 
overall survival. Tumor size will be calculated  with biweekly caliper  measurements. Compounds 
will be administered daily by oral lavage. Experi ments will be terminated on day 28 or when any 
tumor exceeds 1,500 mm3 in greatest dimension. Relative tu mor growth inhibi tion (TGI) will be 
calculated by relative tumor growth of treated mice (T) divided by relative tumor growth of 
FRQWUROPLFH,RU7&:HZLOOXVHWKHIROORZLQJGHILQLWLRQV 5HVSRQVH  -20% TGI; Stable 
GLVHDVH   WR7*,7XPRUSURJUHVVLRQ¬ï 7*,3HUVWXG\WKHUHZLOOE HIRXUFRKRUWV
treated with control (i.e. DM SO), single agents (for exampl e talazoparib and PD0235901), and 
drug combination. We will enroll 8 tumor bearin g mice per treatment group. With this sample 
size and using a 1-sided t-test, we can detect a 33% or greater growth inhibition with 80% power 
at a 5% level of significance. Experiments will be repeated once. Differences in response rates 
will be determined using Satterwaite‚Äôs t-test (une qual variances) with 1-sided 5% Type I error. 
Kaplan-Meier survival data will be analyzed using a log rank test. 
 Pitfalls/alterative appr oaches: The proposed experiments are likely to reveal new mechanisms 
involved in DNA homologous recombin ation repair that can be e xploited therapeutically. Our 
findings related to the intera ction of the RAF-MEK-ERK pa thway and PARP inhibitors 
sensitivity are an example of successful ap plication of the candidate pathway approach. 
However, the pathways of interest are highl y interconnected. Based on the findings of the 
experiments described, we might ex pand mechanistic analysis to be able to interpret findings. In 
such case we will utilize Reverse Phase Protei n Lysate Array technology as we have done 
before. We expect that CRISPR anal ysis will be technically feasib le and reveal new regulators of 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 79 HR repair. The technology is established in the Ashworth lab. If te chnical challenges are 
encountered, we will collarboarte with Drs. Kampmann and Weissman at UCSF who invented 
the technology. The team at Memorial Sloan Kette ring Cancer Center ha s extensive experience 
with establishing PDX models and we don‚Äôt expect any problems with this  part of the aim.  
 Sites Performing Correlative Study:  Dr. Michael Korn (UCSF) and Dr. Yelena Janjigian (Memorial Sloan Kettering) 
Box 1705, UCSF San Francisco, CA 94143-1705 Michael.Korn@ucsf.edu  9.3.5 T Cell Receptor Diversity.  
 By using next generation sequencing of TCR »ïUHSHUWRLUH'U)RQJ¬∂VODEKDVGHPRQVWUDWHGWKDW
maintenance of pre-existing high-fr equency clonotypes is associated  with clinical response and 
improved overall survival following ipilimumab [ 79]. Using these established methods, we will 
determine the T cell clon otypes in blood of clinical trial patients obtained pre- and post-
treatment. Repertoire diversity will be measured using Shan non‚Äôs and clonality [86, 87]. 
Repertoire change between serial timepoints will be measured using Morisita‚Äôs distance, which 
is not significantly influence by sa mple size [88, 89]. Numbers will be reported as distances with 
1 indicating maximal dissimilarity. Paired t te st will be applied to each diversity metric 
comparing pre-and post-treatment to  test if there is a significant  treatment effect. Two-sample 
Wilcoxon rank sum test will be util ized to compare the clonality  index at each time point 
between patients with and without BRCAness. All analyses will be done by statistical software. 
Statistical significance will be decl ared at an alpha level of 0.05, and no adjustment will be made 
for multiple comparisons unless noted. Identification of differen tially abundant clonotypes pre 
and post-treatment for each sample will be performed using a DESeq R package modified to account for normal variation in th e repertoire over time and to compensate for the lack of 
replicates in the experimental  design. Multiple testing adjustments will be accomplished by 
controlling FDR for each sample. Downstream analys is will be applied to those significant clone 
to see if multiple T cell cl onotypes with different nucleotid e sequences may converge upon the 
same amino acid sequence, wh ich would be consistent with antigen selection.  
 Where available, comparisons of TCR transcri pt frequency and repertoi re diversity (Shannon‚Äôs 
and clonality indices) will be made between pre-  and post-treatment biopsies by paired Wilcoxon 
rank sum test. At an alpha leve l of 0.05, 20 samples would ensure  80% power to detect effect 
size of 0.66 in repertoire diversity  to declare that there is a significant difference in TCR 
frequency between pre- and post-tr eatment biopsies. We also plan  to compare biopsies from 
patients with and without BRCAness.  We routinely test PBMC processed in our labor atory for HLA-A2 expression. For patients who 
possess this HLA allele (approximately 40% of UCSF patients) and are known to have HPV+ 
tumors, we use MHC-peptide tetramers, specifi c for HPV derived epitopes (Beckman Coulter, 
Brea, CA) to FACS sort HPV reactive CD8 T cells. These sorted T cells will also be subjected to 
TCR sequencing. We will then use the clone-specifi c sequences to track th ese antigen-reactive T 
cells in both the blood and tissue with  established methodologies [79]. 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 80  
Pitfalls/alternative appr oaches: As we have seen in panc reatic adenocarcinoma, BRCA2 carreirs 
can possess a higher number of neoepitopes. We anticipate that patients with the highest 
neoepitope burden (e.g. with BRCAness phenotype) wi ll have a lower clonality indices (i.e. 
greater TCR diversity) in both the blood and the tumors. The tetramer sorting experiments will 
allow us to determine the relative contribution of  virus-specific T cells to the modulated immune 
responses with PARPi. However, the circulating T cell repertoire may not reflect what is going 
on in the tumors. Our approach will allow us to  determine whether the TCR repertoire in the 
blood can serve as a surrogate for the TCR repert oire in the tumor. We  may find that a high 
neoantigen burden could actually lead to increased clonality (i.e. decreased diversity) in tumors due to focusing of the immune response to th ese immunodominant epitop es. Nevertheless our 
approach will be able to as sess for this alte rnative hypothesis. We do not anticipate any 
difficulties in performing these as says. These results would lay ra tionale for combinations with 
immunotherapy in the future.   Site(s) Performing Correlative Study:  Dr. Michael Korn (UCSF) Box 1705, UCSF San Francisco, CA 94143-1705 Michael.Korn@ucsf.edu  9.3.6 Circulating Tumor DNA (Exploratory Correlative). 
Peripheral blood will be placed in a biorepository  for assessment of circulating tumor DNA and 
molecular profiling at a later date.  9.3.6.1  Specimen Receipt and Processing at the EET Biobank  
Plasma specimens will be transferred to the EET Biobank for extraction of cfDNA. 
 9.3.6.2  Site Performing Correlative Study 
Circulating Tumor DNA will be performed by the NCLN Genomics La boratory under the 
direction of Mickey Williams, Ph. D.  
 9.3.6.3  Shipment of specimens from the EET Bioba nk to Site Performing Correlative Study 
 
Specimens will be shipped from the EET Biobank to: NCLN Genomics Laboratory at The Univ ersity of Texas MD Anderson Cancer 
Center 6565 MD Anderson Blvd Suite 3.4019 Houston, TX 77030 Attn: CTO, NCLN Lab, Jincy Veli yathu or Khushali Rajendra Patel 
 
9.3.6.4  Contact Information for Notifi cation of Specimen Shipment 
Thomas Forbes, NCLNGenomicsReceiving@nih.gov  
  
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 81  
10. STUDY CALENDAR 
 Phase 1 and Phase 2: 
Baseline evaluations are to be conducted within the 28-day scr eening period. CT scans and x-
rays must be done <4 weeks prior to the start of therapy.  In the event th at the patient‚Äôs condition 
is deteriorating, laboratory evaluations should be repeated within 48 hours prior to initiation of 
the next cycle of therapy.  
 Pre- 
Study11 Cycle 1  
(¬±2 days)  Cycle 2 
(¬±2 days) Cycle 3 
(¬±2 days) Cycle 4 
(¬±2 days) Cycles 5 ‚Äì 7  
(¬±2 days) Cycle 8 and 
later 
(¬±2 days) Follow up5 
Day  1 8 1 8 1 8 1 8 1 8 1 8  
Olaparib  A----------------------------------------------------------------------------------------------- √Ü  
Ramucirumab13  B  B  B  B  B  B   
Informed consent X11              
BROCA-HR Testing X              
Pre-treatment Biopsy1 X1              
On-treatment Biopsy2            X2   
Research blood for biobank  X X X X  X  X  X  X  X 
Demographics X              
Medical history X              
Adverse Event Evaluation X X X X  X  X  X  X  X 
Physical exam X X  X  X  X  X  X  X 
Vital signs X X  X  X  X  X  X  X 
H e i g h t  X               
Weight X X  X  X  X  X  X  X 
Performance status X X  X  X  X  X  X  X 
INR and PTT X              
CBC w/diff, plts X X X X  X  X  X  X  X 
Serum chemistry3 X X X X  X  X  X  X  X 
Buccal swab X              
TSH10 X          X10     
Urinalysis8 X X  X  X  X  X  X   
EKG 9 X               
Tumor measurements12,14 
X Tumor measurements are repeated every  6-weeks ¬± 7 days14. Documentation 
(radiologic) must be provided for pati ents removed from study for progressive 
disease. Imaging should include chest, abdomen, and pelvis. X7 
Radiologic evaluation12,14 X Radiologic measurements should be performed every 6-weeks ¬± 7 days14 for the 
duration of enrollment. Imaging should  include chest, abdomen, and pelvis. X7 
B-HCG X4 X             
ECHO (if indicated) X6              
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 82 A: Olaparib:  Dose as assigned; administration schedule 
B: Ramucirumab:  Dose as assigned ; administration schedule 
1:      Mandatory for all patients in  both phases of study between 3 ‚Äì 28  days before day 1 of treatment. 
2:      Optional for all patients if felt to  be safe in the opinion of the investig ator. The on treatment biopsy should be obta ined between days 3 ‚Äì 
11  of cycle 8 (week 16).  
3: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus, p otassium, 
total protein, SGOT [AST], SGPT [50] , sodium, magnesium, and GGT. 
4: Serum pregnancy test (women of childb earing potential) one test 28 days prior to s tarting treatment. Day 1 serum pregnancy t est should 
be prior to starting treatment.  
5: Off-study evaluation: 4 weeks after comi ng off study. Patients will continue to be  evaluated for surviv al every 3 months. 
6:      Prior treatment with anthracycli nes, prior treatment with trastuzumab, NYHA cl assification of II controlled with treatm ent (see Appendix   
B), prior central thoracic radiation, history of  myocardial infarction with in the prior 12 months, pr ior history of impaired ca rdiac function. 
7:     For patients who discontinue the study treatment for reasons other than dis ease progression will continue to undergo res taging scans every 
6 weeks ¬± 7 days or earlier if clinically indicated, until the documentation of disease progression (see section 5.6  for duration of follow 
up). 
8:    Full urinalysis at screening, a ur ine dipstick protein level may substitute for a full urinalysis for on treatment visits  although a full 
urinalysis may be done  if clinically indicated. 
9:    Within 7 days prior to startin g treatment and when clinically indicated. 
10: TSH monitoring should be done every 12 weeks or as indicated. 11. The screening period is 28 days a nd patients must start day 1 of treatment  within 28 days of signing consent. 
12 Radiologic evaluations should include the chest, abdomen, and p elvis. When appropriate, additio nal sites of imaging may be a pplicable 
depending on disease extent. 
13. Ramucirumab should be run ov er 60 minutes (+/- 15 minutes). 
14. Patients that remain on trea tment for > 6 months may decrease the response as sessment scan interval to every 12 weeks (+/- 7 days) at the 
discretion of the investigator.  
 
 
11. MEASUREMENT OF EFFECT 
 Although the clinical benefi t of these drugs has not yet been established, the intent of offering 
this treatment is to provide a possible therapeuti c benefit, and thus the patient will be carefully 
monitored for tumor response and sy mptom relief in addition to safe ty and tolerability. Patients 
with measurable disease will be assessed by stan dard criteria.  For the purposes of this study, 
patients should be re-evaluated every week for th e first 3 weeks, then every 2 weeks thereafter.  
In addition to a baseline scan, confirmatory s cans will also be obtained ever 6 weeks following 
initial documentation of an objective response. Patients on tr eatment for > 6 months may 
decrease the response assessment in terval to every 12 weeks (+/- 7 days) at the discretion of the 
investigator.  11.1 Antitumor Effect ‚Äì Solid Tumors 
 For the purposes of this study, patients should be re-evaluated for response every ever 6 weeks.  
In addition to a baseline scan, confirmatory scans should also be obtained 6 weeks following 
initial documentation of  objective response. Patients on trea tment for > 6 months may decrease 
the response assessment interval to every 12 weeks (+/- 7 days) at the discretion of the 
investigator.  Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Cr iteria in Solid Tumors (RECIST) guideline 
(version 1.1) [ Eur J Ca  45:228-247, 2009].  Changes in the la rgest diameter (unidimensional 
measurement) of the tumor lesi ons and the shortest diameter in the case of malignant lymph 
nodes are used in the RECIST criteria.  11.1.1  Definitions 
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 83 Evaluable for toxicity.  All patients will be ev aluable for toxicity from the time of their 
first treatment with olap arib and ramucirumab. 
 Evaluable for objective response.  All patients who receive tr eatment will be counted for 
response rate evaluation.  These patients will have their response classified according to 
the definitions stated below.  (Note:  Pa tients who exhibit objectiv e disease progression 
prior to the end of cycle 1 will also be considered evaluable.) 
 Evaluable Non-Target Disease Response.  Pati ents who have lesions present at baseline 
that are evaluable but do not meet the definiti ons of measurable diseas e, have received at 
least one cycle of therapy, and have had their disease re-eva luated will be considered 
evaluable for non-target disease.  The res ponse assessment is ba sed on the presence, 
absence, or unequivocal progr ession of the lesions.  
 11.1.2  Disease Parameters 
 
Measurable disease.  Measurable lesions ar e defined as those that can be accurately 
measured in at least one dimension (l ongest diameter to be recorded) as ¬ï20 mm ¬ïF m) 
by chest x-ray or as ¬ï10 mm ¬ïF m) with CT scan, MRI, or calipers by clinical exam.  
All tumor measurements must be recorded  in millimeters (or decimal fractions of 
centimeters). 
 
Note:  Tumor lesions that are situated in a pr eviously irradiated area might or might not 
be considered measurable.    Malignant lymph nodes.  To be considered pathologically enlarg ed and measurable, a 
lymph node must be ¬ï15 mm ¬ïF m) in short axis when assessed by CT scan (CT scan 
slice thickness recommended to be  no greater than 5 mm [0.5 cm]).  At baseline and in 
follow-up, only the short axis will be measured and followed.  Non-measurable disease.  All other lesions (or site s of disease), including small lesions 
(longest diameter <10 mm [<1 cm] or SDWKRORJLFDOO\PSKQRGHVZLWK¬ï 10 to <15 mm >¬ï1 
to <1.5 cm] short axis), ar e considered non-measurable disease.  Bone lesions, 
leptomeningeal disease, ascites, pleu ral/pericardial effusions, lymphangitis 
cutis/pulmonitis, inflammatory breast diseas e, and abdominal masses (not followed by 
CT or MRI), are considered as non-measurable.  Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesi ons (neither measurab le nor non-measurable) 
since they are, by definition, simple cysts.  ‚ÄòCystic lesions‚Äô thought to represent cystic me tastases can be considered as measurable 
lesions, if they meet the de finition of measurability desc ribed above. However, if non-
cystic lesions are present in the same patient,  these are preferred for selection as target 
lesions.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 84 Target lesions.  All measurable lesions up to a maximum of 2 lesions per organ and 5 
lesions in total, representative of all involved organs, should be identified as target 
lesions  and recorded and measured at baseline.  Target lesions shoul d be selected on the 
basis of their size (lesions w ith the longest diameter), be representative of all involved 
organs, but in addition should be those that lend themselves to reproducible repeated 
measurements.  It may be the case that, on occasion, the larg est lesion does not lend itself 
to reproducible measurement in which circum stance the next largest lesion which can be 
measured reproducibly should be selected.  A sum of th e diameters (longest for non-
nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and 
reported as the baseline sum diameters.  If lymph nodes are to be in cluded in the sum, 
then only the short axis is added into the su m.  The baseline sum diameters will be used 
as reference to further characterize any ob jective tumor regression in the measurable 
dimension of the disease.  Non-target lesions.  All other lesions (or sites of disease) in cluding any measurable 
lesions over and above the 5 target  lesions should be identified as non-target lesions and 
should also be recorded at baseline.  Measur ements of these lesions  are not required, but 
the presence, absence, or in rare cases unequivocal progression of each should be noted 
throughout follow-up.  
 11.1.3  Methods for Evaluation of  Measurable Disease 
 
All measurements should be taken and reco rded in metric notation using a ruler or 
calipers.  All baseline evaluations should be  performed as closely as possible to the 
beginning of treatment and never more than  4 weeks before the beginning of the 
treatment.  The same method of assessment and the same te chnique should be used to characterize 
each identified and reported lesion at ba seline and during follow-up. Imaging-based 
evaluation is preferre d to evaluation by clinical examin ation unless the lesion(s) being 
followed cannot be imaged but ar e assessable by clinical exam. 
 Clinical lesions   Clinical lesions will onl y be considered measurable when they are 
superficial ( e.g., skin nodules and palpable lymph nodes) and ¬ï10 mm ¬ïFP  diameter 
as assessed using calipers ( e.g., skin nodules).  In the case of skin lesions, documentation 
by color photography, including a ruler to estimate the size of the lesion, is 
recommended.   Chest x-ray   Lesions on chest x-ray are acceptable as  measurable lesions when they are 
clearly defined and surrounded by aerated lung.  However, CT is preferable.  
 Conventional CT and MRI  This guideline ha s defined measurability of lesions on CT 
scan based on the assumption that CT slice thickness is 5 mm (0.5 cm) or less.  If CT 
scans have slice thickness greater than  5 mm (0.5 cm), the minimum size for a 
measurable lesion should be twi ce the slice thickness.  MRI is  also acceptable in certain 
situations ( e.g. for body scans).   
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 85  
Use of MRI remains a complex issue.  MRI ha s excellent contrast, spatial, and temporal 
resolution; however, there are many image acq uisition variables involved in MRI, which 
greatly impact image quality, lesion conspicu ity, and measurement.  Furthermore, the 
availability of MRI is vari able globally.  As with CT, if an MRI is performed, the 
technical specifications of the scanning sequences used should be optimized for the 
evaluation of the type and site of disease.  Fu rthermore, as with CT, the modality used at 
follow-up should be the same as was used at baseline and the lesions should be 
measured/assessed on the same pulse sequence.   It is beyond the scope of the RECIST 
guidelines to prescribe specific MRI pulse sequence parameters fo r all scanners, body 
parts, and diseases.  Ideally, the same type  of scanner should be used and the image 
acquisition protocol should be followed as closely as possible to prior scans.  Body scans 
should be performed with breath-hold scanning techniques, if possible. 
 PET-CT  At present, the low dose or atte nuation correction CT portion of a combined 
PET-CT is not always of optimal dia gnostic CT quality for use with RECIST 
measurements.  However, if the site can doc ument that the CT performed as part of a 
PET-CT is of identical diagnostic quality to a diagnostic CT (with IV and oral contrast), 
then the CT portion of the PET-CT can be used for RECIST measurements and can be 
used interchangeably with conventional CT in  accurately measuring cancer lesions over 
time.  Note, however, that the PET portion of the CT introduces additional data which 
may bias an investigator if it is not routinely or  serially performed.   
 
Ultrasound  Ultrasound is not usef ul in assessment of lesion size and should not be used 
as a method of measurement.  Ultrasound exa minations cannot be reproduced in their 
entirety for independent review at a later date  and, because they ar e operator dependent, it 
cannot be guaranteed that the same techniqu e and measurements will be taken from one 
assessment to the next.  If new lesions are identified by ul trasound in the course of the 
study, confirmation by CT or MRI is advised.  If there is conc ern about radiation 
exposure at CT, MRI may be used inst ead of CT in sele cted instances. 
 Endoscopy, Laparoscopy  The utilization of  these techniques for objective tumor 
evaluation is not advised.  However, such t echniques may be useful  to confirm complete 
pathological response when biopsies are obtaine d or to determine relapse in trials where 
recurrence following complete response (CR) or surgical resection is an endpoint. 
 Tumor markers  Tumor markers alone cannot be  used to assess response.  If markers are 
initially above the upper normal li mit, they must normalize for a patient to be considered 
in complete clinical response.   Specific guidelines for both  CA-125 response (in recurrent 
ovarian cancer) and PSA response (in recurren t prostate cancer) have been published 
[JNCI  96:487-488, 2004; J Clin Oncol  17, 3461-3467, 1999; J Clin Oncol  26:1148-1159, 
2008].  In addition, the Gynecologic Ca ncer Intergroup has developed CA-125 
progression criteria which are to  be integrated with objective tumor assessment for use in 
first-line trials in ovarian cancer [ JNCI  92:1534-1535, 2000]. 
 Cytology, Histology  These techniques can be  used to differentia te between partial 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 86 responses (PR) and complete re sponses (CR) in rare cases ( e.g., residual lesions in tumor 
types, such as germ cell tumors, where known residual benign tu mors can remain). 
 The cytological confirmation of the neoplastic  origin of any effusion that appears or 
worsens during treatment when the measurable  tumor has met criteria for response or 
stable disease is mandatory to differentiate between res ponse or stable disease (an 
effusion may be a side effect of the treatment) and progressive disease. 
 FDG-PET  While FDG-PET response assessme nts need additional study, it is sometimes 
reasonable to incorporate the use of FDG-P ET scanning to complement CT scanning in 
assessment of progression (par ticularly possible 'new' disease).  New lesions on the basis 
of FDG-PET imaging can be identified acco rding to the following algorithm:  
a. Negative FDG-PET at baseline, with a posit ive FDG-PET at follow-up is a sign of 
PD based on a new lesion. 
b. No FDG-PET at baseline and a positive FDG- PET at follow-up:  If the positive FDG-
PET at follow-up corresponds to a new site of  disease confirmed by CT, this is PD.  If 
the positive FDG-PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow-up CT  scans are needed to  determine if there is truly progression 
occurring at that site (if so, the date of PD will be the date of the initial abnormal 
FDG-PET scan).  If the positive FDG-PET at  follow-up corresponds to a pre-existing 
site of disease on CT that is not progressi ng on the basis of the an atomic images, this 
is not PD. 
c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy 
in cases where a residual radiographic abnorma lity is thought to re present fibrosis or 
scarring.  The use of FDG-PET in this  circumstance should be prospectively 
described in the protocol a nd supported by disease-specific medical literature for the 
indication.  However, it must be acknowledged that both appr oaches may lead to false 
positive CR due to limitations of FDG-PET and biopsy resolution/sensitivity. 
 Note:  A ‚Äòpositive‚Äô FDG-PET scan lesion means one which is FDG avid with an uptake greater than twice that of the surroundi ng tissue on the attenuation corrected image.  
 
11.1.4  Response Criteria 
 
11.1.4.1  Evaluation of Target Lesions 
 
Complete Response (CR):  Disappearance of  all target lesions.  Any pathological 
lymph nodes (whether target or  non-target) must have reduc tion in short axis to <10 
mm (<1 cm).  Partial Response (PR):  At least a 30% decreas e in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters. 
 Progressive Disease (PD):  At  least a 20% increase in th e sum of the diameters of 
target lesions, taking as reference the smallest sum on study (this includes the 
baseline sum if that is the sm allest on study).  In addition to the relative increase of 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 87 20%, the sum must also demonstrate an absolu te increase of at le ast 5 mm (0.5 cm).  
(Note:  the appearance of one or more ne w lesions is also considered progressions). 
 Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as refe rence the smallest sum diameters while on 
study.  
11.1.4.2  Evaluation of Non-Target Lesions 
 Complete Response (CR):  Disappearance of all non-target lesions  and normalization 
of tumor marker level.  A ll lymph nodes must be non-pa thological in size (<10 mm 
[<1 cm] short axis).  Note:  If tumor markers are initially above the upper normal limit, they must 
normalize for a patien t to be considered in co mplete clinical response. 
 Non-CR/Non-PD:  Persistence of one or  more non-target lesion(s) and/or 
maintenance of tumor marker level above th e normal limits. 
 Progressive Disease (PD):  Appearance of one or more ne w lesions and/or 
unequivocal progression  of existing non-ta rget lesions.  Unequivocal progression  
should not normally trump targ et lesion status.  It must be representative of overall 
disease status change, not a single lesion increase. 
 Although a clear progression of ‚Äúnon-target‚Äù  lesions only is ex ceptional, the opinion 
of the treating physician shoul d prevail in such circumstances, and the progression 
status should be confirmed at a later time by the review pa nel (or Principal 
Investigator). 
 11.1.4.3  Evaluation of Best Overall Response 
 The best overall response is the best response  recorded from the start of the treatment 
until disease progression/recurrence (taking as reference for progressive disease the smallest measurements record ed since the treatment star ted).  The patient's best 
response assignment will depend on the ach ievement of both measurement and 
confirmation criteria.  
For Patients with Measurable Disease ( i.e., Target Disease) 
 
Target 
Lesions Non-Target 
Lesions New 
Lesions* Overall 
Response Best Overall Response when 
Confirmation is Required** 
CR CR No CR ¬ï4 wks. Confirmation 
CR Non-CR/Non-
PD No PR 
¬ï4 wks. Confirmation CR Not evaluated No PR 
PR Non-CR/Non- No PR 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 88 PD/not 
evaluated 
SD Non-CR/Non-
PD/not evaluated No SD Documented at least once ¬ï4 
wks. from baseline 
PD An y Yes or No PD 
no prior SD, PR or CR Any PD*** Yes or No PD 
Any An y Yes PD 

 See RECIST 1.1 manuscript for fu rther details on what is evidence of a new lesion. 
**    Confirmation will be obtained at the regul arly scheduled interval of every 6 weeks for 
study patients and for patients who come o ff study for reasons other than disease 
progression. 
***  In exceptional circumstances, unequivocal  progression in non-targ et lesions may be 
accepted as disease progression. 
 
Note:  Patients with a global deterioration of  health status requir ing discontinuation of 
treatment without objective evidence of di sease progression at that time should be 
reported as ‚Äú symptomatic deterioration.‚Äù   Every effort should be  made to document the 
objective pro gression even after discon tinuation of treatment. 
 
For Patients with Non-Measurable Disease ( i.e., Non-Target Disease) 
 
Non-Tar get Lesions New Lesions Overall Response 
CR No CR 
Non-CR/non-PD No Non-CR/non-PD* 
Not all evaluated No not evaluated 
Unequivocal PD Yes or No PD 
Any Yes PD 

 ‚ÄòNon-CR/non-PD‚Äô is preferred over ‚Äòstable dise ase‚Äô for non-target di sease since SD is 
increasingly used as an endpoint for assessment of efficacy in so me trials so to assign this 
category when no lesions can be measured is not advised 
 11.1.5  Duration of Response  
 
Duration of overall response:  The duration of  overall response is measured from the time 
measurement criteria are met for CR or PR (w hichever is first recorded) until the first 
date that recurrent or progressive disease is  objectively documented (taking as reference 
for progressive disease the smallest measurem ents recorded since the treatment started). 
 The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented.   
 Duration of stable disease:  Stable disease is measured from the start of the treatment 
until the criteria for progression are met, ta king as reference the smallest measurements 
recorded since the treatment started, including the baseline measurements.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 89  
11.1.6  Progression-Free Survival  
 
PFS is defined as the duration of time from st art of treatment to time of progression or 
death, whichever occurs first.   
11.1.7  Response Review 
 
Radiology assessments for Yale site will be provided by the Yale  tumor metric core. 
Assessment for other pa rticipating sites should be perfo rmed per the site‚Äôs own tumor 
metric core.  
  12. STUDY OVERSIGHT AND DATA REPORTING / REGULATORY 
REQUIREMENTS 
 Adverse event lists, guidelines, and instru ctions for AE reporting can be found in Section 7.0  
(Adverse Events: List and Reporting Requirements). 
 12.1 Study Oversight 
 This protocol is monitored at seve ral levels, as described in this section.  The Protocol Principal 
Investigator is responsible for mo nitoring the conduct and progress of the clinical trial, including 
the ongoing review of accrual, pa tient-specific clinical and la boratory data, and routine and 
serious adverse events; reporting of expedite d adverse events; and accumulation of reported 
adverse events from other trials testing the same drug(s).  The Protocol Pr incipal Investigator and 
statistician have access to the data at all time s through the CTMS web-ba sed reporting portal.   
 For the Phase 1 portion of this study, all decisi ons regarding dose escalation/expansion/de-
escalation require sign-off by the Protocol Principal Investigator  through the CTMS/IWRS.  In 
addition, for the Phase 1 portion, the Protocol Principal Investigator  will have at  least monthly, 
or more frequently, conferen ce calls with the Study Invest igators and the CTEP Medical 
Officer(s) to review accrual, progress, and adverse events an d unanticipated problems.   
 During the Phase 2 portion of the study, the Protocol Principal Investigator will have, at a minimum, quarterly conference calls with the Study Investigators and the CTEP Medical 
Officer(s) to review accrual, progress, and pharmacovigilance.  Decisions to proceed to the 
second stage of a Phase 2 trial will require sign-o ff by the Protocol Principa l Investigator and the 
Protocol Statistician.  All Study Investigators at participating sites who re gister/enroll patients on a given protocol are 
responsible for timely submissi on of data via Medidata Rave and timely reporting of adverse 
events for that particular study.  This includes timely review of  data collected on the electronic 
CRFs submitted via Medidata Rave.  All studies are also reviewed in  accordance with the enrolling inst itution‚Äôs data safety monitoring 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 90 plan. 
 12.2 Data Reporting 
 Data collection for this study will be done exclus ively through Medidata Rave.  Access to the 
trial in Rave is granted through the iMedidata ap plication to all persons  with the appropriate 
roles assigned in the Regulatory Support System (R SS).  To access Rave via iMedidata, the site 
user must have an act ive CTEP IAM account ( https://eapps-ctep.nci.nih.gov/iam ) and the 
appropriate Rave role (Rave CRA, Read-Only, CRA, Lab Admin, SL A, or Site Investigator) on 
either the LPO or Participating Organization rost er at the enrolling site. To hold the Rave CRA 
role or CRA Lab Admin role, the user must hold  a minimum of an AP registration type. To hold 
the Rave Site Investigator role, the individua l must be registered as an NPIVR or IVR. 
Associates can hold read only roles in Rave.   Upon initial site registration appr oval for the study in RSS, all pe rsons with Rave roles assigned 
on the appropriate roster will be sent a study in vitation e-mail from iMedidata.  To accept the 
invitation, site users must l og into the Select Login ( https://login.imedida ta.com/selectlogin ) 
using their CTEP-IAM user name and password, and click on the ‚Äúaccept‚Äù link in the upper 
right-corner of the iMedidata page.  Please note, s ite users will not be able to access the study in 
Rave until all required Medidata and study specific  trainings are completed.  Trainings will be in 
the form of electronic learnings  (eLearnings), and can  be accessed by clicki ng on the link in the 
upper right pane of the iMedidata screen.   
 
Users that have not previously ac tivated their iMedidata/Rave account  at the time of initial site 
registration approval for the study in RSS will also receive a sepa rate invitation from iMedidata 
to activate their account. Account  activation instructions are lo cated on the CTSU website, Rave 
tab under the Rave resource ma terials (Medidata Account Ac tivation and Study Invitation 
Acceptance).  Additional information on iMedidat a/Rave is available on the CTSU members‚Äô 
website under the Rave tab or by contacting the CTSU Help Desk at 1-888-823-5923 or by e-
mail at ctsucontact@westat.com . 
 
12.2.1  Method 
 
This study will be monitored by the Clinical Trials Monitoring Service (CTMS).  Data 
will be submitted to CTMS at least once ev ery two weeks via Medidata Rave (or other 
modality if approved by CTEP).  Inform ation on CTMS reporti ng is available at 
http://theradex.com/clinicalTechnologies/?National-Cancer-Institute-NCI-11 .  On-site 
audits will be conducted three ti mes annually (one annual site vi sit and two data audits).  
For CTMS monitored studies, af ter users have activated thei r accounts, please contact the 
Theradex Help Desk at (609) 799-7580 or by email at CTMSSupport@theradex.com  for 
additional support with Rave  and completion of CRFs. 
 
12.2.2  Responsibility for Data Submission 
 
For ETCTN trials, it is the re sponsibility of the PI(s) at th e site to ensure that all 
investigators at the ETCTN Sites understand th e procedures for data submission for each 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 91 ETCTN protocol and that protoc ol specified data are submitte d accurately and in a timely 
manner to the CTMS via the electronic da ta capture system, Medidata Rave.   
 Data are to be submitted via Medidata Rave  to CTMS on a real-time  basis, but no less 
than once every 2 weeks.  The timeliness of da ta submissions and timeliness in resolving 
data queries will be tracked by CTMS.  Me trics for timeliness will be followed and 
assessed on a quarterly basis.  For the purpos e of Institutional Performance Monitoring, 
data will be considered delinquent if it is greater than 4 weeks past due. 
 Data from Medidata Rave and CTEP-AERS is reviewed by the CTMS on an ongoing 
basis as data is received.  Queries will be issued by CTMS directly within Rave.  The 
queries will appear on the Task Summary Tab within Rave for the CRA at the ETCTN to 
resolve.  Monthly web-based reports are pos ted for review by the Drug Monitors in the 
IDB, CTEP.  Onsite audits will be conducted by the CTMS to ensure compliance with regulatory requirements, GCP, and NCI polic ies and procedures w ith the overarching 
goal of ensuring the integrity of data genera ted from NCI-sponsored clinical trials, as 
described in the ETCTN Program Guidel ines, which may be found on the CTEP 
(http://ctep.cancer.gov/protoco lDevelopment/electronic_app lications/adverse_events.htm
)  and CTSU websites. 
 An End of Study CRF is to be completed by th e PI, and is to incl ude a summary of study 
endpoints not otherwise captured in the data base, such as (for phase 1 trials) the 
recommended phase 2 dose (RP2D), and a de scription of any dose-limiting toxicities 
(DLTs).  CTMS will utilize a core set of e CRFs that are Cancer Data Standards Registry 
and Repository (caDSR) compliant ( http://cbiit.nci.nih.gov/ncip/ biomedical-informatics-
resources/interoperability-and-semantics/metadata-and-models ).  Customized eCRFs will 
be included when appropriate to meet unique study requirement s.  The PI is encouraged 
to review the eCRFs, working closely with  CTMS to ensure prospectively that all 
required items are appropriately captured in the eCRFs prior to study activation.  CTMS 
will prepare the eCRFs with built-in edit check s to the extent possible to promote data 
integrity.  CDUS data submissions for ETCTN trials activated after March 1, 2014, will be carried 
out by the CTMS contractor, Theradex.  C DUS submissions are performed by Theradex 
on a monthly basis.  The trial‚Äôs lead institu tion is responsible for timely submission to 
CTMS via Rave, as above.  Further information on data submission procedures can be  found in the ETCTN Program 
Guidelines (http://ctep.cancer.gov/protoco lDevelopment/electronic_app lications/adverse_events.htm
). 
12.3 CTEP Multicenter Guidelines 
 N/A  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 92 12.4 Collaborative Agreements Language 
 The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/a re provided to the NCI 
under a Collaborative Agreement (CRADA, CT A, CSA) between the Pharmaceutical 
Company(ies) (hereinafter referred to as ‚ÄúCo llaborator(s)‚Äù) and the NCI Division of Cancer 
Treatment and Diagnosis.  Therefore, the follo wing obligations/guidelines , in addition to the 
provisions in the ‚ÄúIntellectual Property Option to Collaborator‚Äù  
(http://ctep.cancer.gov/in dustryCollaborations2/in tellectual_property.htm ) contained within the 
terms of award, apply to the use of the Agent(s) in this study: 
 1. Agent(s) may not be used for any purpose outside the scope of th is protocol, nor can 
Agent(s) be transferred or li censed to any party not particip ating in the clinical study.  
Collaborator(s) data for Agent(s)  are confidential and proprietar y to Collaborator(s) and shall 
be maintained as such by the investigators.  The protocol documents  for studies utilizing 
Agents contain confidential info rmation and should not be shar ed or distributed without the 
permission of the NCI.  If a copy of this protocol is requested by a patient or patient‚Äôs family 
member participating on the st udy, the individual should sign a c onfidentiality agreement.  A 
suitable model agreement can be downloaded from: http://ctep.cancer.gov . 
 
2. For a clinical protocol where there is an i nvestigational Agent used in combination with 
(an)other Agent(s), each the subject of differ ent Collaborative Agreements, the access to and 
use of data by each Collaborator shall be as fo llows (data pertaining to such combination use 
shall hereinafter be referred to as "Multi-Party Data‚Äù): 
 
a. NCI will provide all Collaborators with pr ior written notice regarding the existence and 
nature of any agreements governing their co llaboration with NCI, the design of the 
proposed combination protocol, and the existe nce of any obligations that would tend to 
restrict NCI's participation in th e proposed combination protocol. 
 
b. Each Collaborator shall agree to permit use of  the Multi-Party Data from the clinical trial 
by any other Collaborator solely to the extent  necessary to allow said other Collaborator 
to develop, obtain regulatory approval  or commercialize its own Agent. 
 
c. Any Collaborator having the right to use th e Multi-Party Data from these trials must 
agree in writing prior to the commencement of  the trials that it w ill use the Multi-Party 
Data solely for development, regulatory approval, and commerci alization of its own 
Agent. 
 3. Clinical Trial Data and Results and Raw Da ta developed under a Collaborative Agreement 
will be made available to Collaborator(s), the NCI, and the FDA, as appropriate and unless 
additional disclosure is require d by law or court order as de scribed in the IP Option to 
Collaborator ( http://ctep.cancer .gov/industryCollaborations2/ intellectual_property.htm ).  
Additionally, all Clinical Data and Results and Raw Data will be collected, used and 
disclosed consistent with all applicable federa l statutes and regulations  for the protection of 
human subjects, including, if applicable, the Standards for Privacy of Individually 
Identifiable Health Information  set forth in 45 C.F.R. Part 164. 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 93  
4. When a Collaborator wishes to initiate a data request, the request shoul d first be sent to the 
NCI, who will then notify the appropriate i nvestigators (Group Chair for Cooperative Group 
studies, or PI for other studies) of Collaborator's wish to contact them. 
 5. Any data provided to Collabora tor(s) for Phase 3 studies must be in accordance with the 
guidelines and policies of the responsible Data  Monitoring Committee (DMC), if there is a 
DMC for this clinical trial. 
 6. Any manuscripts reporting the resu lts of this clinical trial must be provided to CTEP by the 
Group office for Cooperative Group studies or by the principal i nvestigator for non-
Cooperative Group studies for imme diate delivery to Collaborator( s) for advisory review and 
comment prior to submission for publication.  Collaborator(s) will have 30 days from the 
date of receipt for review.  Co llaborator shall have the right to request that publication be 
delayed for up to an additional 30 days in order to ensure that Collaborator‚Äôs confidential and 
proprietary data, in addition to  Collaborator(s)‚Äôs intellectual property rights, are protected.  
Copies of abstracts must be provided to CTEP for forwarding to Collaborator(s) for courtesy 
review as soon as possible and preferably at l east three (3) days prio r to submission, but in 
any case, prior to presentation at the meeti ng or publication in th e proceedings.  Press 
releases and other media presenta tions must also be forwarded to CTEP prior to release.  
Copies of any manuscript, abstract and/or press release/ media presentati on should be sent to: 
 
Email:  ncicteppubs@mail.nih.gov  
 
The Regulatory Affairs Branch will then distribu te them to Collaborator(s).  No publication, 
manuscript or other form of publ ic disclosure shall contain a ny of Collaborator ‚Äôs confidential/ 
proprietary information.   12.5 Genomic Data Sharing Plan 
 Investigators will submit large-scale human genomic  data and relevant associated tissue to an 
NIH-designated data repository in a timely  manner. Investigators will also submit any 
information necessary to interpret the submitted genomic data, such as study protocols, data 
instruments, and survey tools. The NIH will release data submitted to NIH-designated data repositories no later than 6 months after the initi al data submission begins , or at the time of 
acceptance of the first publica tion, whichever comes first. 
 13. STATISTICAL CONSIDERATIONS 
 13.1 Study Design/Endpoints 
 This is a phase 1 and 2 open-label single arm c linical trial with no randomization of olaparib 
with ramucirumab for patients with metast atic gastric and gastroesophageal junction 
adenocarcinoma who have failed at least one prior line of chemotherapy. The study has a phase 1 
dose escalation lead in phase for olaparib with standard dose ra mucirumab. The primary 
objective of phase 1 is to deter mine the safe dose of olaparib w ith ramucirumab. Olaparib will be 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 94 increased up to 300 mg twice daily in tablet  dosing. Based on published toxicity profiles for 
olaparib and ramucirumab outlined in section 5.2  the probability of DLT is in the range of 0.15 
to 0.25. The primary objective of phase 2 is to measure the ef ficacy for olaparib plus 
ramucirumab by objective response rate (ORR). In pha se 2, 40 patients will be enrolled as a pilot 
study to help determine the foundation for a biom arker stratification de sign in a larger study. 
Incidence rates for the BROCA-HR biomarker will be measured in all enrolled patients for both stages. If the incidence rate of the BROCA-HR biom arker is too low (<10%) or efficacy is seen 
it is unlikely we would not proceed to a larger  study. The historical control for ramucirumab 
monotherapy is an ORR of 3%, and we will assume a null hypothesis of 5%.   Primary Endpoints: Phase 1 : Dose limiting toxicity for olaparib in co mbination with ramucirumab and the maximum 
tolerated dose (or the maximum safe dose).  
Phase 2: Objective response rate by RECIST v1.1 crit eria for combined therapy with olaparib 
and ramucirumab.  Analytic Plan for Primary Endpoints: Phase 1: A 3+3 dose escalating approach will be used  to determine what dose is the safe dose 
and should be used in the Phase 2 portion of the study. 
 Phase 2:   Because we do not know the true distribu tion of our biomarker we will proceed with 
this 40 patient pilot study to help plan a larger study based on both our observed biomarker 
prevalence and our response rates. If response ra tes are observed regardless of biomarker status 
the subsequent study may not be biomarker driven or an alternative biomarker may be used. 
Based on published data in the COSMIC and TCGA databases we expect the genes characteristic 
for HRD in the BROCA-HR biomarker to be posi tive in approximately 35% of cases. These 
genes are: ATM, ATR, BARD1, BLM, BRCA 1, BRCA2, BRIP1, CHEK2, MRE11A, NBN, 
PALB2, RAD51, RAD51C, RAD51D , RBBP8, SLX4, XRCC2, CDK 12. Based on the proposed 
prevalence of these genes we will enroll to 40 patients and proceed as follows: 
 Sample Size Justification: 
 
1. If there are 6 or more BROCA-HR+ patient s (34 or less BROCA-HR- patients): If 
there are no responses in BROCA-HR+ pa tients and no response in BROCA-HR- 
patients, then it is unlikely we will proceed to a larger study with this combination.  
x For BROCA- +5SDWLHQWVWKHSUREDELOLW \RI¬ïUHVSRQVHVLV!LI
the true UHVSRQVHUDWH¬ï  
x For BROCA-HR- patients: The probability of ¬ïUHVSRQVHLV!LI  the 
WUXHUHVSRQVHUDWHLV¬ïDQGWKHSUREDELOLW\RI¬ïUHVSRQVH RILI
WKHWUXHUHVSRQVHUDWHLV¬ï  
 
2. If there are 6 or more BROCA-HR+ pa tients (34 or fewer BROCA-HR-): For 
BROCA-HR- patients, the study  will require at least 4 responses for success if we 
have at least 26 BROCA-HR- patients (65% incidence rate). The probability of 4 
responses is 80% if the true response rate  is 20%. The study will require at least 3 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 95 responses for success if we have at l east 20 BROCA-HR- patients (50% incidence 
UDWHWKHSUREDELOLW\RI¬ïUHV SRQVHV LIWKHWUXHUHVSRQ VHUDWH ,WLV
very unlikely the incidence rate of  BROCA-HR- will be less than 50%. 
 
3. If there are less than 6 BROCA-HR+ patients (35 or more BROCA-HR- patients): 
If no responses are observed in either cohor t, then it is unlikely we will proceed to 
a larger study with this combination. 7KHSUREDELOLW\RI¬ï%52&$ -HR+ 
patients is > 85% if the true incidence of BROCA- +5LV¬ï7KHSUREDELOLW\
RI¬ï 6 BROCA-HR+ patients is > 99% if th e true incidence rate of BROCA-HR+ 
LV¬ï  
 
Based upon the results in the above scenarios we will discuss with CTEP on the plan to proceed 
to a larger study.  Analysis Plan: 
 The objective response is define d as a complete or partial response, as determined by 
investigator assessment using RECIST v 1.1 and confirmed by repeated assessment > 4 weeks 
after initial documentation. Patient s with missing or no response a ssessments are classified as 
non-responders. The ORR will be estimated using the 95% confidence interval (CI) based on 
Wilson‚Äôs method. A 5% 2-sided alpha will be used.  
The Wilcoxon rank sum test and Fi sher‚Äôs exact test will be ap plied to study the association 
between the response status and the continuous and categorical variables, respectively. The 
generalized non-linear model and l ogistic regression will be a pplied for multivariable data 
analysis. The adjusted p-value and 95% CI of the odds ration (OR) will be reported. 
 For the PAR assay and PDX generation involving bi opsy samples, the findings will be primarily 
hypothesis generating and will use descriptive stat istics. In addition, with the proposed sample 
size of 20, the half-width of the 90% CI will be  less than 20% with respect to the binary 
endpoint. It has at least 85% power  to detect a correlation coeffici ent > 0.5 with one-side type I 
HUURU ZLWKUHVSHFW WRWKHFRQWLQXRXVHQGSRLQW  
   13.2 Sample Size/Accrual Rate 
 Planned sample size Phase I: 6 patients 
Planned sample size Phase II : 40 patients 
Accrual Rate: 10/month 
  
PLANNED ENROLLMENT REPORT 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 96 Racial Categories Ethnic Categories 
Total 
Not Hispanic or Latino Hispanic or Latino 
 Female Male Female Male  
American Indian/ Alaska 
Native 0 0 0 0 0 
Asian 2 2 0 0 4 
Native Hawaiian or 
Other Pacific Islander 0 0 0 0 0 
Black or African 
American 5 4 0 0 9 
White 16 15 3 2 36 
More Than One Race 0 0 0 0 0 
Total 23 21 3 2 49 
PHS 398 / PHS 2590 (Rev. 08/12 Approved Through 8/31/2015)  OMB No. 0925-0001/0002 
 
 13.3 Stratification Factors 
 
The patients will not be stratified by mutational stat us, and all biomarkers are either integrated or 
exploratory. Subset analysis of primary, sec ondary, and exploratory endpoints will also be 
performed based on the presence or ab sence of the integrated biomarkers. 
 13.4 Analysis of Secondary Endpoints 
 Analytic Plan for Secondary Endpoints: 
x For lifetime data analysis, e.g., progression free survival and overall survival, the 
BROCA-HR status will be compared for dur ation of response surv ival with Kaplan-
Meier estimates and log-rank tests. The Rothma n confidence interval (CI), which is based 
on Greenwood‚Äôs variance, Thomas and Gr unkemeier CI, and the simultaneous 
confidence bands by Nair and Hall and We llner, will be reported. In addition, the 
possible risk factors wi ll be compared for survival with  log-rank test. For multivariate 
analysis, the proportional hazards Cox model wi ll be applied to investigate potential 
prognostic factors, such as age and stage of  disease of the PFS data. The adjusted p-
values of the hazard ratios and the adjusted 95% confidence interval will be reported.  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 97 x Toxicity rates will be tabulated by type and grade and compared to established rates for 
ramucirumab monotherapy. Ninety -five percent confidence in tervals will be calculated 
for each of these. 
 Analytic Plan for Exploratory Endpoints: 
x The association of BROCA HR assay with Signa ture 3 will be assessed using a series of 
contingency table analyses. For instance, we can examine the association of the presence 
of an individual mutation from the BROCA HR  panel with the signature 3 (yes/no) using 
Fisher‚Äôs exact test. Next, using a Cochran Mantel Haenzel test we can examine the 
relationship across the measures. Finally, we wi sh to examine the rela tionship of each of 
these measures with response. To do this mult iple logistic regressi on models can be fit 
with the response (CR/PR vs SD/PD) consider ed as the outcome variable and the 3 assay 
measures can be used predictors. This mode l can include interactions among the assays. 
Additional covariates including patient level charac teristics (age, gender) and group can 
be included in these models. These anal yses are exploratory therefore no formal 
adjustment for multiple comp arisons will be performed, however it is understood that 
these tests will be considered hypothesis generating primarily.  
 
x Tumor cells for PDX model, and biobanke d tumor tissue and peripheral blood will be 
used for future studies.  
 13.5 Reporting and Exclusions 
 13.5.1  Evaluation of Toxicity 
 
All patients will be evaluable for toxicity from the time of their first treatment with 
olaparib and ramucirumab.  
 
13.5.2  Evaluation of Response 
 
All patients included in the study must be asse ssed for response to tr eatment, even if there 
are major protocol treatment devi ations or if they are inelig ible.  Each patient will be 
assigned one of the following categories:  1) complete response, 2) partial response, 3) 
stable disease, 4) progressive  disease, 5) early death from  malignant disease, 6) early 
death from toxicity, 7) early death because of other cause, or 9) unknown (not assessable, 
insufficient data).  [Note:  By arbitrary convention, cat egory 9 usually designates the 
‚Äúunknown‚Äù status of any type of data in a clinical database.] 
 All of the patients who met the eligibility criteria (with the possible exception of those 
who received no study medication) should be included in the main analysis of the 
response rate.  Patients in response categori es 4-9 should be considered to have a 
treatment failure (disease progr ession).  Thus, an incorrect treatment schedule or drug 
administration does not result in exclusion from the analysis of the response rate.  Precise 
definitions for categories 4-9 will be protocol specific.   All conclusions should be based on all eligib le patients.  Subanalyses may then be 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 98 performed on the basis of a subset of patie nts, excluding those for whom major protocol 
deviations have been identified ( e.g., early death due to other reasons, early 
discontinuation of treatment,  major protocol violations , etc.).  However, these 
subanalyses may not serve as the basis for drawing conclusions concerning treatment 
efficacy, and the reasons for excluding patien ts from the analysis should be clearly 
reported.  The 95% confidence interv als should also be provided.  
   
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 99 REFERENCES 
  1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2016.  CA: a cancer journal for 
clinicians, 2016. 66(1): p. 7-30. 
2. Torre, L.A., et al., Global cancer statistics, 2012.  CA: a cancer journal for clinicians, 
2015. 65(2): p. 87-108. 
3. American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton 
CC, et al (Eds), Springer, New York 2010. p.117. 
4. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015.  CA: a cancer journal for 
clinicians, 2015. 65(1): p. 5-29. 
5. Society, A.C. Connecticut Cancer Statistics . 2016; Available from: 
https://cancerstatisticscenter.cancer.org/ . 
6. Cunningham, D., et al., Capecitabine and oxaliplatin for advanced esophagogastric 
cancer.  New England Journa l of Medicine, 2008. 358(1): p. 36-46. 
7. Fuchs, C.S., et al., Ramucirumab monotherapy for previous ly treated advanced gastric or 
gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, 
multicentre, placebo-co ntrolled, phase 3 trial.  The Lancet, 2014. 383(9911): p. 31-39. 
8. Wilke, H., et al., Ramucirumab plus paclitaxel versus pl acebo plus paclitaxel in patients 
with previously treated advanced gastric or gastro-oesophageal junction 
adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.  The Lancet 
Oncology, 2014. 15(11): p. 1224-1235. 
9. Bang, Y.-J., et al., Trastuzumab in combination with ch emotherapy versus chemotherapy 
alone for treatment of HER2-positive advan ced gastric or gastro-oesophageal junction 
cancer (ToGA): a phase 3, open-label, randomised controlled trial.  The Lancet, 2010. 
376(9742): p. 687-697. 
10. Bang, Y.-J., et al., Randomized, double-blind phas e II trial with prospective classification 
by ATM protein level to eval uate the efficacy and tolerability  of olaparib plus paclitaxel 
in patients with recurrent or metastatic gastric cancer.  Journal of Clinical Oncology, 
2015: p. JCO. 2014.60. 0320. 
11. Kubota, E., et al., Low ATM protein expression and de pletion of p53 correlates with 
olaparib sensitivity in ga stric cancer cell lines.  Cell Cycle, 2014. 13(13): p. 2129-2137. 
12. Alexandrov, L.B., et al., A mutational signature in gastric  cancer suggests therapeutic 
strategies.  Nature communications, 2015. 6. 
13. Kim, H.S., et al., Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) 
gene and ATM protein loss in primary gastric cancer with microsatellite instability.  PloS 
one, 2013. 8(12): p. e82769. 
14. Network, C.G.A.R., Comprehensive molecular c haracterization of gastric 
adenocarcinoma.  Nature, 2014. 513(7517): p. 202-209. 
15. COSMIC. COSMIC Catalogue of Soma tic Mutations in Cancer .  July 26 2016]; 
Available from: can cer.sanger.ac.uk. 
16. Forbes, S.A., et al., COSMIC: exploring the world's know ledge of somatic mutations in 
human cancer.  Nucleic acids research, 2015. 43(D1): p. D805-D811. 
17. Wilcoxen, K.M., et al. Use of homologous recombinati on deficiency (HRD) score to 
enrich for niraparib sensiti ve high grade ovarian tumors . in ASCO Annual Meeting 
Proceedings . 2015. 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 100 18. Wilcoxen, K., et al., Abstract C53: Homologous recomb ination deficienc y (HRD) of high 
grade serous ovarian tumors from th e NOVA Phase III clinical study.  Molecular Cancer 
Therapeutics, 2015. 14(12 Supplement 2): p. C53-C53. 
19. Helleday, T., The underlying mechanism for the PARP  and BRCA synthetic lethality: 
clearing up the misunderstandings.  Molecular oncology, 2011. 5(4): p. 387-393. 
20. Murai, J., et al., Trapping of PARP1 and PARP2 by clinical PARP inhibitors.  Cancer 
research, 2012. 72(21): p. 5588-5599. 
21. Farmer, H., et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic 
strategy.  Nature, 2005. 434(7035): p. 917-921. 
22. Menear, K.A., et al., 4-[3-(4-cyclopropanecarbonylp iperazine-1-carbonyl)-4-
fluorobenzyl]-2 H-phthalazin-1-one: a novel bioa vailable inhibitor of poly (ADP-ribose) 
polymerase-1.  Journal of medicinal chemistry, 2008. 51(20): p. 6581-6591. 
23. Ledermann, J., et al., Olaparib maintenance therapy in platinum-sensitive relapsed 
ovarian cancer.  New England Journal of Medicine, 2012. 366(15): p. 1382-1392. 
24. Fong, P.C., et al., Inhibition of poly (ADP-ribose) po lymerase in tumors from BRCA 
mutation carriers.  New England Journa l of Medicine, 2009. 361(2): p. 123-134. 
25. Fong, P.C., et al., Poly (ADP)-ribose polymerase inhibi tion: frequent durable responses 
in BRCA carrier ovarian cancer correl ating with platinum-free interval.  Journal of 
Clinical Oncology, 2010. 28(15): p. 2512-2519. 
26. Audeh, M.W., et al., Oral poly (ADP-ribose) polymerase  inhibitor olaparib in patients 
with BRCA1 or BRCA2 mutations and recurrent  ovarian cancer: a proof-of-concept trial.  
The Lancet, 2010. 376(9737): p. 245-251. 
27. Gelmon, K.A., et al., Olaparib in patients with recurrent high-grade serous or poorly 
differentiated ovarian carcinoma or triple-n egative breast cancer: a phase 2, multicentre, 
open-label, non-randomised study.  The lancet oncology, 2011. 12(9): p. 852-861. 
28. Kaufman, B., et al., Olaparib monotherapy in patient s with advanced cancer and a 
germline BRCA1/2 mutation.  Journal of Clinical Oncology, 2015. 33(3): p. 244-250. 
29. Lee, J.-M., et al., Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 
mutation-associated breast or ovarian cancer with biomarker analyses.  Journal of the 
National Cancer Institute, 2014. 106(6): p. dju089. 
30. Jantus-Lewintre, E., et al., 
Combined VEGF-A and VEGFR-2 concentrations in plasma: 
diagnostic and prognostic im plications in patient s with advanced NSCLC.  Lung Cancer, 
2011. 74(2): p. 326-331. 
31. Oh, S.Y., et al., The relationship of vascular endothelial growth factor gene 
polymorphisms and clinical outcome in advanced  gastric cancer patients treated with 
FOLFOX: VEGF polymorphism in gastric cancer.  BMC cancer, 2013. 13(1): p. 1. 
32. Moghaddam, S.M., et al., Significance of vascular endothe lial growth factor in growth 
and peritoneal dissemination of ovarian cancer.  Cancer and Metastasis Reviews, 2012. 
31(1-2): p. 143-162. 
33. Jimenez, X., et al., A recombinant, fully human, bispec ific antibody neutralizes the 
biological activities mediated by both vascul ar endothelial growth factor receptors 2 and 
3. Molecular cancer therapeutics, 2005. 4(3): p. 427-434. 
34. Goldman, J., et al., Cooperative and redundant roles of VEGFR-2 and VEGFR-3 
signaling in adult lymphangiogenesis.  The FASEB Journal, 2007. 21(4): p. 1003-1012. 
35. Jung, Y., et al., Effects of combination anti-vascular endothelial growth factor receptor 
and anti-epidermal growth factor  receptor therapies on the grow th of gastric cancer in a 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 101 nude mouse model.  European Journal of Cancer, 2002. 38(8): p. 1133-1140. 
36. Shah, M.A., et al., Multicenter phase II stud y of irinotecan, cispla tin, and bevacizumab in 
patients with metastatic gastric or gastroesophageal junction adenocarcinoma.  Journal 
of Clinical Oncology, 2006. 24(33): p. 5201-5206. 
37. Bindra, R.S., et al., Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.  
Cancer research, 2005. 65(24): p. 11597-11604. 
38. Lu, Y., et al., Hypoxia-induced epigenetic regul ation and silencing of the BRCA1 
promoter.  Molecular and cellular biology, 2011. 31(16): p. 3339-3350. 
39. Bindra, R.S. and P.M. Glazer, Basal repression of BRCA1 by multiple E2Fs and pocket 
proteins at adjacent E2F sites.  Cancer biology & therapy, 2006. 5(10): p. 1400-1407. 
40. Bindra, R.S. and P.M. Glazer, Genetic instability and the tumor microenvironment: 
towards the concept of microe nvironment-induced mutagenesis.  Mutation 
Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2005. 569(1): p. 75-
85. 
41. Bindra, R.S., et al., Down-regulation of Rad51 and decreased homologous recombination 
in hypoxic cancer cells.  Molecular and ce llular biology, 2004. 24(19): p. 8504-8518. 
42. Bindra, R. and P. Glazer, Repression of RAD51 gene expression by E2F4/p130 complexes 
in hypoxia.  Oncogene, 2007. 26(14): p. 2048-2057. 
43. Tentori, L., et al., Poly (ADP-ribose) polymerase (P ARP) inhibition or PARP-1 gene 
deletion reduces angiogenesis.  European Journal of Cancer, 2007. 43(14): p. 2124-2133. 
44. Hegan, D.C., et al., Inhibition of poly (ADP-ribose) polymerase down-regulates BRCA1 
and RAD51 in a pathway mediated by E2F4 and p130.  Proceedings of the National 
Academy of Sciences, 2010. 107(5): p. 2201-2206. 
45. Lim, J., et al., VEGFR3 inhibition chemosensitizes ovar ian cancer stemlike cells through 
down-regulation of BRCA1 and BRCA2.  Neoplasia, 2014. 16(4): p. 343-353. e2. 
46. Liu, J.F., et al., Combination cediranib and olaparib versus olaparib alone for women 
with recurrent platinum-sensitive ovar ian cancer: a randomised phase 2 study.  The 
Lancet Oncology, 2014. 15(11): p. 1207-1214. 
47. Loveday, C., et al., Germline mutations in RAD51D confer susceptibility to ovarian 
cancer.  Nat Genet, 2011. 43(9): p. 879-82. 
48. Loveday, C., et al., Germline RAD51C mutations confer su sceptibility to ovarian cancer.
 
Nat Genet, 2012. 44(5): p. 475-6; author reply 476. 
49. Meindl, A., et al., Germline mutations in breast and ovarian cancer pedigrees establish 
RAD51C as a human cancer susceptibility gene.  Nat Genet, 2010. 42(5): p. 410-4. 
50. Rafnar, T., et al., Mutations in BRIP1 confer high risk of ovarian cancer.  Nat Genet, 
2011. 43(11): p. 1104-7. 
51. Walsh, T., et al., Mutations in 12 genes for inher ited ovarian, fallopian tube, and 
peritoneal carcinoma identified by massively parallel sequencing.  Proc Natl Acad Sci 
USA, 2011. 108(44): p. 18032-7. 
52. Network, T.C.G.A., Integrated genomic analyses of ovarian carcinoma.  Nature, 2011. 
474(7353): p. 609-15. 
53. Bryant, H.E., et al., Specific killing of BRCA2-deficient  tumours with inhibitors of 
poly(ADP-ribose) polymerase.  Nature, 2005. 434(7035): p. 913-7. 
54. Kaye, S.B., et al., Phase II, open-label, randomized, multicenter study comparing the 
efficacy and safety of olaparib, a poly (ADP-r ibose) polymerase inhibitor, and pegylated 
liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 102 ovarian cancer.  J Clin Oncol, 2012. 30(4): p. 372-9. 
55. Ledermann, J., et al., Olaparib maintenance therapy in pat ients with platinum-sensitive 
relapsed serous ovarian cancer: a preplanned  retrospective analysis of outcomes by 
BRCA status in a randomised phase 2 trial.  The Lancet. Oncology, 2014. 15(8): p. 852-
61. 
56. McCabe, N., et al., Deficiency in the repair of  DNA damage by homologous 
recombination and sensitivity to pol y(ADP-ribose) polymerase inhibition.  Cancer Res, 
2006. 66(16): p. 8109-15. 
57. Pennington, K.P., et al., Germline and somatic mutations in homologous recombination 
genes predict platinum response and survival  in ovarian, fallopian tube, and peritoneal 
carcinomas.  Clinical cancer research : an official journal of the Americ an Association for 
Cancer Research, 2014. 20(3): p. 764-75. 
58. Adamo, A., et al., Preventing nonhomologous end joini ng suppresses DNA repair defects 
of Fanconi anemia.  Mol Cell, 2010. 39(1): p. 25-35. 
59. Patel, A.G., J.N. Sarkaria, and S.H. Kaufmann, Nonhomologous end joining drives 
poly(ADP-ribose) polymerase (PARP) inhibito r lethality in homologous recombination-
deficient cells.  Proc Natl Acad Sci U S A, 2011. 108(8): p. 3406-11. 
60. Birkbak, N.J., et al., Telomeric allelic imbalance indi cates defective DNA repair and 
sensitivity to DN A-damaging agents.  Cancer Discov, 2012. 2(4): p. 366-75. 
61. Nik-Zainal, S., et al., Mutational processes molding the genomes of 21 breast cancers.  
Cell, 2012. 149(5): p. 979-993. 
62. Wang, Z.C., et al., Profiles of genomic instability in high-grade serous ovarian cancer 
predict treatment outcome.  Clin Cancer Res, 2012. 18(20): p. 5806-15. 
63. Fong, P.C., et al., Inhibition of poly(ADP-ribose) po lymerase in tumors from BRCA 
mutation carriers.  N Engl J Med, 2009. 361(2): p. 123-34. 
64. Walsh, T., et al., Detection of inherited mutations fo r breast and ovarian cancer using 
genomic capture and massively parallel sequencing.  Proc Natl Acad Sci U S A, 2010. 
107(28): p. 12629-33. 
65. Wickramanyake, A., et al., Loss of function germline mutations in RAD51D in women 
with ovarian carcinoma.  Gynecol Oncol, 2012. 
66. Bunting, S.F., et al., 53BP1 inhibits homologous recombi nation in Brca1-deficient cells 
by blocking resection of DNA breaks.  Cell, 2010. 141(2): p. 243-54. 
67. Bouwman, P., et al., 
53BP1 loss rescues BRCA1 deficiency and is associated with triple-
negative and BRCA-mutated breast cancers.  Nat Struct Mol Biol, 2010. 17(6): p. 688-95. 
68. Johnson, N., et al., Stabilization of mutant BRCA1 pr otein confers PARP inhibitor and 
platinum resistance.  Proc Natl Acad Sci U S A, 2013. 110(42): p. 17041-6. 
69. Alexandrov, L.B., et al., Signatures of mutational pr ocesses in human cancer.  Nature, 
2013. 500(7463): p. 415-421. 
70. Alexandrov, L.B., et al., Deciphering signatures of muta tional processes operative in 
human cancer.  Cell reports, 2013. 3(1): p. 246-259. 
71. Helleday, T., S. Eshtad, and S. Nik-Zainal, Mechanisms underlying mutational signatures 
in human cancers.  Nature Reviews Genetics, 2014. 15(9): p. 585-598. 
72. Pfeifer, G.P., et al., Tobacco smoke carcinogens, DN A damage and p 53 mutations in 
smoking-associated cancers.  Oncogene, 2002. 21(48): p. 7435-7451. 
73. Kinders, R.J., et al., Development of a quantitative enzyme immunoassay for 
measurement of PAR as a pharmacodynam ic biomarker of PARP activity.  Clinical 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 103 Cancer Research, 2006. 12(19 Supplement): p. A5-A5. 
74. Di Micco, R., et al., Oncogene-induced senescence is a DNA damage response triggered 
by DNA hyper-replication.  Nature, 2006. 444(7119): p. 638-642. 
75. Gilad, O., et al., Combining ATR suppression with oncogenic Ras synergistically 
increases genomic instability, causing synthetic le thality or tumorigenesis in a dosage-
dependent manner.  Cancer research, 2010. 70(23): p. 9693-9702. 
76. Morgan, M.A., et al., Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 
involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.  Cancer research, 2010. 70(12): p. 4972-4981. 
77. Kirkpatrick, D.S., et al., Phosphoproteomic characterizati on of DNA damage response in 
melanoma cells following MEK/PI3K dual inhibition.  Proceedings of the National 
Academy of Sciences, 2013. 110(48): p. 19426-19431. 
78. Daemen, A., et al., Cross-platform pathway-based analysi s identifies markers of response 
to the PARP inhibitor olaparib.  Breast cancer research and treatment, 2012. 135(2): p. 
505-517. 
79. Cha, E., et al., Improved survival with T cell cl onotype stability after anti‚ÄìCTLA-4 
treatment in cancer patients.  Science translati onal medicine, 2014. 6(238): p. 238ra70-
238ra70. 
80. Ciriello, G., et al., Emerging landscape of oncogenic si gnatures across human cancers.  
Nature genetics, 2013. 45(10): p. 1127-1133. 
81. Weinstein, J.N., et al., The cancer genome atlas pan-cancer analysis project.  Nature 
genetics, 2013. 45(10): p. 1113-1120. 
82. Birkbak, N.J., et al., Telomeric allelic imbalance indi cates defective DNA repair and 
sensitivity to DN A-damaging agents.  Cancer discovery, 2012. 2(4): p. 366-375. 
83. Popova, T., et al., Ploidy and large-scale genomic instab ility consistently identify basal-
like breast carcinomas w ith BRCA1/2 inactivation.  Cancer research, 2012. 72(21): p. 
5454-5462. 
84. Abkevich, V., et al., Patterns of genomic loss of hete rozygosity predict homologous 
recombination repair defects in  epithelial ovarian cancer.  British journal of cancer, 2012. 
107(10): p. 1776-1782. 
85. Marquard, A.M., et al., Pan-cancer analysis of genomic scar signatures associated with 
homologous recombination deficiency suggests novel indications for existing cancer 
drugs.  Biomarker research, 2015. 3
(1): p. 1. 
86. Rempala, G.A. and M. Seweryn, Methods for diversity and o verlap analysis in T-cell 
receptor populations.  Journal of mathematical biology, 2013. 67(6-7): p. 1339-1368. 
87. Pielou, E.C., Species-diversity and pattern -diversity in the study of ecological succession.  
Journal of theoretical biology, 1966. 10(2): p. 370-383. 
88. Morisita, M., 0HDVXULQJRILQWHUVSHFL¬øFDVVR FLDWLRQDQGVLPLODULW\EHWZHHQFR PPXQLWLHV  
Mem. Fac. Sci. Kyushu Univ. Series E, 1959. 3: p. 65-80. 
89. Wolda, H., Similarity indices, sample size and diversity.  Oecologia, 1981. 50(3): p. 296-
302. 
   
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 104 APPENDIX A PERFORMANCE STATUS CRITERIA 
 
ECOG Performance Status Scale Karnofsky Performance Scale 
Grade Descriptions Percent Description 
0 Normal activity.  Fully active, able 
to carry on all pre-disease performance without restriction. 100 Normal, no complaints, no evidence 
of disease. 
90 Able to carry on normal activity; 
minor si gns or s ymptoms of disease. 
1 Symptoms, but ambulatory.  
Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature ( e.g., light 
housework, office work). 80 Normal activity with effort; some 
signs or symptoms of disease. 
70 Cares for self, unable to carry on 
normal activity or to do active work. 
2 In bed <50% of the time.  
Ambulatory and capable of all self-care, but unable to carry out any work activities.  Up and about more than 50% of waking hours. 60 Requires occasional assistance, but 
is able to care for most of his/her needs. 
50 Requires considerable assistance and 
frequent medical care. 
3 In bed >50% of the time.  Capable 
of only limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and 
assistance. 
30 Severely disabled, hospitalization 
indicated.  Death not imminent. 
4 100% bedridden.  Completely 
disabled.  Cannot carry on any self-care.  Totally confined to bed or chair. 20 Very sick, hospitalization indicated. 
Death not imminent. 
10 Moribund, fatal processes 
progressin g rapidl y. 
5 Dead. 0 Dead. 
 
  
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 105 APPENDIX B: NEW YORK HEART ASSOCIATION CLASSIFICATIONS 
   Clinical Evaluation of Functional Capacity of Patients with Heart Disease in Relation to 
Ordinary Physical Activity  
Class Cardiac 
S
ymptoms Limitations Need for 
Additional Rest* Physical Ability 
to Work** 
I None None None Full Time 
II Only Moderate Slight Usually only 
slight or occasional Usually full time 
III Defined with 
less than ordinar
y activit y Marked Usually 
moderate  Usually part 
time 
IV May be present 
even at rest, and any activity increases discomfort Extreme Marked Unable to work 
 
* To control or relieve symptoms, as determined  by the patient, rather than as advised by the 
physician 
** At accustomed occupation or usual tasks   
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 106 APPENDIX C PILL DIARY FOR OLAPARIB  
Today‚Äôs Date _______________________   Cycle # _______________________ Patient Name _______________________   Patient Study ID _______________________  
1. Complete one form for each cycle (14 days). 
2. Record the date, the number of tablets you took, and when you took them. 
3. Bring your pill bottles (including empty bottl es) and this form to every appointment. 
4. Do not chew, dissolve, or crush medi cations. DO NOT make up vomited doses. 
5. If you miss a dose, you have up to 2 hours to  make this dose up. Otherwise, write 
‚Äúmissed‚Äù where you would normall y write the time of your dose. 
The first row in the table below is an EXAMPLE ROW  for how to complete this diar
y. 
OLAPARIB 
Take _____ (number) _____ mg tablets twice a da y 12 hours apart with or  without food. You 
should avoid grapefruit, grapefruit juice, and Seville oranges while on study because of their 
affects on the metabol ism of olaparib. 
Day Date 100 mg 150 mg AM PM Comments 
 
1 1/1/17 2 0 8:00 8:00  
 
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
12       
13       
14       
      
 
    
 
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 107 APPENDIX D PATIENT DRUG INFO RMATION HANDOUT AND WALLET 
CARD  Information for Patients, Their Caregivers, a nd Non-Study Healthcare Team on Possible 
Interactions with Other Drug s and Herbal Supplements  
 The patient ____________________________ is enrolled on a clinical trial using the 
experimental study drug, olaparib. This clinic al trial is sponsored by the National Cancer 
Institute.  This form is addressed to the pati ent, but includes important information for others 
who care for this patient.   These are the things that you as a healthcare provider need to know: 
  Olaparib interacts with certain specific enzymes in  the liver and can effect  the ability to process 
other medications, and other medica tions can affect the ability of your body to  process olaparib. 
 Olaparib interacts with a certain specific enzy me in your liver called CYP 3A4 isoenzymes. The 
drug itself induces the CYP3A4 isozymes, and olaparib is broken down by this enzyme and will be affected by other drugs that inhibit or induce this enzyme. 
 Olaparib may also interact with P-glycopr otein, organic anion-tr ansporting polypeptide 
(OATPB1), organic cation transporter 1 and 2 (OCT1 and OCT2), OAT3, multi-drug and toxin 
extrusion proteins (MATE1 and MATE2K), and BRCP. Administration of strong inhibitors and 
inducers of these proteins shoul d be avoided while on olaparib. The manufacturer recommends 
that statins, in particular, s hould be administered w ith caution when given concomitantly with 
olaparib.  To the patient: Take this paper with you to your medical appointments and keep the 
attached information card in your wallet .   
 
Olaparib may interact with othe r drugs which can cause side effe cts. For this reason, it is very 
important to tell your study docto rs of any medicines you are taking before you enroll onto this 
clinical trial.  It is  also very important to tell your doc tors if you stop taking any regular 
medicines, or if you start taking a new medicine while you take part  in this study.  When you talk 
about your current medications  with your doctors, include medicine you buy without a 
prescription (over-the-counter re medy), or any herbal suppleme nts such as St. John‚Äôs Wort. 
Avoid ingesting grapefruit, grap efruit juice, Seville oranges, and Seville orange juice while 
taking olaparib. It is helpful to  bring your medication bottles or an updated medication list with 
you.  Many health care providers can write prescriptions.   You must tell all of your health care 
providers (doctors, physician assist ants, nurse practitioners, pharma cists) you are taking part in a 
clinical trial.   These are the things that you and they need to know:   
NCI Protocol #: 10066 
Version Date: 6/2/2022  
 108 Olaparib must be used very ca refully with othe r medicines that use liver enzymes.  Before you 
enroll onto the clinical trial, your study doctor wi ll work with your regular health care providers 
to review any medicines and herbal  supplements that are considered  strong inducers/inhibitors or 
substrates of CYP 3A4 isoenzyme. 
 
x Please be very careful!  Over-the-counter drugs (including herbal supplements) may 
contain ingredients that coul d interact with you r study drug.  Speak to your doctors or 
pharmacist to determine if there could be any side effects.  
x Your regular health care pr ovider should check a frequently updated medical reference or 
call your study doctor before  prescribing any new medicine or discontinuing any 
medicine.  Your study doctor‚Äôs name is _____________________________________ 
and he or she can be contacted at _____________________________________. 
                                  
NCI Protocol #: 10066 
Version Date: 6/2/2022 
109CLINICAL TRIAL WALLET CARD
Show this card to all of 
your healthcare 
providers and keep it 
with you in case you go 
to the emergency room.
Patient Name:       
Diagnosis:       
Study Doctor:      
Study Doctor Phone #:      
NCI Trial #:  10066
Study Drug(S):  olaparib
For more information: 1-800-4-CANCER
cancer.gov | clinicaltrials.gov

NCI Protocol #: 10066 
Version Date: 6/2/2022  
 110  
         APPENDIX E DIARRHEA MANAGEMENT   Information for patients and caregivers for the management of diarrhea:  
x You should take Imodium 4 mg at the onset of diarrhea. 
x If diarrhea persists, you s hould then take 2 mg every 2 hours with each 
additional bowel movement. No more than 16 mg of Imodium should be 
consumed in a 24-hour period.  
x If you develop more than 4 episodes of diarrhea in 24 hours you should 
call your study doctor. 
  